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Polymorphism, the ability of a substance to crystallize in two or more 
different structures, is a fundamental issue in the Pharmaceutical Industry 
because APIs can indeed afford multiple solid phases. As different crystalline 
forms can have different properties, polymorphic identity can have influence on 
processability, handling, formulability and also the physico-chemical and 
pharmacological properties of the finished drug product. Characterizing the 
various crystalline forms of APIs is therefore crucial. 
Structural studies can help interpreting the origin, and the consequences, of 
polymorphism, yielding important information on phase transitions or thermal 
and chemical stability. As the classical technique for structural analysis, single 
crystal X-ray diffraction, is not always applicable to solid forms of APIs, structure 
solution from powder diffraction data is an ideal solution.  
Here, structure determination from laboratory X-ray powder diffraction 
(XRPD) data is successfully carried out on different APIs, illustrating the potential 
and usefulness of the technique. Three different species are studied (bupropion 
hydrohalide salts, nortriptyline hydrochloride and ibuprofen lysine salt), exploring 
different aspects (conformational and packing polymorphism, 
solvation/desolvation processes, thermodynamic relations and thermally-induced 
phase transitions). 
Finally, a new approach to Quantitative Phase Analysis, implemented in a 
publicly available software, has been tested on an API, particularly relevant when 
accessibility to the complete structural model is hampered by the complexity of 
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1. Polymorphism of Active Pharmaceutical Ingredients 
Polymorphism, the ability of a substance to exist in different crystalline 
forms, has been steadily gaining importance in the pharmaceutical industry over 
the last few years. The mounting attention given to the solid state of 
pharmaceutical ingredients is due to the fact that solid state properties can have a 
deep influence on many aspects of the manufacturing, handling, formulation and 
ultimately efficacy and safety of a drug product.  
Different polymorphs can have very different properties, including but not 
limited to solubility, hygroscopicity, melting point, stickiness, bulk density, 
stability (both chemical and crystallographic), flowability, color, compactability 
and crystal habit. These properties can therefore have influence not only on 
safety and efficacy reproducibility of a drug, but also on industrial handling and 
processability. Moreover, polymorphs of active pharmaceutical ingredients are 
patentable in many of the major patent systems (including the European Patent 
Office, EPO, and the United States Patent and Trademark Office, USPTO). This can 
offer pharmaceutical companies protection and market exclusivity on certain 
aspects of solid-state issues and offer advantages in the life cycle management of 
drug products. 
The knowledge of the solid-state landscapes of active pharmaceutical 
ingredients, therefore, is of fundamental importance in the manufacturing and 





Polymorphism in solid-state chemistry has been defined in many different 
ways. The usually accepted formal definition is the ability of a substance to exist in 
at least two different crystalline forms having the same composition. [1] Strictly 
speaking, therefore, polymorphs must have the same chemical formula and must 
differ only in the organization of molecules in the solid state. In other words, 
according to one of the oldest definitions of polymorphism, two solids are 
polymorphs if their melt and vapor phases are identical. [2] 
Figure 1.1  Polymorphs  Different crystal structures having the same 
composition   
 
The addition of other components in the crystal structure, strictly speaking, 
does not lead to polymorphs, but to salts, solvates or co-crystals, depending on 
the nature of the added component. However, the term polymorph is often 
used loosely, especially in the pharmaceutical industry, to comprehend all the 
solid states of a molecule, including the amorphous state, solvates, hydrates and, 
occasionally, even salts and co-crystals. [3] 
1.1.2 Salts 
When a molecule is combined with an acid or a base and proton transfer 
occurs, a salt is formed. A salt, made up of two charged species,  has a different 
composition from the neutral molecule (free base or acid) and is therefore a 
different chemical entity, generally with different properties like solubility and 




Figure 1.2  Polymorphs of a salt 
       
1.1.3 Solvates and co-crystals 
When an additional neutral molecule is part of the crystalline structure of a 
substance and no proton transfer occurs, the definition of the resulting species 
traditionally depends on the state of the pure co-former (the neutral molecule 
taking part in the crystalline structure) at room temperature. When the co-former 
is liquid at room temperature, the resulting species is called a solvate, while when 
the co-former is solid at room temperature, the resulting species is called a co-
crystal. Obviously, solvates and co-crystals can also exhibit polymorphism.  
Figure 1.3  Polymorphs of solvates or co-crystals 
 
An important subgroup of solvates is represented by hydrates, where the 
co-former which takes part in the crystalline structure is water. Hydrates are of 
particular interest in the pharmaceutical industry because water is non-toxic and 
acceptable in the formulated product. This considerably expands the landscape of 
solid forms potentially usable in formulation, as will be discussed in paragraph 1.3. 
Even though the definitions are theoretically quite clear-cut and simple, in 
reality the boundaries between the various cases are not as simple as may seem. 
For example,  a crystal structure can contain more than one co-former, resulting 
in, for example, solvates of a co-crystal, hydrates of a salt or hydrated solvates. 
Moreover, all of these species can obviously exhibit polymorphism and crystallize 





Figure 1.4  Polymorphs of a solvate of a salt 
                 
More significant in the pharmaceutical industry, the definition of salt and 
co-crystal often can become controversial. When an acid or a base is combined 
with a molecule to give a crystalline structure, the occurrence or not of proton 
transfer should determine whether the resulting species is a salt or a co-crystal. 
However, it is not always evident if proton transfer occurred. This can become a 
major problem especially in the pharmaceutical industry, because, form a 
regulatory point of view, a salt and a co-crystal will be dealt with very differently 
in some countries, and a solvate will generally not be considered acceptable. 
Generally, the pKa difference between the API and the co-former can be used to 
predict whether salt formation has occurred or not. FDA Regulatory guidelines, in 
trying to draw a line between salts and co-crystals, suggest that proton transfer is 
expected when the differences in the DpKa (pKa(acid) - pKa(base)) is greater or 
equal to one, while a co-crystal is expected when the DpKa is less than one. [4] 
This said, pKa values are not easy to determine, especially in non-aqueous solvents 
or when more than one acidic or basic site are present. The clarification given by 
the FDA therefore does not simplify matters much. 
To complicate matters further, the occurrence or not of proton transfer is 
not only experimentally difficult to determine, but is often partial or incomplete in 
the solid state, and often also depends on temperature and pressure. For 
example, di-hydrated phases of oxalic acid (1  and 1!) have been shown to exist 
as neutral species at ambient pressure and as being made up of ionic moieties at 
high pressure. [5, 6] In fact, it is usually more correct to talk about degree of 
proton transfer. [7] This makes the boundary between salt and co-crystal very 
fuzzy indeed.  
 








1.2 Structural Aspects of Polymorphism of Molecular Crystals 
Different polymorphs of a substance therefore have the same chemical 
composition but a different organization in space. In the case of polymorphism of 
ionic crystals made up of only simple components, the differences between 
crystalline forms tend to be due to packing arrangements, as the packed species 
dont have many degrees of internal freedom. In the case of molecular crystals, as 
molecules can have many degrees of internal freedom, the structural differences 
between crystalline forms can be due not only to the packing of molecules having 
the same conformation (packing polymorphism), but also to differences in the 
conformations of molecules (conformational polymorphism). Even though it is 
very common to talk about conformational vs. packing polymorphism, by far the 
most common case is that two polymorphs will differ both in the packing and the 
conformation of the molecule. 
Packing polymorphism can generally be found in molecules which are 
relatively rigid and dont have a lot of conformational flexibility. An interesting 
example of packing polymorphism, discussed in detail in Chapter 3 of this work, 
can be found in the rich solid state landscape of bupropion hydrohalides. [8] 
Bupropion is an atypical antidepressant formulated in different salt forms. 
Bupropion hydroiodide forms I and II are made up of molecules in very similar 
conformation, but are packed rather differently, as shown in Figure 1.5.  
Conformational polymorphism without packing differences is very rare in 
active pharmaceutical ingredients, because differences in conformations will 
generally also lead to differences in the packing arrangement. An example of this 
are forms I and II of Venlafaxine hydrochloride. [9, 10] Venlafaxine hydrochloride 
is an antidepressants which exists in two anhydrous polymorphs. The two crystal 
forms, belonging to space groups Pca21 and P21/n, respectively, are made up of 
venlafaxine molecules having a different orientation of the methoxyl group on the 
aromatic ring, as shown in Figure 1.6. This small difference in conformation results 









Figure 1.6. Venlafaxine HCl molecules in forms a) I and b) II 
a) b)  
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Figure 1.7. Packing of Venlafaxine HCl forms a) I and b) II viewed along the b 
axis. 
a) b)  
Molecular crystals can also be made up of molecules having two or more 
different conformations. In these cases, more than one molecule will be present 
in the asymmetric unit. An example of this is Linezolid, an antibacterial agent. 
Linezolid can crystallize in two anhydrous polymorphs, one of which is made up of 
two crystallographic independent molecules existing in two different 
conformations. [11] The two different molecules, shown in Figure 1.8, are 
arranged in a head-to-tail fashion, favored by polar interactions, forming non-
centrosymmetric dimers (as Linezolid is optically active and cannot have an 
inversion as a symmetry element). 
Figure 1.8. Two crystallographic independent molecules, Linezolid Form IV. 
 
Molecular crystals, being composed of at least partially organic molecules, 
usually contain hydrogen bond donors and acceptors. The formation of different 
hydrogen bonding patterns between molecules in the solid state is often the 
driving force for polymorphism of molecular compounds. 
20 
 
1.2.1 Structure-Properties Relations 
Structural differences cause differences in all the properties of the solid 
state of different polymorphs, in primis thermodynamic stability and solubility 
(usually anti-correlated). This is obviously a very important factor in considering a 
polymorph for use in the pharmaceutical industry, as solubility is often correlated 
with bioavailability. A very famous example of this is the antiretroviral drug 
Ritonavir (shown in Scheme 1.1), which can crystallize in two different anhydrous 
forms with very different solubilities.  













While form I was formulable as semi-solid gel capsules, the appearance of 
the less soluble form II caused crystals to form inside the capsules. Form II could 
not be formulated in the same way as form I. [12] 
The large difference in solubility between forms I and II of ritonavir is due to 
their structures, in particular to the differences in the hydrogen bond motifs. The 
molecule of ritonavir is very large and has many potential hydrogen bond donors 
and acceptors. As a result, the hydrogen bond scheme in both forms I and II is 
very complex. Form II contains stronger hydrogen bonds, as all the strong 
hydrogen bond donors and acceptors are saturated. A key difference is that in 
form II the hydroxyl group of an alcohol acts both as donor and acceptor, while in 
form I the same hydroxyl group acts only as a donor, as is shown in Scheme 1.2. In 
form II, this causes a synergic effect which makes both hydrogen bonds stronger.  
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Scheme 1.2. Hydrogen bond scheme around the hydroxyl group for a) form 






































Moreover, crystal growth for the two forms is different and results in 
crystals of form I having a greater percentage of their surface area with exposed 
hydrogen bond donors compared with crystals of form II. As the cleavage of 
hydrogen bonds is the first step of solubilization, these differences cause form II 
to be much less soluble with respect to form I. [13] 
Just as marked structural differences can cause crystal forms to have very 
different properties, structural similarities lead to crystal forms having similar 
properties. An example of this is Nortriptyline hydrochloride, a triclyclic 
antidepressant which will be discussed in detail in Chapter 4 of this work.  
Nortriptyline hydrochloride can exist in two crystalline anhydrous forms known as 
! and ". [14, 15, 16] The two forms have very similar properties, including 
stability, solubility and hygroscopicity. Structural analysis of the two forms 
showed many strong analogies as shown in Figure 1.9, which help explain the 
similar properties.  
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Figure 1.9. Crystal Structure of nortriptyline hydrochloride, forms a) ! and 
b) ".  
 
The cases illustrated above suggest how structural knowledge is more than 
an academic exercise, as it can offer insight on the behavior of different crystal 
forms, help explain solid state transformations (or lack thereof) and allow to 
predict  properties of different polymorphs. 
1.2.2 Thermodynamic relations between polymorphs 
One of the most important questions to be addressed when characterizing 
polymorphic systems is relative stability between different crystal forms. When 
more than one crystal form is available, knowledge of thermodynamic 
relationships is critical to understanding solid-state behavior.  
One way of representing thermodynamic relationships between 
polymorphs is using energy-temperature diagrams. Energy-temperature diagrams 
are schematic plots of the energetic situation of forms in relation to temperature. 
The most common representations are curves of Gibbs free energy (G) and 
enthalpy (H) as functions of temperature.  
As G = H  TS (where G and H are as defined above, T is absolute 
temperature and S is entropy) and by the definition of molar heat capacity at 
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constant pressure (Cp), the dependences of G and H with temperature are given 
by the following equations: 
= Cp ; = -S  (1.1) 
Both the molar heat capacity and entropy monotonically increase with 
temperature and are always greater than zero. Therefore, the curve H(T) will 
increase monotonically, while the curve G(T) will decrease monotonically. When 
plotting on a diagram the G(T) and H(T) of a solid and a liquid, as is depicted in 
Figure 1.10, the G curves will cross in correspondence of the melting point of the 
solid.  
When studying the thermodynamic relations between polymorphs, it is 
useful to plot the G and H curves of both forms on the same graph. In general, 
given any two polymorphs of a substance, two possible thermodynamic relations 
are possible: the two forms can either be monotropically or enantiotropically 
related. Monotropically related means that one of the two forms is 
thermodynamically more stable at every temperature below the melting point. 
This means that the curves for G of the two solids never cross below the melting 
point. This situation is depicted in Figure 1.11.   
The crossing of the G curves of the two solids (Gs1 and Gs2) with the G curve 
of the liquid (Gl) represent the melting points of the two solids. Form 1 can 
interconvert into form 2, ignoring kinetic considerations, at any temperature 
below fusion, and the enthalpy of conversion is the difference between Hs1 and 
Hs2 at the temperature the conversion occurs. 
In the case of enantiotropically related forms, Gs1 and Gs2 curves cross 
before encountering Gl (i.e. before the melting points). This results in one form 
being thermodynamically more stable above the temperature at which Gs1 and Gs2 
cross (Tt) and the other being thermodynamically more stable below Tt. This case 





Figure 1.10. Energy-Temperature diagram for a liquid and a solid at 
constant pressure 
 




Hl = enthalpy of the liquid 
Hs = enthalpy of the solid 
Gs = Gibbs free of the solid 
Gs = Gibbs free energy of 
the liquid 
DHfus = fusion enthalpy 
Tfus = fusion temperature 
Hl = enthalpy of the liquid 
Hs1 = enthalpy of form 1 
Hs2 = enthalpy of form 2 
Gs1 = Gibbs free of form 1 
Gs1 = Gibbs free of form 2 
Gs = Gibbs free energy of the liquid 
DHs1= fusion enthalpy for form 1 
DHs1= fusion enthalpy for form 2 
Ts1 = fusion temperature of form 1 




Figure 1.12. Energy-Temperature diagram for two enantiotropically related 
forms  
 
Obviously, crystal forms which are thermodynamically less stable than 
others can still be stable for kinetic reasons. If the conversion into other forms is 
kinetically hindered, the net result will be in a practical stability of the less 
stable forms. If this werent the case, only one crystal form would exist for any 
compound at any given temperature. 
1.2.3 Graph Set Notation 
Because understanding and describing hydrogen bonding plays a very 
important part in understanding molecular polymorphism, a way to effectively 
define and categorize hydrogen bonding motifs is useful, as it can make 
comparison of different crystal structures easier. One of the most used methods 
to define and describe hydrogen bonding is the Graph Set Notation. [17, 18] 
The idea behind the Graph Set Notation is to break down complex 
hydrogen bond schemes into simpler patterns which can be then analyzed 
separately. This also allows the hydrogen bonding scheme for different crystalline 
forms to be directly compared.  
  
Hl = enthalpy of the liquid 
Hs1 = enthalpy of form 1 
Hs2 = enthalpy of form 2 
Gs1 = Gibbs free of form 1 
Gs1 = Gibbs free of form 2 
Gs = Gibbs free energy of the liquid 
DHs1= fusion enthalpy for form 1 
DHs1= fusion enthalpy for form 2 
DHt= transition enthalpy 1#2 
Ts1 = fusion temperature of form 1 
Ts2 = fusion temperature of form 2 




There are four types of basic hydrogen bond types, classified according to 
the patterns they form and identified by a single upper case letter:  
1) Chains (C) 
2) Rings (R)  
3) Intramolecular Bonds (S) 
4) Other discrete patterns (D) 
The letter identifying the pattern is then accompanied by two numbers, a 
subscript and a superscript, detailing the number of hydrogen bond donors and 
acceptors, respectively. A third number, indicated in parenthesis, indicates the 
number of atoms involved in the pattern. When the indicators are equal to one, 
they can be omitted.  Therefore, every hydrogen bond basic pattern can be 




This method allows to quickly and simply describe many different hydrogen 
bond patterns. A couple of examples of patterns and their Graph Set identifiers 
are reported in Scheme 1.3.  
Patterns containing only one type of hydrogen bond as described above are 
called motifs and represent the simplest level of hydrogen bond pattern 
description.  The term one type also takes into account the chemical identity of 
the donors and acceptors. If a molecule has more than one hydroxyl group and 
each donates to a carbonyl, the motifs will be as many as the chemically different 
hydroxyl groups present.  
More complex patterns can arise as different motifs (more than one type of 
hydrogen bond) combine to form more complex structures and networks. These 
constitute superior order hydrogen bond networks. If two motifs combine, the 
network formed is second order. If three motifs combine, the network is third 
G = hydrogen bond pattern type 
a = hydrogen bond acceptors 
d = hydrogen bond donors 
n = number of atoms involved in the pattern 
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order, and so on. An example of second order network is represented in Scheme 
1.4. 
Scheme 1.3.  Examples of Hydrogen Bond Motifs  
The chain motif represented in a) can be found for example in Nortryptiline 
hydrochloride, discussed in further detail in Chapter 4. The ring motif represented 



























1.3 Importance of Polymorphism in the Pharmaceutical Industry 
The occurrence of polymorphism in active pharmaceutical ingredients 
(APIs) has an enormous importance for many different reasons. Firstly, the 
structural differences between polymorphs of a compound can cause the solids to 
have different properties and characteristics, some of which can influence 
handling, safety, stability and efficacy of a drug product or substance. The 








































First Order motifs 
N1:  a= ; b=




lead to the choice of the form with the most suitable characteristics, leading to a 
better bioavailbility, longer shelf-life, easier formulation or more robust process 
control. 
1.3.1 Crystal Form Choice 
In the previous paragraphs, the importance of thermodynamic stability was 
discussed. A desirable solid form obviously will have good crystallographic and 
chemical stability to ensure shelf-life and consistent bioavailability. However, the 
more thermodynamically stable forms will generally have the lowest solubilities, 
therefore the lowest bioavailabilities. In some instances, for example for very 
insoluble APIs, the chosen form might not be the most stable but the most 
soluble. Furthermore, other characteristics have to be taken into account. For 
example, the crystal habit, which may depend on crystal form, can play a 
fundamental role in the ease of handling and processablity of a pharmaceutical 
powder. Powders made of needle-shaped crystals, for example, will generally 
have poor flow and electrostatic properties, while those containing prism-shaped 
crystals will have a higher bulk density and will be much easier to handle 
industrially. Moreover, needle shaped crystals will generally create additional 
process complications, for example having higher filtration resistance. [19]  
An example of the influence crystal habit can have in bulk properties can be 
found in the polymorphs of Linezolid mentioned in paragraph 1.2. Figure 1.13 
shows pictures of crystals of forms II and IV. While form II crystallizes as needle-
shaped crystals having poor bulk properties, form IV crystallizes as prism-shaped 
crystals having much better characteristics. [20]  
Different crystal forms may also exhibit different compressability, being 
more or less suitable for tableting. As tablets are the preferred pharmaceutical 
form when possible, this is a very important issue. Hygroscopicity is also a very 
important property to take into account because it can have an effect on the 
stability of the formulated product. An example of different crystalline forms 
(though not strictly polymorphic) having different hygroscopicities is found among 




Figure 1.13. Crystals of Linezolid forms a) II and b) IV. 
   a)  b)  
Rabeprazole sodium salt, shown in Scheme 1.5, is a proton pump inhibitor. 
It is known to exist in several crystalline hydrated forms, including a hemihydrate, 
a monohydrate and a sesquihydrate. While the hemihydrate and the 
sesquihydrate are hygroscopic, the monohydrate is not and also exhibits a better 
chemical stability. [21] 











Many different solid-state properties of crystals have therefore to be taken 
into account when choosing the most suitable solid form for formulation. The 
complete characterization of all forms is therefore crucial to make correct and 
informed choices. 
1.3.2 Biopharmaceutics Classification System 
In order to correctly understand and assess the impact of solubility on 
bioavailability of a drug product, a useful tool, especially used in regulatory issues, 
is the Biopharmaceutics Classification System (BCS). [22, 23] This is a 
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differentiation of active substances into four groups depending on their water 
solubility and their permeability through the gastro-intestinal membrane. It is 
widely used for regulatory purposes to help establish bioavailability and 
bioequivalence, but can also give information regarding which properties can limit 
bioavailability for a specific substance. [24] Details on BCS classes and solubility 
boundaries are given in Table 1.1.  
The Biopharmaceutics Classification System is important when dealing with 
different solid forms of pharmaceutical substances because it gives indication as 
to whether or not polymorphism will have an impact on the bioavailability of the 
formulated product. A very soluble substance, for instance, belonging to classes I 
or III, will not have bioavailability limited by drug solubility. In these cases, 
polymorphism will have small influence on the efficacy of the finished product. 
Conversely, where solubility is low, for example in classes II and IV, polymorphism 
can be an issue in the bioavailability of the formulated drug. 
Table 1.1. Biopharmaceutics Classification System 
A drug substance is considered HIGHLY SOLUBLE when the highest dose strength is 
soluble in < 250 ml water over a pH range of 1 to 7.5. It is considered HIGHLY 
PERMEABLE when the extent of absorption in humans is determined to be > 90% 
of an administered dose, based on mass-balance or in comparison to an 
intravenous reference dose. 
 
1.3.3 Crystal Forms and Patents 
A major role in the importance of solid state issues in the pharmaceutical 
industry is played by patentability of solid forms and the protection that this can 
offer. A patent is the granting by a national government of the right to exclusively 
exploit a particular invention for a limited period of time in exchange for making 
the invention available to society. As patents are granted by individual national 
governments, the rules on what is patentable and what protection can be 
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obtained can vary from country to country. On some level, international 
organizations exist which try to make the granting of patents as homogenous as 
possible throughout groups of countries. An example of this is the EPO, or 
European Patent Organization.  
The two main patent systems when dealing with polymorphism of APIs 
generally are considered to be the EPO (European Patent Organization) and the 
USPTO (United States Patent and Trademark Office), as these cover the main 
global markets for pharmaceuticals. Of course, many other patent systems can 
have deep impact and importance in many specific cases, but only EPO and USPTO 
are briefly discussed here.  
Both EPO and USPTO consider solid forms to be inventions and therefore 
patentable. However, the rules for patentability change slightly from one system 
to the other. In general, in order to be granted a patent, the invention must be 
novel, inventive and useful or industrially applicable. When referred to a 
crystalline form, the novelty is quite easy to define, as a specific solid form must 
not have been prepared before. The inventiveness is less clear-cut and is defined 
differently by the EPO and the USPTO. For the EPO, inventiveness requires a 
technical problem to be solved, for example if the known crystalline forms are 
hygroscopic, the disclosure of a new, non-hygroscopic form will be considered 
inventive, as this solves an existing problem. For the USPTO, the term "non-
obviousness" is used to describe inventiveness. One of the main requirements of 
patentability is that the invention being patented is not obvious, meaning that a 
"person having ordinary skill in the art" would not know how to solve the problem 
at which the invention is directed by using exactly the same mechanism. This 
definition of inventiveness is less rigorous, and therefore the granting of patents 
on crystalline forms are generally slightly easier to obtain with the USPTO than 
with the EPO. [25] 
As far as usefulness and industrial applicability are concerned, while a new 
crystalline form is considered intrinsically industrially applicable by the USPTO (as 
it can be formulated and sold), the EPO requires the new form to have some 
advantageous characteristic over the state of the art. Again, this gives rise to 
differences between what is granted on either side of the Atlantic Ocean. 
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Of course, not only solid forms but also specific solid state characteristics 
(for example a specific range of particle size [26]) and the processes used to 
obtain them are considered inventions and can be protected by patents in many 
patent systems, including EPO and USPTO. This adds considerably to the scope of 
protection obtainable concerning solid-state issues.  
There is another issue regarding solid-state and patents which is gaining 
importance and attracting attention in the pharmaceutical industry: when a 
crystal form is patented, the holder of the patent can in principle not only start a 
litigation against competitors for using it, but also for having small amounts of it in 
their product. For example, according to the American legal system, under 35 
U.S.C. § 271(a), any infringement, even de minimis infringement, is actionable. If a 
competitor has any amount of a crystalline form patented by others, the patent 
holder can file law suits. There is as of yet no legal precedent brought to trial in 
the United States, so there is no case law to establish a precedent, but the 
quantitation of damages could be calculated according to two different 
approaches: 1) the damages due could be proportional to the amount of patented 
crystalline form or 2) the damages due could be proportional to the whole loss of 
revenue, independently of the amount of patented crystalline form present. [25] 
Of course, in case 1) precise quantitation is a big issue, while in case 2) the 
detection limits of the available methods are crucial. In the light of this, 
quantitation methods with lower and lower detection limits are gaining 
importance.  
As the money involved in pharmaceutical development, production, 
formulation and sales is considerable, the importance that patent protection may 
assume, when blocking or hindering competitors, is proportionately considerable. 
1.3.4 Crystal Form Characterization 
The existence of patent issues regarding the solid state in the 
pharmaceutical industry adds importance to the necessity of structural 
characterization of polymorphs. In fact, very often scientific issues fall in the 
background of purely legal issues. For instance, there are cases in the patent 
literature where mixtures of polymorphs are taken for a different form. The 
determination of the crystallographic cell through indexing of the powder 
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diffractogram would ascertain the monophasic nature of a sample, avoiding these 
kinds of situations. Another example of lack of sound science in the patent 
literature are cases when the same crystalline form is object of several different 
patent applications under different names. An example of this discussed in the 
scientific literature is Cefdinir (Scheme 1.6). [27] 











Cefdinir is a potent antibiotic [28] which can exist in several different 
crystalline forms, both anhydrous and hydrated. This case has been object of a 
patent litigation in 2009. Interestingly, a monohydrate form has been object of six 
different patent applications under different names. [29, 30, 31, 32, 33, 34] In all 
cases, the crystalline form was characterized by XRPD of varying quality. This 
instance is not uncommon in pharmaceutical patent literature and underlines the 
importance of high quality characterization of solid forms. 
1.3.5 Crystal Form Quantitation 
In the light of the scientific, legal and practical importance that crystal form 
quantitation can have in the pharmaceutical industry, quantitation methods also 
have a role to play in polymorphism and solid state analysis of pharmaceuticals. 
Many quantitation methods exist, making use of IR spectroscopy [35], SS-NMR 
[36], DSC (only for solvates and hydrates [37]) and other techniques. [38] 
However, the most precise methods which also tend to have the lowest LODs are 
based on powder diffraction. [18] The lowest LODs obtained to date make use of 
XRPD using synchrotron radiation. [39,40] This will be further discussed in Chapter 
2 (section 2.1.6). 
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The approaches which can be used for XRPD crystal form quantitation are 
varied. The most used methods are the Rietveld method and the single peak 
method, both having strengths and drawbacks.  
The Rietveld method makes use of the full diffraction profile of samples. 
The knowledge of the crystal structures of all phases involved, necessary for the 
application of this method, allows to construct the theoretical XRPDs and to 
compare them with the XRPD of the unknown mixture.  The theoretical basis and 
mathematical procedure are discussed in more detail in Chapter 2. With the 
Rietveld method, it is possible to get the best precision and accuracy as well as the 
lowest LODs for the same radiation source. The main strength of this method is 
the fact that it uses the full diffraction profile, so the influence of preferred 
orientation and other aberrations due to sample preparation is minimized.  
As for the single peak method, its main strength is that it does not require 
the knowledge of the crystal structures of the phases involved. In fact, very often 
the structure of pharmaceutical polymorphs is not only not known, but very 
difficult if not impossible to determine with single crystal methods. However, the 
single peak method is heavily influenced by preferred orientation, as a single 
representative peak is chosen for each phase under analysis. The method requires 
the construction of a calibration curve for all phases involved, and therefore pure 
monophasic standards of all phases are necessary. A more detailed discussion of 
quantitation methods can be found in Chapter 6. 
1.4  Aims and Scope 
The main aim of this work is to explore the possibilities offered by structural 
analysis and to apply them to active pharmaceutical ingredients, in order to study 
their solid-state landscape and offer insight into the behavior of different 
crystalline forms. Also, the vast majority of the analyzed structures have been 
obtained using state-of-the-art powder diffraction methods for structure solution, 
highlighting the usefulness and versatility of the technique. 
Chapters 3, 4 and 5 of this work are dedicated to structural analysis applied 
to active pharmaceutical ingredients. The deeper understanding of the properties 
of different crystalline forms can help, as explained in the previous paragraphs, in 
all phases of drug production, in patent issues, in life cycle management and in 
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the correct reading and interpretation of the information available in the scientific 
and patent literature. 
In Chapter 3, the rich and varied solid-state landscape of Bupropion 
hydrohalides is analyzed and discussed making extensive use of structure solution 
from powder data, bringing to light interesting features, similarities and 
differences between phases. In particular, all phases analyzed are constituted by 
bupropion molecules in similar dimer conformations, differing only in the packing 
arrangement of the dimers. Conformational analysis using gas phase molecular 
modelling is also used and discussed. 
In Chapter 4, structural analysis is used to explain the polymorphic behavior 
of Nortriptyline hydrochloride. In particular, the similar properties of the two 
known polymorphs and their lack of solid-state interconversion are addressed and 
explained. 
In Chapter 5, structure resolution from powder data is used to study the 
thermal behavior of the anti-inflammatory drug Ibuprofen lysine salt. Ibuprofen 
lysine salt undergoes a fully reversible conversion into a different crystalline form 
upon heating. Structural and thermal analysis offer an explanation of this 
behavior.  
As discussed in the present chapter, quantitative analysis is another crucial 
issue when dealing with the solid-state of APIs. The knowledge of structures of 
different crystalline forms can help in quantitative analysis, as it allows the 
Rietveld method to be successfully applied. However, other Quantitative Phase 
Analysis (QPA) methods have been reported in the literature which make use of 
the full diffraction profile (the main advantage of the Rietveld method) but do not 
require the knowledge of the structure of the phases involved. [41] The possibility 
to use a similar full profile method without the necessity of the knowledge of the 
crystalline structures is very promising and interesting for pharmaceutical solids 
This method has, to our knowledge, been applied only once to APIs, [42] but the 
full potential of the method was not explored. Therefore, one aim of this work is 
to apply a structureless full profile method to the quantification of 
pharmaceuticals and to compare the results obtained with results obtainable by 
the classical Rietveld method. This is explored in Chapter 6. 
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The solid-state of Pharmaceutical solids (APIs) is a complex and varied field. 
In this field more than in others, the partnership between Industry and Academia 
is necessary and sought. The Industrial world is often oblivious to state-of-the-art 
methods and solutions, while the Academic world does not have a clear view of 
industrial necessities and problems that need to be addressed. Partnership and 
team work can benefit both worlds. Both roles, know-hows and points of view are 
necessary and a synergy is useful for successful problem solving. Reflections on 
this point together with the work that has been done to promote this kind of 
knowledge sharing are contained in Chapter 7. 
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2. Techniques for Structural Analysis 
2.1 X-Ray Powder Diffraction 
2.1.1 Interaction of X-Rays with matter 
X-rays are an electromagnetic radiation having a wavelength ( ) between 
0.1 and 100 Å. As the energy of electromagnetic radiation is inversely proportional 
to the wavelength, X-rays, having small values of  , are highly energetic and 
therefore have high penetration in matter with a refraction index in any medium 
very close to 1. [1] 
Interaction between radiation and matter (therefore also between X-rays 
and crystals) can happen in three ways: 
a) Elastic (coherent) Scattering. The scattered radiation has the same 
wavelength as the incident (primary) radiation. 
b) Inelastic (incoherent) Scattering (or Compton Scattering). The scattered 
radiation partially loses energy in the collision and therefore has a 
different (longer) wavelength from the incident radiation. 
c) Absorption.  
To fully describe  the interaction of X-rays with matter taking into account 
all three phenomena, the dynamical theory of diffraction is necessary, which is 
mathematically quite complex. However, when considering specifically the 
interaction of X-rays with crystals, it is generally sufficient to consider only the 
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elastic scattering due to electrons according to the Thompson model, therefore 
using the kinematical theory of diffraction. [2] 
When considering the interaction of X-rays with electrons, every electron 
interacts with the electrical field associated with the electromagnetic radiation by 
oscillating with the same frequency. Therefore, every electron generates a new 
spherical wavefront propagating in all directions and having the same wavelength 
as the incident radiation. This is shown schematically in Figure 2.1. The new 
wavefronts interact with each other causing interference (both constructive and 
destructive). The diffracted intensity will be non-zero only when the diffracted 
radiation from every electron is in phase, therefore where there is constructive 
interference. As the electron density is higher in the internal electron core, as 
opposed to the lower electron density of the valence electrons, the diffraction of 
X-rays will happen mainly around nuclei. This is the principal assumption upon 
which structural analysis using diffraction of X-rays is based. The organization of 
the nuclei in space can be evaluated by observing the interference (diffraction) 
pattern of X-rays generated in the reciprocal space by the real-space lattice. 
Figure 2.1. Schematic representation of interference patterns given by the 
interaction of electrons with X-rays 
 
2.1.2 Crystals and Reciprocal Lattice 
A crystal can be ideally thought of as an ordered structure of atoms or 
molecules which continues periodically in all directions. In order to describe a 
periodic structure, a very convenient thing is to use a lattice. A lattice can be 
simply described by identifying the smallest repeating unit, called the unit cell. 
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Given any kind of periodic structure, an infinite number of unit cells can be chosen 
to describe it, as schematically represented in two dimensions in Figure 2.2.  
Figure 2.2. Schematic representation of the crystalline lattice 
Given any periodic structure, an infinite number of unit cells can be chosen to 
describe it. In the case illustrated below, the periodic structure formed by the 
repeating lightning bolts can be described by any of the cells 1, 2 and 3.  
 
Analogously to the way in which two-dimensional unit cells depicted in 
Figure 2.2 describes a two-dimensional lattice, a three-dimensional lattice can be 
described by a three-dimensional unit cell, which in turn can be described by 
three non-coplanar vectors, a, b and c. Any point in the lattice can then be 
indicated by a vector q defined by equation (2.1). 
   (2.1) 
Instead of using vectors a, b and c, the same unit cell can be described using 
six scalar quantities: the lengths of the three vectors, a, b and c, and the angles 
between!the!vectors,!",!#!and!$.!This!is!shown!in!Figure!2.3. 


























The situation described in Figure 2.2, repeated in Figure 2.4a, is not 
common, as the full content of the unit cell represents the repeating unit. Usually, 
only a part of the content of the unit cell will be repeated in space (therefore 
inside the unit cell as well), describable by simple geometrical transformations 
called symmetry elements (rotations, inversions, reflections, translations or 
combinations thereof). This is called the asymmetric unit. As an example, the two-
dimensional structure of Figure 2.4b can be described knowing the asymmetric 
unit (the red lightning bolt), the unit cell (the black box) and the symmetry 
elements, meaning the geometrical transformations that describe how to obtain 
the yellow lightning bolts from the red one. 
Figure 2.4. Two-dimensional structures and their unit cells 
The asymmetric unit of structure a) is represented by the full content of the unit 
cell, the yellow lightning bolt. The asymmetric unit of structure b) is represented by 
the red lightning bolt, which can be transformed into the yellow lightning bolt 
inside the unit cell by inversion around the blue point. 
 
Other useful concepts when dealing with crystal structures are 
crystallographic planes and the way to describe them. The!term!crystallographic!
plane! is! a! geometrical! concept! which! really! indicates! a! family! of! parallel,!
equidistant planes (where interplanar distance is defined d). These can be defined 
























parts into which the first plane of the family next to the origin divides a, b and c. A 
couple of examples are depicted for clarity in Figure 2.5.   
Figure 2.5. Crystallographic Planes 
Millers Indices indicated in round parenthesis are used to identify crystallographic 
planes. 
 
A mathematical concept very useful when dealing with diffraction by 
crystals is the reciprocal lattice. [2] The reciprocal lattice is defined by three 
vectors, a*, b* and c* (analogously to a, b and c already discussed for the real 
space lattice) constructed so that the following conditions are met: 
  (2.2) 
     (2.3) 
As the dot represents the scalar product between two vectors and is equal 
to the product of the length of the two vectors times the cosine of the angle 
between them, equation (2.2) implies that a* is perpendicular to both b and c, b* 
is perpendicular to both a and c and c* is perpendicular to both a and b. 
Considering the definitions of both scalar product and vector product, the 
following can be derived: 
 ;   ;   (2.4) 
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(where V and V* are, respectively, the volumes of the real space and the reciprocal 
cell). 
The families of crystallographic planes described above can also be 
represented in the reciprocal space with a vector perpendicular to the 
crystallographic planes having length equal to: 
   (2.6) 
This means than an infinite number of parallel crystallographic planes can 
be defined by a single vector d* having origin in the origin of both the direct space 
and reciprocal unit cell or by a single point positioned at the end of vector d*. This 
is schematically depicted in two dimensions in Figure 2.6. 
Figure 2.6. Two-dimensional representation of direct space and reciprocal 
lattice 
 
2.1.3 Braggs Law and Laues Equations 
There are two ways to describe the mathematical conditions of constructive 
interference,!Braggs!law!and!Laues!equations.! In its most simple interpretation, 
Braggs!law!considers!a!crystallographic!plane,!described!by!Millers!indices hkl, to 
act as a mirror for x-rays. Constructive interference will therefore only happen 
when the path difference for two rays reflecting off different parallel planes is a 

















can be calculated by simple geometrical considerations. This is depicted in figure 
2.7.  
Figure 2.7.!Graphical!representation!of!Braggs!Law  
 
The condition for constructive interference is that the path difference 
between the wave that reflects two different crystallographic planes having the 
same hkl values is equal to a multiple of the wavelength of the incident radiation. 
In the picture, where two crystallographic planes hkl have an interplanar distance 
of d, this condition is fulfilled if AB + BC = n .! !As!AB!=!BC!and!AB!=!d sin%!from!
simple trigonometric considerations, the geometrical condition of constructive 
interference can therefore be expressed by equation (2.7), which represents 
Braggs!Law: 
   (2.7) 
Laues! equations! are! a! different! way! to! describe! the! mathematical!
conditions of constructive interference when x-rays interact with a crystal. [3] 
Considering a scattering vector S defined as 
    (2.8) 
where s0 is the direction of propagation of the incident radiation, s is the direction 
of! observation! and!  ! is! the! wavelength! of! the! radiation,! ! the! conditions! for!
constructive interference are 
;  ;   (2.9) 
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 Equations (2.9)! are! known! as! Laues! equations! and! must! be! satisfied!
simultaneously with h, k and l assuming integer values for constructive 
interference.!Laues!equations!can!also!be!expressed!differently!making!use!of!the!
reciprocal space: 
   (2.10) 
  In other words, as  is another way to express d* as 
defined in paragraph 2.1.2, the scattering vector S has module, and therefore 
diffraction intensity, greater than zero, where it coincides with vector d*(hkl), 
therefore terminating on a point of the reciprocal lattice. 
2.1.4 X-Ray Powder Diffraction Apparatus  
The aim of any diffraction experiment is the measurement of the intensity 
profile in reciprocal space. [4] When X-rays hit a sample, radiation will be 
diffracted where constructive interference is possible, as described in the previous 
paragraph. If the sample is a single crystal, the diffraction will happen along the 
points of the reciprocal lattice where!Laues!equations!are!satisfied, as shown in 
Figure 2.8a. If the sample contains more crystals having different orientations, the 
reciprocal lattices of the various crystals will superimpose (Figure 2.8b). Il the 
sample is constituted by an infinite number of crystals randomly oriented, the 
diffraction pattern will be made up of continuous lines (Figure 2.8c). A ray of the 
concentric circles obtained represents the powder diffraction pattern observed 
during an X-ray Powder Diffraction (XRPD) experiment. 
Figure 2.8. Diffraction by a Single Crystal a), several crystals b), and a 




A diffraction experiment substantially needs three components:  
1) a radiation (X-ray) source  
2) a crystalline sample  
3) a detector to measure the diffracted intensity 
In between these components, other (optical) components may be added 
to  modify the X-ray beam. The three main components listed above can be 
placed in different geometrical conformations. The two geometries most used in 
laboratory XRPD experiments are Bragg-Brentano (or parafocusing, or reflection) 
and Debye-Scherrer (or transmission). 
In Bragg-Brentano geometry, the sample analyzed is packed flat and the 
diffracted radiation is measured after reflection off the sample. This is 
schematically shown in Figure 2.9a. The advantages of this method are in the easy 
and quick sample preparation, while the main disadvantage is that the diffracted 
intensity is highly influenced by sample characteristics, above all preferred 
orientation. 
In transmission geometry, the radiation passes through the sample before 
reaching the detector. The sample can be packed in different ways, for example in 
cylindrical capillaries or in flat discs. The most used configuration is the cylindrical 
sample. This instrument configuration is showed in Figure 2.9b. Data collected in 
transmission geometry is generally less influenced by sample effects like preferred 
orientation, but sample preparation is longer and more complex.  
Figure 2.9. Bragg-Brentano (Reflection) a) and Debye-Scherrer 
(Transmission) b) Geometries 
 
There are many different types of X-ray sources. In this section, only 
laboratory X-ray sources will be dealt with. [2] For synchrotron and other high 
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energy sources, see paragraph 2.1.5. The two most common laboratory sources of 
X-rays are sealed tubes and rotating anode tubes. 
 Sealed tubes are made up of a fixed anode coupled with a cathode sealed 
under high vacuum inside a metal and glass or ceramic tube. Electrons are 
emitted by the anode, generally tungsten, and accelerated towards the cathode 
by a high electrostatic potential (generally around 40 kV). The high-energy 
electrons impact against the cathode, displacing core electrons and causing X-ray 
emission. Metal filters are then used to cut off some of the unwanted 
wavelengths, making the radiation as monochromatic as possible (other 
monochromators can be used as optical components if necessary). As most of the 
energy supplied to the tube is converted into heat, sealed tubes require very 
efficient cooling to maintain working conditions. 
The wavelength and emission profile of the obtained X-rays depends on the 
material of the cathode. Some of the most common materials used for cathodes 
and the resulting wavelengths are reported in Table 2.1, together with the metal 
used as a filter. For the analysis of molecular crystals, which tend to have 
relatively large crystalline cells and therefore many diffraction peaks at high 
interplanar spacings (therefore low angles) a longer wavelength allows a better 
resolution of diffraction peaks, distributing the peaks over larger angular ranges. 
Copper is generally the cathode of choice for XRPD as it is the most versatile, 
allowing for good resolution while avoiding the necessity of large angular ranges.   
Table 2.1. Materials generally used for cathodes and resulting wavelengths. 
[2] 
Anode Material K"1 [Å] K"2 [Å] K# [Å] Filter 
Cr 2.28975 2.293652 2.08491 V 
Fe 1.93608 1.94002 1.75664 Mn 
Co 1.78900 1.79289 1.62082 Fe 
Cu 1.54059 1.54441 1.39225 Ni 
Mo 0.709317 0.71361 0.63230 Zr 
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Rotating anode tubes have a better thermal efficiency than sealed tubes. 
This is achieved using bulky anodes which are rotated, therefore constantly 
moving a more chilled portion of the anode towards the impact zone. A higher 
brightness of X-rays is achievable. However, this radiation source is less durable 
than the sealed tube and is therefore used only for specific applications.  
When analyzing powder samples, it is important for the sample to have 
certain characteristics. [5] First of all, the sample should contain all possible 
orientations of the crystals randomly distributed. Secondly, the crystallites should 
be as homogenous in size and shape as possible. Crystal shape can deeply 
influence peak intensity, especially in Bragg-Brentano geometry, because 
anisotropic shapes (for example rods or plates) will preferentially offer the 
incident beam a series of crystal faces which will be more represented than 
others. Careful grinding and preparation of the sample can minimize these effects. 
The use of transmission geometry with a cylindrical sample can also minimize 
preferred orientation effects. Sample preparation considerations are especially 
important for quantification purposes or when trying to solve structures from 
powders.  
Several different types of detectors are available for laboratory 
instrumentation. As the characteristics (and the prices!) of detectors vary 
considerably, the detector choice is important when considering laboratory 
equipment. Until a few years ago, scintillation point detectors based on 
fluorescent crystals like sodium iodide (NaI) doped with 1% thallium were the 
most commonly used. The crystals present in the detector absorb X-rays and emit 
blue photons. The blue photons are multiplied by a photomultiplier and then 
converted into electric current. Scintillation detectors have the advantage of high 
linearity, high stability and long working life, together with a relatively low price. 
However, over the last few years, they have been gradually replaced by solid-state 
detectors, which have the advantage of being potentially very small and therefore 
can be mounted in arrays (both linear and two-dimensional). This shortens 
considerably measurement time, yielding high signal-to-noise ratio. 
In fact, over the last few years, silicon or germanium solid-state detectors 
have become more and more used in powder diffractometry. A silicon or 
germanium single crystal doped with lithium interacts with an X-ray photon 
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causing electron vacancies proportional in number to the energy of the incoming 
photon. This generates an electric current which can be amplified and measured. 
The mounting of these kinds of crystals in an array allows to individually measure 
the current coming from each point of the array, therefore providing information 
about the incoming radiation from every specific location of the detector. This can 
shorten measurement times by two orders of magnitude, with a limited loss of 
resolution. The main disadvantage of this type of detector, apart from the 
considerably higher price compared to the scintillator, is that is has poor linearity 
for high photon fluxes. This can cause artefacts when observing particularly 
intense peaks.  
In this work, two different types of diffractometers have been used for data 
collection, one working in reflection geometry on flat samples and one working in 
transmission geometry on cylindrical samples. The experimental conditions used 
are reported below. 
Refection XRPD on Flat Sample  Experimental Conditions: The flat sample 
diffractograms were acquired on a Bruker D8 Advance !:! diffractometer 
equipped with a silicon strip detector (LynxEye) and having a goniometer radius of 
300 mm. Nickel-filtered CuK" was used. The samples were generally placed in an 
aluminum sample holder equipped with a quartz monocrystal plate or in a silicon 
monocrystal sample holder (both 0.2 mm deep). When necessary, the samples 
were gently ground in an agate or glass mortar with a pestle.  
When the analysis was run for identification or indexing purposes, the 
range investigated was generally 5-55° in 2! with a step size of 0.02° and a scan 
speed of 0.5 sec/step. When the analysis was run for structure resolution or 
Rietveld refinement, the range investigated was 5-105° in 2! with a step size of 
0.02°. The diffractogram was then acquired for about 15 h in recycling mode. 
Transmission XRPD on cylindrical samples  Experimental Conditions: The 
transmission diffractograms on cylindrical samples were acquired on a Bruker D8 
Advance !:! diffractometer equipped with a silicon strip detector (LynxEye) and 
having a goniometer radius of 280 mm. Nickel-filtered CuK" was focused on the 
detector through the sample using a focusing mirror. The samples were gently 
ground in an agate or glass mortar with a pestle and then packed in glass 
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capillaries having a diameter of 1 mm. The capillary was rotated at 30 rpm during 
the measurement. The data, generally to be used for structure solution or Rietveld 
refinement, were acquired in the 5-105° in 2! with a step size of 0.02°. 
Diffractograms were generally acquired for 15 or 64 h in recycling mode. 
Single Crystal XRPD Analysis  Experimental Conditions: The single crystal data 
contained in this work were collected on an Enraf-Nonius diffractometer using 
graphite monochromated MoK" radiation (l=0.71073 Å). Data collection and data 
reduction strategy followed standard procedures implemented in the 
diffractometers software. The structures were solved by direct methods using 
SIR97 program [6] and refined on F2 by full-matrix least-squares procedure using 
SHELXL-97, [7] with anisotropic factors for all non-hydrogen atoms. Hydrogen 
atoms (apart from the hydrogen atoms of the molecule of 1-propanol of the 1-
propanol solvate of Bupropion hydrobromide, see Chapter 3) were placed in 
geometrically calculated positions and refined by a riding model.  
2.1.5 Non-ambient Diffractometry 
As XRPD is a relatively quick and easy technique which requires minimal 
sample preparation, it is well-suited for other applications like studying the 
sample in non-ambient conditions. The variables typically explored are 
temperature and pressure. For pharmaceutical solids, variable temperature XRPD 
can be extremely useful because API production, handling and formulation can 
cause at various stages the solid to undergo heating. The knowledge of behavior 
upon heating can therefore yield precious information. Moreover, variable 
temperature XRPD is extremely useful when studying desolvation processes or 
when establishing thermodynamic relationships between polymorphs. 
The conditioning of the sample during an XRPD experiment can be achieved 
using a furnace chamber mounted inside the diffractometer connected with an 
automated temperature controller. Some of the issues to be addressed during 
variable temperature XRPD experiments are the need for homogeneous heating 
while avoiding oxidation or degradation of the sample. This is usually achieved by 
creating an enclosed, controlled atmosphere environment inside the furnace. 
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In this work, a custom-made controlled-temperature sample holder (shown 
in Figure 2.10) was successfully used for several variable temperature XRPD 
studies. The sample is heated in air, therefore care must be taken to ensure no 
thermal degradation or oxidation occurs. Moreover, thermal gradients can be 
generated on the sample, so careful and critical data evaluation is necessary. 
However, when studying pharmaceutical solids, transitions and other events are 
normally observed at relatively low temperatures (usually below 200°C), therefore 
an open chamber is usually well-suited for the desired applications.  
Figure 2.10. Temperature controlled open sample holder (Officina 
Elettrotecnica di Tenno, Ponte Arche, Italy). 
 
Variable temperature XRPD  Experimental Conditions: The variable temperature 
XRPD experiments were run on a Bruker D8 Advance !:! diffractometer equipped 
with a silicon strip detector (LynxEye) and having a goniometer radius of 300 mm. 
Nickel-filtered CuK" was used. Samples were placed in an open, custom-made 
aluminum sample holder capable of heating the sample in air from room 




Generally, a significant 2! range, usually about 15° wide depending on the 
aim of the experiment, was chosen and data was acquired after heating of the 
sample in 10° or 20°C steps, using a step size of 0.02° in 2! and a scan speed of 0.5 
sec/step. After reaching the desired maximum temperature (generally the end of 
the observed event, typically either melting or complete conversion into a different 
phase), the sample was cooled using the same temperature steps used in heating 
and the diffractograms acquired again. Once room temperature was reached, the 
sample was visually inspected and a final analysis was run in the 5-55° in 2! range 
to check both the chemical and the crystallographic purity. When deemed 
necessary, the chemical purity was also checked by solution 1H-NMR (for 
experimental details, see paragraph 2.3.2). 
2.1.6 Synchrotron Radiation 
Synchrotron radiation can be fruitfully employed in powder diffraction 
experiments because of its elevated brilliance and coherence. Moreover, the wide 
emission X-ray spectrum makes it possible to select very specific wavelengths and 
highly monochromatic radiation. These factors make XRPDs collected with 
synchrotron radiation very high quality, having a low signal-to-noise ratio and 
narrow diffraction peaks. 
When electrons moving at relativistic speeds are subjected to centripetal 
accelerations in curved trajectories, electromagnetic radiation is emitted. [8] The 
wavelengths obtained range from radio frequencies to short-wavelength X-rays. 
Electrons circulating with energies in the order of the GeV are maintained in large 
storage rings (tens or even hundreds of meters in diameter). They can then be 
subjected to centripetal accelerations, therefore emitting radiation, in different 
devices: 
1) Bending Magnets  A magnetic field forces the change in trajectory. 
2) Insertion Devices  electrons are forced into sinusoidal trajectories by 
a linear sequence of alternating magnets. 
The radiation which can be obtained by synchrotron sources for XRPD 
experiments is many orders of magnitude more energetic than that obtained by 
laboratory sources. This gives many advantages, starting from very quick 
experiments (coupled with fast area or linear detectors) and very low detection 
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limits for trace amounts of contaminating crystalline forms.  [9, 10] This, as 
discussed in Chapter 1, can be a very important issue to address when dealing 
with polymorphism of pharmaceutical substances.  
Synchrotron Radiation XRPD Experiments: The synchrotron data contained in this 
work were acquired at the Powder diffraction station of the X04SA-MS beamline of 
the SLS synchrotron facility at the Paul Scherrer Institute, from samples loaded in 
0.5 mm Lindemann glass capillaries, using DebyeScherrer geometry and 15 keV 
radiation (#=0.827006 Å), partial He beam path, and a Mythen detector covering 
120° 2! with 0.0038° resolution. Data were carefully absorption-corrected and 
subtracted for air and capillary scattering contributions before analysis. 
2.2 Structure solution from Powder Diffraction Data and 
Quantitation methods 
As discussed in Chapter 1, structure solution can be extremely useful and in 
some cases necessary in the study of pharmaceutical polymorphism. The 
traditional single crystal analysis, though offering structures of better quality and 
reliability, is seldom available for pharmaceutical applications for many reasons. 
Not all crystal forms can crystallize in specimens suitable for analysis, or crystal 
forms may come from desolvation or heating processes and can therefore be 
available only in polycrystalline form. In cases such as these, structure solution 
from powder data is the only viable method. [11] 
Traditionally, in order to solve a structure from X-ray diffraction data, it is 
necessary to extract integrated intensities for each reflection. The integrated 
intensities depend on the squares of the modules of the structure factors Fh. The 
structure factor is a mathematical function describing the amplitude and phase of 
a wave diffracted from a specific crystallographic plane hkl. Solving a structure 
substantially implies solving for the phases of the structure factors knowing the 
modules. When no structure information is known a priori, the methods are called 
ab-initio. There are substantially two different approaches to the problem, 
reciprocal space methods (here, for simplicity, Direct methods only are 
considered) and real-space methods. [2] 
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Direct Methods operate in reciprocal space and are generally used with 
single crystal data. The only initial information required is the unit cell description 
and the knowledge of the cell content. No information regarding atom 
connectivity is used. The working assumptions are atomicity and positivity, 
meaning the electron density is considered concentrated around the atoms 
(atomicity) and it is treated mathematically as having positive value in every point 
(positivity). These methods are not widely used for solving structures of molecular 
solids from powders. 
Real-space methods, operating by definition in real space, make use of the 
prior information usually accessible about atom connectivity, bond length, etc. 
The molecule is therefore initially described as a rigid body, with the addition of 
the necessary torsion angles to describe conformational freedom. Using a rigid 
body as starting geometry, the bond lengths and angles are already described. 
The only variables explored are torsion angles and the relative positioning and 
orientation of the molecules inside the unit cell. This is not only feasible but 
efficient!for!several!reasons:!first!of!all,!bond!lengths!and!angles!dont!vary!much!
from one molecule to another and can be well described using molecular 
modelling with widely available force fields. Secondly, when dealing with crystal 
structures of polymorphic phases, the important information is not the length of 
every single bond, but the relative position of the various functional groups and 
interactions between them (above all hydrogen bonding), which can be 
successfully described by exploring torsion angles and molecular position and 
orientation only. 
These characteristics make real-space methods particularly suitable for 
solving structures of small-molecule pharmaceutical solids. In fact, the molecular 
formula is obviously known and the size and conformational flexibility of the 
molecules are generally well-suited to the method.  
The process of solving structures from powder data can be divided into 
several successive well-defined steps, assuming that high-quality diffraction data 
has been acquired on a pure monophasic sample of the desired crystalline form: 
1) Indexing. Determining cell parameters and attributing hkl indices to 
every diffraction peak observed. 
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2) Space group determination. Assigning of a space group based on the 
volume of the cell, the approximate molecular volume and systematic 
absences. 
3) Structure solution. An approximate solution is obtained using an ab-
initio method. 
4) Structure refinement. The solution obtained in point 3 is refined using 
the Rietveld method. 
 Each one of the steps described above has different critical points. In order 
for structure solution to be successful, every step is essential. 
2.2.1 Indexing and Space Group Determination 
Indexing means determining the cell parameters and attributing to each 
reflection observed in the reciprocal space a unique triplet hkl. When working on 
single crystal data, this is relatively simple, but working with powder data, the 
unavoidable overlapping of diffraction peaks (especially when dealing with 
molecular crystals) makes the procedure more complicated.  
First of all, the position of the peaks must be very precisely evaluated, while 
the intensities do not matter at all. The diffraction peaks must be narrow, to avoid 
overlapping as much as possible. This can be achieved using very thin samples 
when operating in flat-sample geometry.  
Having a series of precise peak values (generally about 20), the peak 
positions are expressed as Qobs, defined as 
  (2.11) 
The process of indexing requires then finding the parameters of the 
reciprocal unit cell aij (with i,j = 1,3), which are the same for each reflection 
observed, and three values hkl which are different for every reflection observed. 
The described parameters have to satisfy the following condition: 
   (2.12) 
where!&!represents!the!pre-assigned tolerance value. 
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Letting the observed Qobs values be N, the number of variable to determine 
is 6+3N. The problem is therefore always underdetermined and yields an infinite 
number of possible solutions, meaning a theoretically infinite number of possible 
cells. The correct one has to be chosen on the basis of several criteria. Firstly, 
knowing the molecular formula and shoichiometry of all the components of the 
solid under examination, it is possible to estimate the molar volume in the solid 
state. A very rough estimate can be obtained by multiplying the number of non-
hydrogen atoms by 18 Å3, a less rough estimate can be obtained using tables of 
average atomic molar volumes in the solid state [12].  Secondly, all reflections 
present must be indexed or attributable to known impurities.  
 In order to help with the choice of crystal cell, several numerical criteria 
have been devised to help validate possible solutions. Aside from the 
considerations regarding density and volume described above, two figures of 
merit are often used, M20 (or De Wolff figure of merit) and FN (or Smith and 
Snyder figure or merit). 
The De Wolff figure of merit [13] is defined as  
   (2.13) 
where Q20 is the Q-value of the 20
th indexed peak, Nposs is the number of possible 
independent reflections for Q<Q20 and  is the average absolute difference 
between the observed and calculated Q. 
The Smith and Snyder figure of merit [14] is calculated as 
   (2.14) 
where N is the number of the observed Bragg peaks, Nposs is the number of 
possible independent reflections up to the Nth observed peak and  is the 
absolute average!difference!between!the!observed!and!calculated!2%!values. 
The space group must then be assigned, taking into consideration the 
number of molecules in the unit cell and the systematic absences (the absence of 
specific hkl reflections based on cell symmetry). This is done using the correlation 

















Both to verify the cell and space group determined and to refine cell 
parameters, it is very useful to apply Whole-Pattern Profile Fitting (WPPF) 
methods. The obtained cell and space groups can be used to simulate a pattern 
with peak positions determined by the unit cell and variable peak intensities. This 
can be done for example with the Le Bail method. [16]  
Peak shapes, important in WPPF methods, can be described in different 
ways. Several mathematical functions are available: Gaussian curves, Lorentzian 
curves, Voigt (a convolution of a Gaussian and a Lorentzian curve), pseudo-Voigt 
(linear combination of Gaussian and Lorentzian curves) and Pearson VII (a 
generalized Lorenzian-Gaussian mixture different from the pseudo-Voigt). These 
mathematical approaches are based on finding a mathematical function able to 
correctly describe the shape of the diffraction peak observed. A different 
approach is to describe peak shape considering the various contributions from 
experimental configuration (goniometer radius, slits, radiation profile, geometry 
used, etc.) and using separate functions to describe each contribution. Peak shape 
is then described with a convolution of the different contributions. This approach 
is called the Fundamental Parameters Approach (FPA) and is schematically 
reported in Figure 2.11. [17] 
Figure 2.11. Graphical Representation of the convolution procedure for 





Indexing and Space Group Determination, general procedure: A general protocol 
was applied to all phases studied. Exact peak positions of the different phases 
were determined using standard peak search methods followed by profile fitting 
methods incorporated in the program TOPAS-R [18], also used for indexing and 
determining approximate cell parameters for each phase. The unit cell parameters 
were then refined with the structureless Le Bail mode of the Rietveld method. For 
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each XRPD dataset, the background was modeled using a Chebyshev polynomial, 
peak profiles were described by the Fundamental Parameters Approach and an 
average isotropic thermal factor was attributed to all atoms. Density 
considerations and the analysis of systematic absences lead to space group 
determination and Z-evaluation. 
2.2.2 Structure Solution 
The aim of the structure solution step is to derive an approximate structural 
model to be later refined. In real-space methods, as described at the beginning of 
section 2.2, this is achieved by constructing an initial molecular fragment 
(generally using molecular modelling when a previously solved structure of a 
different polymorph is not available) based on known atom connectivity and 
moving it in real-space. [19] The positions of the atoms of the molecular 
fragments can be described either by Cartesian coordinates or by a Z-matrix 
carrying internal coordinates (bond lengths, bond angles and torsion angles). The 
powder diffraction profile is then calculated and compared with the experimental 
powder data using a cost function (CF). The aim is to find an absolute minimum of 
the cost function, which should correspond to an approximate solution. 
The position of a molecular fragment can be described by the coordinates 
of its center of gravity x, y and z, by three angles which describe its orientation 
, and  and!by!the!necessary!torsional!angles!'1,!'2,!'3.!These!parameters!
are included in the so-called parameter vector P: 
  (2.15) 
A trial parameter vector P is used to calculate intensities  for all i points 
of the diffraction pattern. These are then compared with the observed for all 
points using a cost function : 
  (2.16) 
where wi is the statistical weight of the single i point and is generally taken as 
1/yio. The parameter vector is then changed (randomly or otherwise) and the cost 
function is calculated again. The new configuration can then be discarded or 
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accepted depending on a pre-chosen criterion, and the iterations continue. The 
way in which the new parameter vector is generated and the acceptance criteria 
vary depending on the method (Monte Carlo, Simulated Annealing, Genetic 
Algorithm, etc.), but the idea is always to find the parameter vector Po which 
minimizes the cost function and is therefore a possible structural solution. 
Structure Solution, general method: Approximate structure solutions were 
generally found by employing a semirigid molecular fragment, typically 
constructed using the molecular modeling optimization routine of 
ACD/ChemSketch, version 12.01. The molecule, or molecules, under examination 
were made flexible about the necessary acyclic torsion angles, for example those 
of side chains. When necessary, the pertinent halide ion was added as a freely 
floating atom. If the phase under examination was a solvate, the solvent molecule 
was also modelled and added. For Ibuprofen lysine salt (see Chapter 5), the 
molecules of Ibuprofen and lysine were modelled and moved separately, but 
simultaneously, during structure solution. Approximate location and orientation of 
the molecular fragments were found using the simulated annealing algorithm 
incorporated in TOPAS-R. Each simulated annealing was run until a chemically and 
crystallographically reasonable structure solution was repeatedly found.  
The CPU time and iterations necessary to yield a solution varied depending 
on the number of fragments and torsion angles explored. The background, peak 
description and thermal factor, already optimized in the Le Bail step described 
with the indexing procedure, were kept fixed to keep the number of variables as 
low as possible. 
In this phase, the 2! range typically employed was 5-55°. 
2.2.3 Rietveld Refinement 
The Rietveld method [16] is based on the comparison between a calculated 
and an experimental diffraction profile. Like in other WPPF methods, the 
difference is evaluated using a cost function minimized using a non-linear least-
squares approach.  
The cost function to be minimized is the weighted sum of squares, 
analogous to the cost function  reported as equation 2.16, already used 
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during structure solution. The values for  are calculated according to equation 
2.17 
  (2.17) 
where   is a scale factor,  is the profile shape function,  is an 
asymmetry function,  is the preferred orientation correction,  is the 
calculated background and  the calculated intensity of reflection h as defined in 
equation 2.18 
   (2.18) 
where  is the multiplicity of reflection h,  is the square of the modulus of 
the structure factor for reflection h and  is the Lorentz-polarization correction. 
As the structure factors need to be calculated starting from the structure, 
the Rieltveld method requires knowledge of all structural and instrumental 
parameters, and allows the refinement of any variable chosen (cell data, 
background description, scale factors, atomic positions, etc.). In the case of 
Rietveld refinement after structure solution as described in paragraph 2.2.2, it 
allows the refinement of cell data, molecular position, orientation and of course 
of the torsion angles used to describe molecular flexibility (as well as background 
description and other relevant parameters). 
Rietveld Refinement of a structural solution, general procedure: After an 
approximate structure solution was found with the simulated annealing method 
described in paragraph 2.2.2, it was refined using the Rietveld routine embedded 
in TOPAS-R. The cell parameters, background polynomial, thermal factor 
attributed to all atoms were optimized together with the molecular fragment 
positions and orientation and the torsion angles. The full XRPD profile was used in 
the refinement, typically in the 5-105° 2! range. 
2.2.4 Quantitation Methods 
The Rietveld method can also be fruitfully employed for quantification, as 
briefly described in paragraph 1.3.5. While the calculation of the cost function 
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(equation 2.16) remains the same, the calculation of the intensity (equation 2.17) 
can be modified to allow calculation of intensity from more than one structure 
represented in the sample. As an example, equation 2.19 shows how equation 
2.17 would be modified for a sample containing two different phases 1 and 2, 
while equation 2.18 to obtain values of  remains unchanged. 
    (2.19) 
From the values obtained for the scale factors  and  it is possible to 
obtain the relative amounts of the two phases 1 and 2.  
As crystal structures of active pharmaceutical ingredients are not always, if 
not seldom, available, a very interesting Quantitative Phase Analysis (QPA) 
method proposed in the literature uses the full XRPD profile but does not require 
the knowledge of the structure of the phases involved. [20] This method uses a 
Rietveld-like calculation method, modifying the equations to use intensities 
extracted from the observed diffraction profile. In order to do this, the moduli of 
the observed structure factors need to be placed on an absolute scale to be 
comparable with those calculated form the crystal structure. The moduli of 
structure factors are on an absolute scale when they are expressed relative to the 
scattering of an isolated electron under the same conditions. The necessary scale 
factor  can be obtained using the Wilson Plot. [21] Equation 2.18 therefore 
becomes  
    (2.20) 
where  is the absolute scale for phase j and  are the observed structure 
factors. To obtain , the average scattered intensity of the crystal  is compared 
with the theoretical values to be expected form a completely random 
arrangement of atoms inside a unit cell of the same content, as expressed in 
equation 2.21, 
q l    (2.21) 
where  is the mean intensity value in a chosen interval of 2q,  are the 
squares of the atomic structure factors for the atoms present in the unit cell,  is 
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an isotropic atomic thermal vibration factor and l is the wavelength of the 
radiation used. Taking the natural logarithm of both sides of equation 2.21 and 
rearranging, equation 2.22 is obtained. 
q l    (2.22) 
Plotting  for chosen intervals of 2q against q l  a line having 
intercept equal to  and slope equal to  should be obtained. This is 
called the Wilson Plot. 
This QPA method has been implemented in a publicly available software 
called QUANTO [22] but has been applied, to our knowledge, only once to active 
pharmaceutical ingredients. [23] Seeing the promising characteristics of the 
method, as it does not require the knowledge of the crystal structures but only 
the XRPDs of pure samples of the phases involved for intensity extraction, it was 
deemed useful to explore the scope of the method when applied to APIs.   
Quantitative Phase Analysis (QPA), general procedure: High quality powder data 
of the pure phases to be used in QPA (acquired as described in paragraph 2.1.4) 
was analyzed with the software QUANTO. Initially, a Le Bail fit was carried out for 
each pure phase using and refining the known cell data, generating a list of 
reflections with the associated moduli of the observed structure factors. For each 
XRPD dataset, the background was modeled using a Chebyshev polynomial and 
peak profiles were described with pseudo-Voigt functions. A second run, providing 
the program with the unit cell contents as well as the refined cell parameters, 
allowed to extract integrated intensities for each indexed peak, saving the data in 
a separate file to be used during quantitation. High quality powder data of known 
mixtures were then analyzed both with a classical Rietveld approach and with the 
intensities extracted from the pure phases. The program automatically applied the 
Wilson plot to place extracted intensities on the absolute scale when intensity files 
were used in place of structure information. Again, the background was modeled 
using a Chebyshev polynomial and peak profiles were described with pseudo-Voigt 
functions. More details regarding the whole procedure are reported in Chapter 6. 
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2.3 Other techniques for Crystal Form Characterization 
Many other techniques are available for characterizing various aspects of 
crystalline phases, for example Infrared spectroscopy (IR), Raman spectroscopy, 
Nuclear magnetic resonance spectroscopy (NMR), dynamic vapor sorption (DVS),  
and various thermal methods, including differential thermal analysis (DTA), 
differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). In 
the present work, wide use was made of DSC and NMR to characterize samples. 
2.3.1 Differential Scanning Calorimetry (DSC) 
When heating a solid sample, thermal events (for example solvent loss, 
transitions into other forms, melting or thermal decomposition) will be induced. 
Information can be obtained when heating a sample and an inert reference in the 
same conditions, measuring the temperature difference between the sample and 
the reference. Different events will either cause heat to be absorbed or released. 
This is the basis of Differential Thermal Analysis (DTA). As DTA offers only 
qualitative but not quantitative information, the technique evolved in Differential 
Scanning Calorimetry (DSC).  
DSC measures the heat flow between the sample and the reference during 
heating (or cooling). Two different approaches are possible in order to do this: 
a) Power compensation  The sample and reference are kept at the same 
temperature and the power needed to do this is measured. 
b) Heat flux  The heat differential between the sample and the reference is 
measured as a function of temperature. 
In both cases, the output is a curve of heat flow (dQ/dt) as a function of 
temperature. Generally, the heat flow is given in J/g and the temperature in °C, 
even though using absolute temperature is sometimes considered useful. 
Endothermic events can be depicted both as above or as below the baseline, 
depending on the convention used. This is generally clearly marked on the axis to 
avoid confusion. [24] 
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Because heat Q depends on the specific heat capacity (Cp) according to Q = 
Cp&T, the heat flow can be correlated with the specific heat capacity, [25] as 
shown in equation 2.23. 
 = CP     (2.23) 
Therefore, the DSC trace can also be expressed in Cp as a function of 
heating. This is of particular significance when the baseline shifts, for example 
during the glass transition of an amorphous phase. 
Integration of equation 2.23 with the temperature shows how the area 
underlying the curve is proportional to the energy involved in the process, in 
particular $Q. At constant pressure, $H=$QP$V, where P is pressure and $V is 
change in volume (expansion work). When operating with open crucibles the 
pressure can be considered constant and, as the phenomena observed are 
generally solidàsolid transitions or solidàliquid transitions, $V is negligible. 
Therefore, $Q=$H. DSC therefore gives a direct measurements of the enthalpy 
change associated with observed phenomena.  
DSC analysis can play an important role in studying polymorphism of 
pharmaceutical compounds because different crystalline forms will in principle 
have different thermal profiles, including but not limited to different melting 
points. The phenomena observable with DSC are several. Scheme 2.1 holds the 
most common types of events observed, classified according to whether they are 
accompanied by heat release (exothermic) or heat absorption (endothermic). The 
glass transition, being a shift in the baseline, is classified separately.  
DSC is a precious tool in characterizing crystalline forms because it allows to 
determine, for example, whether a specific form has crystallization solvent, 
whether it converts before melting into a different phase and whether the 
transition is exothermic or endothermic. This in particular allows determination of 
thermodynamic relationships between crystalline forms. [26] As discussed in 




Scheme 2.1. Events observable by DSC 
 
DSC is justifiably considered a destructive technique. However, with 
custom-made temperature programs, it can be a powerful tool to prepare specific 
crystalline forms. For example, it is possible to achieve controlled desolvations 
and study other solid-solid transitions. [27] 
Throughout this work, DSC has been extensively used to characterize solid 
forms. Moreover, custom-made temperature programs have been used to 
prepare previously unknown crystalline forms. This use of preparative DSC is 
further described and discussed in Chapter 3. 
Differential Scanning Calorimetry Experiments: Differential Scanning Calorimetry 
measurements contained in the present work were run on a Mettler-Toledo 822e 
calorimeter. The samples (typically, in the 3-5 mg range) were loaded in aluminum 
pans with pierced lids and generally heated at 10 °C/min (depending on the aim of 
the experiment) under a flow of nitrogen (80 ml/min).  The temperature range 
explored, depending on the aim of the experiment, was generally between 30 and 
300°C. When the experiment required it, custom-made temperature programs 
were designed with cooling steps as well as heating steps, depending on the 
desired outcome.  
Transition temperatures in the DSC traces were determined using the onset 
method, the temperature at which the tangent segment taken in the first 
inflection point of the curve crosses the baseline.  
When required for analytical purposes, the pans were opened after the 
analysis and the recrystallized or otherwise modified solids analyzed via XRPD 











 Glass transition 
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2.3.2 Nuclear Magnetic Resonance (NMR) 
Nuclear Magnetic Resonance (NMR) spectroscopy is a technique which 
allows to obtain information on the chemical environment of nuclei based on the 
study of the interaction of nuclear angular momentum with an externally applied 
magnetic field. The application of a strong external magnetic field causes formerly 
degenerate energy levels of the nuclei to split in 2I+1 states, where I is nuclear 
spin quantum number of the nucleus under exam. The energy difference between 
adjacent states  is equal to 
    (2.24) 
where  is the gyromagnetic ratio,  is the reduced Plank constant,  is the 
applied magnetic field and  is the Larmor frequency. What is measured during 
an NMR experiment is . This depends on the chemical environment of the 
single nuclei and is therefore used to extract a lot of chemical information. 
With several modifications, the NMR technique can be applied both to 
molecules in solution and molecules in the solid-state. The kind of information 
obtained in the two cases is rather different. In solution, molecular tumbling 
mediates to isotropic values many anisotropic contributions (for example dipole 
coupling and quadrupole coupling). This causes NMR spectra recorded in solution 
to have sharp signals, mainly used for chemical identification purposes. Solid-
State NMR yields information of different nature, because the anisotropic 
contributions are not mediated by molecular tumbling. In principle, solid-state 
NMR therefore offers more information than solution NMR.  
Some techniques are available which simplify the spectrum enough to make 
the information acquirable and readable. For example, Magic Angle Spinning 
(MAS) allows to mediate some anisotropic contributions and high power 
decoupling is used to eliminate J-coupling. Solid-State NMR can therefore be used 
to extract important information about the solid state, complementary to those 
which can be obtained from powder diffracion. For example, SS-NMR can be used 
to determine how many crystallographically non-equivalent molecules are present 
in the asymmetric unit. This is crucial information to have when attempting to 
solve structures form powder data. An example of this is the solving of the 
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structure of form IV of Linezolid from powder data reported in the literature. [28] 
SS-NMR allowed to determine the presence in the asymmetric unit of two 
crystallographic independent molecules, forming non-centrosymmetric dimers in 
the structure. 
In the present work, SS-NMR has not been used, but wide use has been 
made of solution 1H- and 13C-NMR to study the chemical composition of phases, 
to verify the chemical identity after thermal treatments or other procedures and 
to gather relevant chemical information.  
Nuclear Magnetic Resonance Experiments in Solution: 1H- and 13C-NMR 
experiments were run on a Mercury 300 Varian spectrometer generally using d6-
DMSO as a solvent. Sample concentration was in the range 0.01-0.04 M.  
Proton Spectra for chemical identification were generally acquired with a 
delay of 1 second between acquisitions for 16 acquisitions. When the aim of the 
spectrum was to quantify the solvent present, the delay was brought to 30 
seconds. Carbon spectra were generally acquired with a delay of 4 seconds 
between acquisitions for about 15 h (about 10000 acquisitions).  
Chemical Shift values are given in ppm using TMS as an external reference. 
Signal attribution was based on chemical shift and signal multiplicity. When 
deemed necessary, exchange of the mobile protons with deuterated water was 
carried out to confirm signal attribution. 
2.4 Preparation of Crystal forms 
Crystal forms can be prepared in many different ways. The main method 
employed industrially is crystallization from solution, as this allows purification as 
well as control of particle size and crystal shape, in addition to easy separation of 
the finished product from the mother liquor. Moreover, it is easily industrially 
applicable and highly controllable. However, not all crystalline forms can be 
prepared from crystallization from solution. Other techniques are available, like 
desolvation, heating, grinding, vapor digestion, slurry conversions, solvent 
removal by evaporation, spray drying or freeze drying, anti-solvent precipitation, 




Crystallization from solution is the most employed technique not only 
because of the purification issues and industrial applicability, but also because 
many parameters can be varied and managed, allowing control on the outcome of 
the crystallization. Choice of the solvent, temperature, stirring, concentration, 
cooling rates, ripening times can all affect crystallization outcome. Understanding 
the parameters involved and their influence on the process is vital to successfully 
controlling a crystallization procedure. 
The driving force of any crystallization is the supersaturation, the difference 
between the concentration in solution of the species to be crystallized and the 
equilibrium solubility concentration at a given temperature. [30] Once 
supersaturation is achieved, crystallization occurs through two mechanisms, 
nucleation and crystal growth. The kinetics of the two processes is different, and 
therefore nucleation and crystal growth can occur at different supersaturation 
levels. Typically, crystal growth can occur at lower supersaturations than 
nucleation. A metastable zone therefore exists below the solubility curve where 
crystal growth could occur, but in the absence of nuclei it does not. Only at the 
edge of the metastable zone does spontaneous nucleation occur. At this point, 
the supersaturation decreases while crystallization occurs. This is depicted in 
Figure 2.12. 




As crystallization is driven by supersaturation which is tied to solubility, the 
understanding of solubility is essential to understanding (and controlling) 
crystallization. To understand how solubility, a thermodynamic property, is tied to 
thermodynamic stability, it is useful to consider chemical potential !. When a 
crystalline form 1 is thermodynamically more stable than another form 2, as 
explained in Chapter 1, G1 < G2. This, at constant pressure, implies !1 < !2. Since ! 
= !0 + RT ln a, where R is the universal gas constant, T is temperature and a is 
activity, the chemical potential can be linked to the concentration of the species in 
solution. In fact, the activity can be assumed equal to the concentration admitting 
an activity coefficient of 1. At equilibrium, therefore,  
 ;   (2.25) 
where S1 and S2 are the solubilities of the two forms at the temperature T. As !1 < 
!2, this implies that S1 < S2. This means that not only the most thermodynamic 
stable form always has lower solubility, but also that the solubility curves for the 
different!crystal!forms!follow!the!trend!of!Gibbs!free!energy (discussed in Chapter 
1). Therefore, the relationships between solubility curves for monotropic and 
enantiotropic polymorph pairs are depicted in Figure 2.13. 
Analogously to what previously discussed in Chapter 1, kinetic 
considerations are very important in understanding crystallization outcome. 
Different cooling rates will achieve different supersaturations before spontaneous 
nucleation sets in. This allows to control which crystalline form nucleates and 
grows. 





Crystallization experiments, general procedure: The active pharmaceutical 
ingredients used in this work have been donated by Dipharma Francis S.r.l., 
Baranzate (MI), Italy. The solvents and other reagents used were purchased from 
Sigma-Aldrich (St. Louis, MO, USA) and used without further purification. 
Crystallization of the different pharmaceutical compounds studied in this work 
were generally carried out on 2-5 g of substance. Typically, the solid was placed in 
a round-bottomed flask equipped with a thermometer and a reflux condenser and 
placed under magnetic stirring in inert atmosphere, generally nitrogen gas. The 
solid was suspended in an initial amount of solvent, the solvent was heated to 
reflux using an oil bath and more solvent was added portion-wise until complete 
dissolution was obtained.  
 When the experiment required fast cooling, the oil bath was removed and 
immediately replaced by an ice bath. When the experiment required slow cooling, 
the heating of the oil bath was stopped but the oil bath was left in position to cool 
naturally. In the cases in which a more controlled cooling was necessary, small 
double-walled reactors with oil circulation were used. The temperature of the 
circulating oil was controlled by electronic programmable thermo-cryostats, 
allowing to design specific cooling ramps. 
The crystallized solid obtained was typically retrieved by filtering the 
suspension on Buchner, Hirsch or Gooch filters. The solids were generally analyzed 
wet using the necessary techniques, then dried under vacuum and analyzed again.  
Once a metastable crystalline form is generated in solution, it can still 
evolve into a more stable form, especially if suspended in a solvent. This not only 
means waiting time between crystallization and filtration is important, but it is 
also the principle used in slurry transformations (generally called Solvent-
Mediated Phase Transitions, or SMPT). [31] Different solvents can be used to 
promote different phase transitions. This is especially true when the species 
involved are solvates, therefore having solvent molecules in the crystalline 
structure. In this work, slurry experiments have been used to transform one 
solvate form into another (see Chapter 3 for more details). 
Slurry Experiments, general procedure: The active pharmaceutical ingredients 
used in this work have been donated by Dipharma Francis S.r.l., Baranzate (MI), 
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Italy. When necessary for the experiments, the solids were crystallized and/or 
otherwise treated before the slurry experiment. The solvents used were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and used without further purification. 
Slurries of the different crystal phases treated were generally carried out on 0.2-2 
g of substance. Typically, the solid was placed in a round-bottomed flask equipped 
with a thermometer and a reflux condenser and placed under magnetic stirring in 
inert atmosphere, generally nitrogen gas, at room temperature. The amount of 
solvent used varied depending on phase solubility. When necessary to work at 
non-ambient temperatures, a heated oil bath was used. The slurry times were 
generally between ten minutes and 2 hours. 
2.4.2 Other techniques 
Many other less conventional techniques are available when seeking to 
prepare a specific (or new) crystalline form, as mentioned at the beginning of this 
section. The only crystallization method apart from crystallization from solution 
that was used in this work is heating. Heating can be effective in promoting phase 
transitions and desolvation processes.  
Heating to induce desolvation and/or phase transition: In the instances where 
heating was required to obtain phase transitions, this was obtained by different 
means. When a vacuum was necessary to favor desolvation, a laboratory oven 
(operating in the 30-120°C renge) was used and connected to a mechanical 
vacuum pump. When heating at very specific and precise temperature was 
necessary, the heating was carried out until phase transition occurred directly in a 
DSC pan, as described in paragraph 2.3.1.  
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3. Packing Polymorphism of Bupropion Hydrohalides 
Bupropion, or (±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one, 
depicted in Scheme 3.1, is an atypical antidepressant belonging to the class of 
aminoketones. It is chemically unrelated to tricyclic antidepressants and, while its 
neurochemical mechanism of action is not well known, it is thought to act as a 
serotonin, norepinephrine and dopamine reuptake inhibitor. [1] Bupropion is 
used mostly as a smoking cessation aid and for Seasonal Affective Disorder (SAD). 
[2] 





Even though Bupropion has a stereocenter and has been successfully 
separated into the R and S enantiomers, it is generally used as a racemate 
because the enantiomers undergo rapid racemization. [3] Bupropion, now 
marketed under several names, was first prepared and studied in the early 1970s. 
[4] As Bupropion has an amine group and can form acid addition salts, it is 
marketed in salt form. In particular, it was initially prepared as hydrochloride salt, 
and was later introduced as hydrobromide salt, reported to have better 
characteristics, being more stable and less hygroscopic. [5]  
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Both Bupropion hydrochloride and hydrobromide have high solubility in 
water, belonging to Class I of the Biopharmaceutics Classification System [6, 7] 
(high solubility and high permeability). This implies that bioavailability is not 
limited by solubility, and that polymorphism can therefore have little impact on 
the safety and efficacy of the final product. However, solid-state issues can still be 
crucial for manufacturing and handling, particularly at the production and 
formulation stages (as is shown in this case by the introduction of the better 
performing hydrobromide salt over the hydrochloride salt). 
Both Bupropion hydrochloride and hydrobromide salts have been shown to 
exist in different polymorphic solid forms. In particular, two different anhydrous 
and unsolvated forms are known for each of the hydrochloride [8, 9] and 
hydrobromide [10] salts. Both salts have also been shown to form solvates. [15, 
11]  
Several crystal structures have been solved, both for the hydrochloride and 
the hydrobromide salts. In particular, the structures of the two anhydrous 
polymorphs of bupropion hydrochloride have been solved from powder data 
before the beginning of this work, while the two anhydrous polymorphs of 
bupropion hydrobromide have been solved from single crystal [12] after we had 
solved (but not published) the structures form powder data. The published 
structures confirm the data, here presented, obtained by us. In scientific and 
patent literature, the solved structures for an ethanol solvate of bupropion 
hydrochloride and a propanol solvate of bupropion hydrobromide have also been 
reported. [15, 11] 
The structures of both the anhydrous and the solvated phases show many 
interesting similarities, which will be discussed in detail in the following sections. 
The richness of the solid-state landscape of bupropion makes it a good research 
field for structural analysis, because it allows to explore similarities and 
differences between crystal phases, highlighting the key factors in crystal form 
diversity. In other words, by performing detailed structural analysis on a large 
number of crystalline structures with similar components, it may be possible to 




Isostructural salts, salts of different acids which show identical crystal 
packing, are particularly interesting because variations in solid state properties 
can be attributed mainly to the distinct properties of the different acids involved. 
This can be explained by the fact that crystal lattice contributions will be similar, 
therefore the main differences will be due to the acids involved. [13]  
In order to add to the solid-state landscape of bupropion and to explore 
further the possibility of isostructural salts, the pharmaceutically uninteresting but 
structurally relevant hydroiodide salt was prepared and studied, yielding four 
different anhydrous non-solvated polymorphs. Moreover, studying the 
desolvation of the known ethanol solvate of the hydrochloride salt, two additional 
non-solvated forms were observed. This yielded a total of ten anhydrous phases 
of bupropion salt with three different hydrohalide acids. 
As the known solvates of bupropion salts also showed interesting structural 
similarities, the solvation behavior of bupropion was also explored by preparing 
four new different solvates of bupropion hydrobromide and solving their 
structures from powder diffraction data. The crystal structure reported in the 
literature for the 1-propanol solvate of bupropion hydrobromide [11] presented 
some inconsistent features compared with the known structures of bupropion, so 
we decided to solve the structure again from single crystal. The data here 
presented for the propanol solvate of bupropion hydrobromide are therefore 
original. 
The solid forms of bupropion hydrohalide salts here characterized and 
explored are therefore ten anhydrous and un-solvated phases (four 
hydrochloride, two hydrobromide and four hydroiodide polymorphs) and six 
solvated phases (an ethanol solvate of the hydrochloride salt and five different 
solvates of the hydrobromide salt). 
3.1 Anhydrous Bupropion Hydrohalides 
The structures of two new bupropion hydrochloride polymorphs and the 
four new bupropion hydroiodide polymorphs, as well as the structures of the two 
known hydrobromide polymorphs,  were solved by state-of-the-art powder 
diffraction methods and compared with the known structures of the 
hydrochloride salt. A total of ten crystalline structure were therefore compared 
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for structural similarities. For clarity, Table 3.1 summarizes the nomenclature of 
all known salts and their polymorphs, together with literature references and brief 
comments regarding the identity of the forms. In particular, we believe the forms 
reported in the literature as forms II and IV to be the same form. This is further 
discussed in paragraph 3.1.1. 
3.1.1 Identity of Bupropion hydrobromide forms reported in the literature 
Hu and co-workers report in [12] the structure of an anhydrous form of 
Bupropion HBr they call form IV. Form IV is considered different from Bupropion 
HBr form II described in US 7,241,805 on the basis that the declared positions of 
the diffraction peaks are different. However, US patent US 7,241,805 does not 
report diffraction peak positions. Peak positions for form II are reported in patent 
application WO 2010/015692 and are reproduced in Table 3.2 alongside the peak 
positions declared by Hu and co-workers for form IV. The middle column of Table 
3.2 holds the difference between the corresponding peak positions reported for 
the two forms. The peak positions for Bupropion hydrobromide forms II and IV 
show that the two forms correspond in reality to the same crystal phase. The 
presence of a small systematic error in peak positions can be due to sample 
displacement or to other instrumental artifacts. 
In order to confirm the identity of Bupropion hydrobromide forms II and IV, 
the XRPD trace reported in the patent literature for form II was compared with 
the calculated powder pattern obtained from the structure of form IV (the 
structure designation in the Cambridge Structural Database is ICEPOX01).  
As the XRPD trace for form II (shown in Figure 3.1a) showed heavy 
preferred orientation and significant peak broadening, suitable corrections were 
performed to make the XRPD traces comparable. In particular, the program 
TOPAS-R was used to calculate a powder pattern from ICEPOX01. The preferred 
orientation along hkl direction (001) was taken into account by using the March-
Dollase formula (r=0.48). Beam overflow was added to the calculations to account 
for the low intensity of the peaks at lower angles. A small crystal size was 
employed to account for peak broadening. The calculated XRPD trace obtained is 
reported in Figure 3.1b. Figure 3.1c reports the calculated XRPD trace obtained 
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from ICEPOX01 without beam overflow, crystal size and preferred orientation 
corrections for comparison. 
The comparison of the XRPD traces confirms that Bupropion HBr forms II 
and IV correspond to the same crystalline phase. 







used in this 
work 
Bupropion · HCl 
Form I 
[8]  BClI 
Bupropion · HCl 
Form II 
[9]  BClII 
Bupropion · HCl 
Form III 
[14]  BClIII 
Bupropion · HCl 
Form IV 
[14]  BClIV 
Bupropion · HBr 
Form I 
[12] 
This form was initially characterized in [10] 
only by XRPD and DSC; subsequently the its 
crystal structure was published in [12] 
BBrI 
Bupropion · HBr 
Form II 
[10] 
This form was characterized in the patent 
literature by XRPD and DSC and corresponds 
to Bupropion·HBr Form IV published in [12]. 
See paragraph 3.3.1 for details. 
BBrII 
Bupropion · HBr 
Form IV 
[12] 
The structure here reported corresponds to 
Bupropion·HBr Form II published in [10]. See 
paragraph 3.1.1 for details. 
BBrII 
Bupropion · HI 
Form I 
[14]  BII 
Bupropion · HI 
Form II 
[14]  BIII 
Bupropion · HI 
Form III 
[14]  BIIII 
Bupropion · HI 
Form IV 




Table 3.2. Comparison of XRPD peak positions for Bupropion hydrobromide 
forms II and IV. 
Peaks attributed to 
Bupropion HBr Form II in 
WO 2010/015692 
[° in 2!] 
Difference between first 
and third column 
(average 0.12(3)°) 
Peaks attributed to 
Bupropion HBr form IV 
in Chinese J. Struct. 
Chem. 2011, 30(11), 
1591-1596 
[° in 2!] 
6.53 0.15 6.38 
12.18 0.10 12.08 
- - 12.78 
13.03 0.13 12.90 
14.18 0.14 14.04 
15.92 0.16 15.76 
16.52 0.12 16.40 
18.01 0.11 17.90 
18.83 0.08 18.75 
19.28 0.07 19.21 
- - 20.34 
20.67 0.10 20.57 
21.64 0.09 21.55 
21.95 0.13 21.82 
23.11 0.13 22.98 
24.18 0.09 24.09 
25.75 - - 
25.83 0.12 25.71 
26.83 0.11 26.72 
27.14 0.19 26.95 
27.87 0.13 27.74 
28.81 0.13 28.68 
29.67 - - 
30.07 0.14 29.93 
31.82 0.14 31.68 




Figure 3.1. Comparison of the XRPD trace of form II and the calculated 
powder pattern of form IV. 
a) Extract from WO2010/015692, Powder Pattern for Bupropion HBr form II 
 
b) Calculated Powder Pattern for ICEPX01 corrected for Preferred Orientation and 
Beam Overflow 
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3.1.2 Crystal Form Preparation 
The two new bupropion hydrochloride crystal forms were found by 
performing controlled desolvation of the ethanol solvate of bupropion 
hydrochloride (see section 3.2) using reduced pressure, variable temperatures 
and preparative DSC. The two forms, denominated forms III and IV (BClIII and BClIV 
in this work) were never obtained as monophasic samples, but only in mixtures. 
Powder diffraction allows to solve structures from non-monophasic samples, as 
long as the structure and composition of the contaminant phase is known. It was 
therefore possible to solve the structures of all phases.  
The previously reported ethanol solvate of Bupropion hydrochloride [15] 
was obtained by dissolving 2 g of bupropion hydrochloride in 8 mL of ethanol at 
reflux and rapidly cooling the resulting solution in an ice bath to obtain 
crystallization. Different desolvation protocols were specifically tailored to obtain 
a mixture rich in BClIII or in BClIV. 
A mixture rich in form BClIII was obtained by slow desolvation of the ethanol 
solvate at room temperature under reduced pressure. The XRPD of the mixture 
was recorded after several weeks and found to be a mixture of BClIII and BClI 
(about 15%). As the structure for form BClI was known, it was possible to solve the 
structure of form BClIII from the mixture of the two forms obtained. 
A mixture rich in form BClIV was obtained during a specifically designed 
preparative DSC experiment: after heating the ethanol solvate in a pierced 
aluminum sample holder to 110°C at 10°C/min under a flow of nitrogen, the DSC 
pan was opened and a mixture of BClIV (85%) and BClIII (15%) was retrieved. The 
data for form BClIII was then used to solve the structure for form BClIV from the 
mixture rich in BClIV .  
The chemical identity of the sample after thermal treatment was confirmed 
by 1H-NMR analysis.  Slightly different desolvation experiments yielded mixtures 
of different compositions, but never pure phases.  
Bupropion hydrobromide was obtained by dissolving 3 g of Bupropion 
hydrochloride in 7 mL of water and slowly adding aqueous KBr at room 
temperature under magnetic stirring until the formation of a precipitate was 
observed. The mixture was then heated to obtain complete dissolution and slowly 
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cooled to crystallize BBrII. The identity of the halide ion was confirmed by 
precipitation of the silver halide from a clear aqueous solution of the obtained 
solid using a 0.1 M solution of AgNO3. The yellow precipitate confirmed the 
identity of the bromide ion.   
A monophasic sample of BBrI was prepared by dissolving 20.0 g of BBrII in 
refluxing isopropanol (100 mL)  and water (8 mL) and rapidly cooling the mixture 
with an ice bath. The crystallized solid (pure BBrI) was isolated by filtration at 0°C. 
The structures of BBrI and BBrII were solved by powder diffraction methods, 
but during the course of this work the two single crystal structures discussed in 
previous paragraphs were published. The single crystal structures matched the 
structures solved by us by powder diffraction. In this work, the crystal and 
structural data obtained by powder diffraction are presented and used in the 
structural comparisons. 
Bupropion hydroiodide was obtained by dissolving 3 g of Bupropion 
hydrochloride in 7 mL of water at room temperature and adding aqueous KI drop 
by drop under stirring until the precipitation of a white solid was observed. The 
solid obtained, recovered by filtration at room temperature, was a mixture of BII 
and BIII. The identity of the halide ion was confirmed by precipitation of the silver 
halide with 0.1 M AgNO3 from a clear aqueous solution. The yellow coloring of the 
precipitate confirms the halide to be iodide and not chloride.  
Monophasic BII was obtained by recrystallizing 0.5 g of Bupropion 
hydroiodide in 5 mL of isopropanol and recovering the solid by filtration, while 
monophasic BIII was obtained by recrystallizing 0.5 g of Bupropion hydroiodide in 
2 mL of water and filtering the crystallized solid at 0°C. BIIII was obtained during a 
specifically designed preparative DSC experiment by heating BIII in a pierced 
aluminum pan under nitrogen flow to 198°C at 10°C/min, holding at 198°C for six 
seconds and quench cooling to room temperature. The DSC pan was opened and 
monophasic BIIII was retreived. The chemical identity of the sample after heating 
was confirmed by 1H-NMR. 
 Form BIIV was obtained by dissolving of 4.1 g of Bupropion hydroiodide in 5 
mL of refluxing trifluoroethanol. The clear solution obtained was then slowly 
concentrated at room temperature by evaporating the solvent under a flow of 
nitrogen. A white solid crystallized and was recovered by filtration. The sample of 
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form BIIV used for structure solution contained traces of KI, clearly visible in the 
powder diffraction trace as weak, sharp peaks. 
3.1.3 Crystal Data 
As the main aim of this work was structural comparison between the 
different phases, the first step was to compare the cell data from all forms 
analyzed. This is reported in Table 3.3. Figure 3.2 shows the final Rietveld 
refinement plots for the crystal forms solved from powder samples during this 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.2. Final Rietveld refinement plots for a) BClIII, b) BClIV, c) BBrI, d) 
BBrII, e) BII, f) BIII, g) BIIII and h) BIIV with difference plot and peak markers at the 
bottom. The insert shows the high angle region, magnified 5´.  
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Bupropion HBr Form II 100.00 %
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Careful comparison of the cell data for all forms analyzed reveals several 
interesting similarities. Firstly, the cells for the previously known forms BClII and 
BBrII are very similar to one another, having not only the same space group but 
also similar lattice constants. The small difference in volume can be explained by 
the larger size of the bromide ion compared with the chloride ion. 
Secondly, the cells for BClIII, BClIV, BBrI and BIIII have similar lattice 
constants, which may suggest the occurrence of an isostructural group. However, 
the marked difference in the interaxial angles between BClIII and the other three 
solid forms, not recoverable by any cell transformation, suggests the occurrence 
of two different (triclinic) supramolecular arrangements. 
Finally, the cells of BII and BIII appear to have some correlation, as the space 
group is the same and the cell axes have similar values, although scrambled. This 
suggests structural similarities to be explored and analyzed. 
The reported observations regarding space groups and cell constants 
constituted a starting point for our crystal packing analysis, further discussed in 
paragraph 3.1.3. Also, other interesting observations may be made regarding 
crystal density. The V/Z values for the different phases were charted and 
compared, showing, predictably, a trend in the molar volumes of the phases 
according to the identity of the hydrohalide ion involved. This is reported in Figure 
3.3. Worthy of note, the point which lies outside the expected trend refers to the 
V/Z value of BBrII. This value has been confirmed by single crystal data, as 
discussed in previous paragraphs. [12]  














3.1.4 Bupropion molecular conformation 
Molecular conformation is an important aspect when studying crystalline 
phases, as it can offer insight on how stable a phase is and how likely it is to form. 
Conformational analysis and comparison are addressed by observing the freely 
rotating dihedral angles (also used for structure solution, see Chapter 2), like for 
example those describing side chains. The relevant dihedral angles used in 
describing molecular conformation (and during structure solution from powder 
diffraction data) of the bupropion molecule are shown in Scheme 3.2. 
Scheme 3.2. Bupropion ammonium ion and the torsion angles used to 
describe molecular conformation 
 
 The side chains of bupropion molecules in all phases analyzed adopt a 
similar conformation, the observed values being summarized in Table 3.4a. As 
expected, the most variable conformational descriptor in the different forms is "4, 
addressing the syn (C6-C5-C7-C8 torsion near 180°) or anti (near 0°) disposition of 
the Cl-Ar and CO residues. The rest of the molecule, in particular the side chain, 


































































































































































































































































































































































































































































































































































































































































































The fact that all crystalline forms so far isolated contain the Bupropion 
molecule in very similar conformation suggests that it is energetically very 
favored. In order to verify and analyse this, molecular mechanics optimizations 
were performed for Bupropion molecules in the gas phase [16]. A conformational 
scan was run, yielding several local minima. The potential energy values derived 
using the MM3 force field for the two best (but significantly different) 
conformations (syn and anti, addressed by "4) are nearly identical (see Table 3.4b), 
the calculated energy difference between the two conformations being only 0.23 
kcal mol-1 ("1, "2 and "3 differing by 0.2° or less). Worthy of note, angles "1 and "3 
have values similar to those observed in the solid state. This suggests that this 
conformation is indeed energetically favored. However, "2 (in the gas phase 
approaching the -175° value) is significantly different from that observed in the 
solid state (with absolute values falling in the narrow 74-85° range). The 
significance of the values of the dihedral angles is that in the gas phase 
calculations, the main side chain of bupropion is positioned in an all trans 
conformation, while in the solid state, the main chain is positioned in a gauche 
conformation at dihedral "2. A closer inspection of the dihedral angles of 
bupropion and their significance on overall conformation shows that "2 is 
responsible for the orientation of the hydrogen atoms bonded to the nitrogen 
atom, therefore affecting the ability of the molecule to form hydrogen bonds. This 
is particularly significant because of the hydrogen bond scheme found in all 
bupropion crystalline phases described in the next paragraph. A gauche 
conformation at "2 causes the hydrogen atoms on the nitrogen to be more 
available for hydrogen bonding. Molecular modelling calculations in the gas phase 
and comparison with the conformation in the crystal structure of a solvated form 
of bupropion have also been carried out by Froimovitz and others, [15] 
substantially confirming our findings. 
All ten phases of anhydrous bupropion hydrohalides show the same 
hydrogen bond motif, being made up of bupropion molecule dimers held together 
by hydrogen bonding between two bridging halide ions and two NH2
+ moieties, as 
schematically shown in Figure 3.4, generating a centrosymmetic unit. According to 
the graph set notation discussed in Chapter 1, [17] this hydrogen bond motif is 
classified , as it is a ring structure made up of 8 atoms and held together by 
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four hydrogen bond donors (the hydrogen atoms covalently bonded to the 
nitrogen atoms) and two hydrogen bond acceptors (the halide ions). 
Figure 3.4. Supramolecular arrangement of bupropion hydrohalide dimers 
(The form depicted is HBrII, which possesses an anti conformation) 
 
The formation of a dimer is an optimal supramolecular arrangement for 
Bupropion hydrohalide molecules, as it allows hydrophilic and charged groups to 
interact with one another within the dimer core (in particular the halide ions and 
the ammonium groups), leaving the more hydrophobic and less polarized groups 
on the outside (the methyl and terz-butyl group on the side chain). All dimers are 
generated by crystallographic inversion symmetry, as an inversion point is 
positioned at the center of the rhombus formed by the halide ions and 
ammonium groups). This suggest that the enantiopure salts, prepared by others 
[18] but not studied here, may show a different supramolecular arrangement.  
On the basis of these results, it is possible that in relatively concentrated 
solutions, Buproprion hydrohalides may also exist as dimers, possibly detectable 
by DOSY NMR experiments. In the 1H-NMR experiments in solution conducted on 
the different hydrohalide salts (the values of peak positions, attributions and J-
couplings are reported in Table 3.5) using a concentration ranging from 0.03 to 
0.08 M, however, the chemical shifts of the ammonium protons, independent of 
sample concentration, suggest that at the concentrations analyzed and using a 
hydrogen bond acceptor as a solvent (d6-DMSO), an ionic pair is maintained, but 
the interaction between the halide ion and the ammonium group of the 
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Bupropion molecule happens with one ammonium proton only. This is suggested 
by the fact that the two ammonium protons (the attribution was confirmed by 
exchanging with D2O) have different resonance frequencies, as shown in Table 
3.5. Moreover, one of the two protons (arbitrarily called HN2 in Table 3.5) has 
different frequencies in the three salts. This is justified only if the proton interacts 
with the halide ion, as the bupropion ammonium ion is identical in the three 
cases. Also, while the signal of HN1 (being a multiplet) shows both the geminal 
coupling with HN2 and the vicinal coupling with the hydrogen on the carbon atom 
the nitrogen is bonded to, the signal for HN2 (a doublet) only shows the geminal 
coupling. Assuming that there is free rotation in solution around the N-C bond and 
therefore the vanishing of this coupling cannot be attributed to a specific blocked 
conformation, we tentatively attribute this phenomenon to the formation of 
hydrogen bonding with the halide ion with significant elongation and polarization 
of this N-H bond.  
In order to understand and explain fully the conformation of the bupropion 
molecules in the hydrogen-bonded dimers, more molecular modelling calculations 
in the gas phase were carried out. In search for a local minimum of the potential 
energy hypersurface which could geometrically approach the conformations 
observed in the different polymorphs, the value of "2 was arbitrarily restrained to 
-80° (chosen because it is close to the value "2 adopts in the solid state to allow 
the hydrogen bonding scheme present in the dimer). The most stable conformer 
obtained in this way (third row in Table 3.4b) closely matches the geometry of the 
syn Bupropion molecules found in the solids, with an energy difference of only 
+3.83 kcal mol-1 above the absolute minimum. Obviously, this small energy 
difference can be easily compensated by the solid state stabilizing effects (mainly 





Table 3.5. 1H-NMR frequencies (given in ppm using TMS as external 
standard) for Bupropion hydrochloride, hydrobromide and hydroiodide salts (in 












































Hydrogen Bupropion HCl Bupropion HBr Bupropion HI 
HtBu 1.30 (s) 1.29 (s) 1.28 (s) 
HMe 1.52 (d, J=7.0 Hz) 1.49 (d, J=7.0 Hz) 1.47 (d, J=7.2 Hz) 
H1 5.28 (m) 5.30 (m) 5.28 (m) 
HAr3 7.64 (m) 7.65 (m) 7.66 (m) 
HAr4 7.82 (d, J=8.1 Hz) 7.84 (d, J=7.9 Hz) 7.84 (d, J=8.1 Hz) 
HAr2 8.15 (d, J=8.1 Hz) 8.15 (d, J=7.9 Hz) 8.14 (d, J=8.1 Hz) 
HAr1 8.24 (s) 8.25 (s) 8.25 (s) 
HN1 8.59 ( broad m) 8.58 (broad m) 8.56 (m) 
HN2 9.52 (d, J=12.3 Hz) 9.16 (d, J=11.7 Hz) 8.93 (d, J=12.3 Hz) 
3.1.5 Crystal Packing Analysis 
As all bupropion hydrohalide phases analyzed and discussed so far show the 
same dimer structure held together by hydrogen bonding, the differences 
between crystal structures must originate from different packing of the dimer 
structures. The packing motifs of the different phases must therefore be the key 
to crystal structure diversity. 
As discussed in paragraph 3.1.1, the cell data for forms BClII and BBrII appear 
to be very similar. A closer look at crystal packing reveals the two phases to be 
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indeed isostructural, differing only in the identity of the halide ion. This is shown 
in figure 3.5.  
Figure 3.5. Comparision of the structures of a) BClII and b) BBrII.  
a)  
b)  
The similarity of the cell axis lengths and the identity of the space group in 
BClIII, BClIV, BBrI and BIIII may suggest the occurrence of an isostructural group. 
However, there is a marked difference in the interaxial angles between BClIII and 
the other three solid forms, not recoverable by any cell transformation. This 
suggests the occurrence of two different (triclinic) supramolecular arrangements. 
A closer look at the packing of the molecule dimers confirms this observation. In 
fact, while in forms BClIV, BBrI and BIIII the dimers are stacked in straight rows, in 
BClIII the stacks are canted in slanted rows. This is particularly evident when 
viewing the structures along the a axis, as shown in Figure 3.6. Forms BClIV, BBrI 
and BIIII are therefore isostructural, differing only in the identity of the halide ion, 




Figure 3.6. Comparison of the bupropion hydrohalide structures of space 
group P-1: a) BClIV, b) BBrI, c) BIIII and d) BClIII.  
a) b)  
c) d)  
BII and BIII have unit cell dimensions and space group symmetry different 
from any other form, but they appear to be similar to one another, as they 
crystallize within the same space group and with similar cell constants, though 
scrambled. This alone implies a different internal symmetry. In fact, a more 
accurate analysis of the packing shows significant differences. In both cases, 
dimers are stacked along the short axis (which represents the height of two 
stacked bupropion dimers) and organized in long chain-like structures parallel to 
the long axis but, while in BIII the dimers are stacked vertically when viewed along 
the medium axis, in BII the stacks are slanted. Moreover, when projecting the 
packing down the short axis to view the chain-like structures, the bupropion 
dimers are organized in a greek key motif in BII and in straight lines in BIII. This is 





Figure 3.7. View of a) BII and b) BIII along the short axis (a for BII, b for BIII). 
a)  
b)  
Finally, forms BClI and BIIV appear to be structurally unrelated to all other 
bupropion hydrohalide forms previously observed. While they are still made up of 
bupropion hydrohalide molecules (respectively, of the syn and anti type) mutually 
embraced in the usual hydrogen bond motif encountered previously, 
both packings are different from that of any other structure analyzed. In form BClI 
the dimers are packed in alternating slanted columns, while in form BIIV the 




Figure 3.8. Crystal packing of a) BClI viewed along the c axis and of b) BIIV 
viewed along the a axis. 
a) b)  
3.1.6 Energetic Considerations 
As discussed in Chapter 1, the thermodynamic relations between 
polymorphs are often crucial for understanding relative stability and thermal 
behavior. However, straightforward and simple conclusions are not always easy to 
achieve, especially when more than two different polymorphs of the same 
substance are to be compared. 
The previously known forms of the hydrochloride salt, BClI and BClII, have 
been reported to be enantiotropically related to one another, BClII being more 
stable at low temperatures. [9] Unfortunately, as described above, forms BClIII and 
BClIV were obtained only in mixtures by partially controlled (to the best of our 
abilities) desolvation of the ethanol solvate. This made it impossible to determine 
the thermodynamic relationships of forms BClIII and BClIV with the known 
hydrochloride forms.  
The thermal behavior of the two known forms of the hydrobromide salt has 
been discussed in the literature. [19] The endothermic conversion from BBrII to 
BBrI at high temperature, together with fact that the molar volume for form BBrII 
is much lower than the molar volume of form BBrI (see Figure 3.3) demonstrates 
that forms BBrI and BBrII are also enantiotropically related, with form BBrII more 
stable at low temperatures.  
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As for the hydroiodides, the thermodynamic relations between the 
different forms are not easy to unravel. Not only are the molar volumes very close 
for the different forms, but the DSC traces, shown in Figure 3.9, offer little 
information. Forms BII and BIIV show no event before the melting point (195.6°C 
and 193.7°C, respectively). Form BIII melts (m.p. 192.7°C) and then recrystallizes 
into form BIIII (m.p. 200.2°C) , but this observation alone does not allow to 
determine if the two forms are monotropically or enantiotropically related. [20] 
Figure 3.9. DSC traces for a) BII b) BIII and c) BIIV.   
a)  b)  
c)  
3.2 Isostructural Burpopion Hydrohalide Solvates 
In addition to the two known solvates, an ethanol solvate of bupropion 
hydrochloride (BClEtOH in the text) and a 1-propanol solvate of bupropion 
hydrobromide (BBrPrOH), the structures of which are reported in the literature, 
four new solvates of bupropion hydrobromide were prepared and three of the 
four structures solved from powder data. In particular, the forms observed are 
solvated with ethanol (BBrEtOH), trifluoroethanol (BBrTFE), ethylene glycol (BBrGly) 
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and tetrahydrofuran (BBrTHF). It was not possible to solve the structure for BBrTHF 
due to rapid loss of solvent and conversion into a different form. It was only 
possible to determine its crystallographic cell constants.  
As is described in the following paragraphs, all solvated form are made up 
of centrosymmetric dimers like already observed for the un-solvated phases. 
However, the crystal structure of BBrPrOH reported in the literature [11] is 
described as made up of non-centrosymmetric dimers constituted by two 
crystallographic independent but very similar bupropion molecules. Analyzing the 
structure with the publicly available software Platon, [21] it was found that the 
molecules had very little deviation from a centro-symmetric dimer (the largest 
deviation on a single atom was 0.3 Å). The attribution of space group P1 instead of 
P-1 is a relatively common mistake, as is reported in the literature, [22] and as the 
structure reported for BBrPrOH did not seem to us consistent with the rest of the 
structures observed, it was decided to solve the structure again from single crystal 
data. The structure here reported for BBrPrOH is therefore determined by us on 
original data. 
3.2.1 Solvate Form Preparation 
Form BClEtOH was obtained by dissolving 2 g of bupropion hydrochloride in 8 
mL of ethanol at reflux and rapidly cooling the resulting solution in an ice bath to 
obtain crystallization. Single crystals of BBrPrOH were obtained by dissolving a few 
milligrams of bupropion hydrobromide in a couple of milliliters of 1-propanol and 
leaving the solution to slowly evaporate at room temperature. Form BBrEtOH was 
obtained by slow cooling of a solution containing 4.0 g of Bupropion 
hydrobromide in 20 ml of ethanol heated to reflux. Form BBrEtOH thus obtained 
was not monophasic, but contained trace amounts of form BBrI visible in the 
XRPD spectrum. This was taken into consideration during structure solution and 
refinement. Monophasic BBrGly was obtained by crystallizing 20 g of Bupropion 
hydrobromide in 27 ml of ethylene glycol. After filtration on a Buchner funnel, the 
solid was washed with small amounts of acetone to remove the excess ethylene 
glycol. Forms BBrTFE and BBrTHF were obtained by slurrying BBrGly in different 
solvents at room temperature. Monophasic BBrTFE was recovered after slurrying 
2.0 g of BBrGly in 2 ml of trifluoroethanol at room temperature overnight. A 
mixture containing BBrTHF (in our best attempt) was obtained by slurrying 1.0 g of 
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BBrGly in 3 ml of tetrahydrofuran for about fifteen minutes at room temperature. 
The sample thus obtained, being a mixture of BBrTHF, BBrGly and BBrI, was only 
suitable for indexing and crystal cell determination. 
3.2.2 Crystal Data 
The crystal data for all six solvates of bupropion hydrohalide salts are 
reported in Table 3.6. Figure 3.10 shows the final Rietveld refinement plots for the 
phases solved by powder diffraction methods, BBrEtOH, BBrTFE and BBrGly. Appendix 
A reports the atomic coordinates of the phases.  
Figure 3.10. Final Rietveld refinement plot for a) BBrEtOH (containing small 
amounts of BBrI) b) BBrTFE and c) BBrGly with difference plot and peak markers at 
the bottom. The insert shows the high angle region, magnified 5´.  
a)  
b)   
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Table 3.6. Comparative crystal cell data of different solid forms of 
Bupropion hydrohalides  (E.s.d.s in parentheses). 
 
































FW [g mol-1] 299.23 350.70 343.6 376.6 351.6 356.6 
Crystal System Triclinic Triclinic Triclinic Triclinic Triclinic Triclinic 
Space Group P-1 P-1 P-1 P-1 P-1 P-1 
a [Å] 7.571(1) 7.827(6) 7.7746(2) 7.9000(2) 7.8338(2) 7.804 
b [Å] 9.310(1) 9.392(6) 9.3626(3) 9.3673(2) 9.3544(2) 9.438 
c [Å] 11.687(1) 11.838(9) 11.6801(2) 11.7354(3) 11.5267(2) 12.113 
a [°] 85.42(1) 85.70(6) 85.99(1) 86.425(1) 87.05(1) 86.72 
b [°] 101.49(1) 101.75(7) 101.39(2) 102.501(2) 103.42(2) 100.12 
g [°] 89.85(1) 90.37(6) 90.18(3) 91.033(2) 90.29(3) 91.87 
V [Å3], Z 804.5, 2 849.6, 2 828.3, 2 846.2, 2 820.5, 2 876.7, 2 
V/Z 402 425 414 423 410 438 
T [K] 293 293 293 293 293 293 
 ![Å] 1.54178 0.71073 1.54178 1.54178 1.54178 1.54178 
"calc [g cm




4.83 4.91 4.92 - 
RBragg
 - 0.047 0.058 0.048 0.067 - 
*Two angles, # and g, were changed to the supplementary value to make 
the cell comparable with the other solvates. 
§The solvate with THF was observed and the crystal cell obtained, but the 
structure was not solved, as the sample was obtained only in mixture with other 




Analogously to the unsolvated phases, several interesting similarities 
between the crystal data of the different phases is observed. First of all, all the 
solvates appear to belong to the same P-1 space group. Secondly, the lattice 
constants seem rather similar in all cases, after accounting for the difference in 
size of the solvent molecules present in the different phases. In order to verify 
this, the molar volume V/Z for each solvated hydrobromide phase was plotted 
against the calculated molar volume of the solvent present. The molar volumes of 
the solvents were calculated form tabulated average atomic volumes. [23] The 
graph obtained is reported in Figure 3.11, and shows good correlation between 
the molar volume of the solvates and of the solvents, suggesting structural 
correlation between the different solvated phases. The only outlier is BBrGly, as 
will be explained in the following paragraphs. 
Figure 3.11. Plot of V/Z for the solvates of Bupropion hydrobromide against 
the calculated molecular volumes of the different solvents. 
 
3.2.3 Structural Analysis and Comparison 
A first analysis of the conformation of the bupropion molecule in the 
solvated phases showed not only a similarity in the bupropion molecule (in 
particular having syn conformation of the chlorine atom bound to the aromatic 
ring with respect to the carbonyl oxygen), but also a strong resemblance with the 






















Calculated Molecular Solvent Volume [Å3] 
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values of the dihedral angles describing molecular conformation in the solvated 
phases are collected in Table 3.7. 
Table 3.7. Synoptic collection of the most relevant conformational features 
of the bupropion molecule in the different solvate forms. Where available, e.s.d.s 











BClEtOH 172.0 -81.2 146.6 170.0 syn 
BBrPrOH 172.2 -83.4 150.4 171.2 syn 
BBrEtOH 179.0(8) -86.1(6) 144.8(4) -163.6(4) syn 
BBrTFE 169.0(7) -81.4(6) 147.9(3) -168.7(4) syn 
BBrGly 169.3(7) -83.4(5) 149.5(3) -163.8(3) syn 
Moreover, as is the case with the unsolvated phases, the bupropion 
hydrohalide structure in all solvated phases is composed of [(bupropionH)2X2] 
dimers held together by the same NH---X---HN bridging hydrogen bond 
motif.  
The analysis of the packing of the bupropion dimers and of the positioning 
of the solvent molecules shows the isostructurality of all solvates analyzed. 
Different isostructural (or isomorphous) solvates have the same type of molecular 
network of the host molecule, inside which the different solvent molecules are 
accommodated. [24] The phenomenon of isomorphic solvates is not uncommon. 
Two examples reported in the literature are the solvates of phenylbutazone and 
finasteride. [25, 26] In this case, the bupropion dimers are stacked diagonally, 
leaving spaces in the lattice in between the diagonal stacks where the solvent 
molecules are positioned. The packing of the different solvated phases analyzed 
(isooriented for easy visual comparison, highlighting the isostructural nature of 
the solvates) is shown in Figure 3.12. 
The solvent molecule is positioned in all cases on an inversion center, 
therefore resulting always disordered when the molecule is non-centrosymmetric 
(as is the case with all solvent molecules except for ethylene glycol). The 
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occupancy of the atoms of the solvent molecules is 0.5, as only half of the sites 
are occupied (all the phases were found to be emisolvates). During structure 
solution for forms BBrEtOH and BBrTFE, therefore, the solvent molecules were 
designed using a Z-matrix having a dummy central atom which was placed on an 
inversion center. The solvent molecule was then rotated but not moved during 
structure solution, and only during the final Rietveld refinement was the position 
of the molecule freed. The solvent molecules in all phases  form additional 
hydrogen bonds by acting as hydrogen bond donors, in particular forming a 
hydrogen bond between their hydroxyl groups and the halide ion. This is depicted 




Figure 3.12. Views of the packing of a) BClEtOH, b) BBrPrOH, c) BBrEtOH, d) 
BBrTFE and e) BBrGly along the a axis. 
a) b)  
c) d)  
e)  
In BBrGly, the ethylene glycol molecule is positioned, as is the case with the 
other solvates, on the center of symmetry of the crystallographic cell and, being a 
centrosymmetric diol, forms two hydrogen bonds with two different bromide 
ions, one with each hydroxyl group. This, as shown in Figure 3.14, causes the 
solvent molecule to be exactly positioned and not disordered, as is the case with 
the other solvates. The double hydrogen bond between the ethylene glycol 
molecule and two different bromide ions also causes the molar volume of BBrGly 
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to be out of the trend shown in Table 3.11. During structure solution, the ethylene 
glycol molecule was described by a Z-matrix having a central dummy atom 
position in an inversion center, but only half of the molecule was described with 
atoms having occupancy 1, leaving the inversion center to generate the other half 
of the molecule.  
Figure 3.13. Relative positioning of the bupropion dimer and the solvent 
molecule in a) BClEtOH, b) BBrPrOH, c) BBrEtOH and d) BBrTFE to show the disorganized 
solvent molecules. 
a) b)  
c)  d)  
Figure 3.14. Relative positioning of the bupropion dimer and the ethylene 




The hydrogen bonding between the solvent molecules and the halogen 
atom was confirmed by analyzing the atom scheme in all solvated phases. The 
distances between the oxygen of the hydroxyl group of the solvent and its closest 
neighbors capable of accepting hydrogen bonding (the halogen ion, the oxygen of 
the carbonyl group and the chlorine atom on the aromatic ring) were tabulated 
and corrected for Van Der Waals radii of the neighbors to correctly asses the 
atomic distance. This, shown in Table 3.8, allows to determine that the solvates 
indeed form hydrogen bonds with the halide ion. 
Table 3.8. Distances between the hydroxyl oxygen of the solvent and its 
closest neighbors corrected to account for the Van Der Waals radii of the different 
atoms.  
The values were obtained by taking the interatomic distances between the 
solvent oxygen and the halide ion, the carbonyl oxygen and the chlorine on the 
aromatic ring and subtracting the Van Der Waals radius of the neighbor. The Van 
Der Waals radii used are as follows: Cl = 1.75 Å, O = 1.52 Å, Br = 1.85 Å. 
 O---X- [Å] O---O=C [Å] O---Cl-Ar [Å] 
BClEtOH 1.64 1.74 2.11 
BBrPrOH 1.61 1.76 2.29 
BBrEtOH 1.69 1.80 1.96 
BBrTFE 1.45 1.62 2.16 
BBrGly 1.54 1.82 2.26 
Even though it was not possible to solve the structure of BBrTHF, having 
obtained only a mixture of BBrTHF, BBrGly and BBrI, it was still possible to obtain the 
cell parameters for BBrTHF. As already discussed, the cell, reported in Table 3.6, 
appears very similar to the cells of the other solvated phases. Having observed the 
isostructurality of all the solvated phases analyzed, it is reasonable to conclude 
that the structure of BBrTHF is also similar to that of the other solvates. The 
formation of hydrogen bonding between the hydroxyl group of the solvents and 
the halide ions, previously discussed, also allows to explain the relative stability of 
the tetrahydrofuran solvate. As the solvent molecule has no hydrogen bond 
donor, it cannot stabilize the structure via hydrogen bonding. The solvent is 
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therefore more weakly retained in the structure and the phase undergoes rapid 
desolvation at ambient temperature and pressure. 
In order to understand and try to predict the behavior of the solvates upon 
desolvation, the crystal structure of the isomorphous solvates of buproprion 
hydrohalides was compared with the structure of the unsolvated phases. The 
solvates appear to have a lot in common with the P-1 family of structures 
discussed in section 3.1, because the bupropion dimers in the solvates appear to 
be stacked along the a axis in slightly rotated stacks, causing the formation of 
narrow channels along the a axis to accommodate the solvent, as is shown in 
Figure 3.15. This disposition is analogous to the P-1 family of structures, where 
the dimers are also stacked along the a axes and organized in straight (BClIV, BBrI 
and BIIII) or slanted (BClIII) rows. It is therefore reasonable to expect the solvates 
to convert into a P-1 phase upon desolvation. 
Figure 3.15. Schematic comparison between the organization of bupropion 




3.2.4 Desolvation Experiments 
In order to confirm the hypotheses made regarding the desolvation 
behavior of solvated phases based upon the structural relations between solvated 
and non-solvated phases, as discussed in the previous paragraph, various 
desolvation experiments were carried out on all solvates in different conditions. 
The desolvation process was studied using ovens operating at reduced pressure 
and DSC. 
The desolvation of BClEtOH, described in paragraph 3.1.2, led to mixtures of 
BClIII and BClIV, as hypothesized by the structural relation between the phases 
discussed in the previous paragraph. Mixtures obtained after slow desolvation 
processes often also contained BClI, probably due to a conversion of BClIII or BClIV. 
It was not possible to confirm this due to the fact that BClIII or BClIV were never 
obtained as pure phases.  
All solvated phases of bupropion hydrobromide converted into BBrI upon 
desolvation. The only difference between the different hydrobromide phases was 
the temperature at which the bulk conversion occurred. For example, while BBrGly  
is very stable at room temprature and doesnt convert into BBrI when heated at 
reduced pressure until about 100°C, BBrEtOH, BBrPrOH and BBrTFE fully convert into 
BBrI at much lower temperatures. This is probably due to the fact that the 
ethylene glycol molecule in BBrGly forms two hydrogen bonds with bromide ions, 
while the ethanol, propanol and trifluoroethanol molecules, respectively in 
BBrEtOH, BBrPrOH and BBrTFE, only form one hydrogen bond each. 
Where obtained, monophasic samples of all solvates of bupropion salts 
were analyzed via DSC. The DSC analyses are reported in Figure 3.16. In all cases, 
the desolvation event is clearly visible as an endothermic band. The desolvation 
enthalpies &Hdesol, collected in Table 3.9, are all very similar to one another, with 
the exception of BBrGly, which has a significantly higher &Hdesol. This could be 
attributed to the presence of two hydrogen bonds between the solvent molecule 
and the rest of the crystalline structure. Also, the shape of the event is different 
compared with the desolvation events of the other solvates, being apparently 
made up of two superimposed events. After an event comparable to the 
desolvation of other solvates, a broad event continues until about 160°C. This 
phenomenon, highlighted in Figure 3.16e, is tentatively attributed to the fact that, 
110 
 
when the hydrogen bonds are broken and the solvent molecule leaves the 
structure, ethylene glycol, unlike the other solvents, is still well below its boiling 
temperature, and needs more energy to vaporize. 
BBrTHF is less stable than the other solvates examined and very rapidly 
converts into BBrI at room temperature. As discussed above, the decreased 
stability of BBrTHF compared with the other solvates might be explained by the 
lack of hydrogen bond donors on the tetrahydrofuran molecule, which makes it 
impossible for the solvent molecule to form hydrogen bonds with the bromide ion 
as is the case with the other solvents.  














Figure 3.16. DSC analyses for a) BClEtOH, b) BBrPrOH, c) BBrEtOH, d) BBrTFE and 
e) BBrGly. The unusual shape of the desolvation event for BBrGly is highlighted with 
a red rectangle. 
a)   b)   
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4. Structural Analysis of Nortriptyline Hydrochloride 
Polymorphs 
Nortriptyline hydrochloride, reported in Scheme 4.1, is a tricyclic 
antidepressant [1] belonging to a class of similar molecules which have been 
marketed for various psychiatric disorders for more than fifty years. Tricyclic 
antidepressants share a similar chemical structure, as well as similar 
mechanisms of action. In particular, they increase brain levels of norepinephrine 
and serotonin and block the action of acetylcholine. [2] This class of molecules 
also has antihistaminic effects and can cause sedation. 







In particular, nortriptyline hydrochloride has been on the market for a 
long time with many different trade names. The crystal chemistry of 
nortriptyline hydrochloride, known to exhibit polymorphism, is, however, 
scarcely investigated. Even though the polymorphic form of nortriptyine 
hydrochloride will have little or no influence on the bioavailability of the drug as 
nortriptyline hydrochloride falls in class I of the Biopharmaceutics Classification 
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System [3, 4] (high solubility and high permeability compounds), knowledge of 
solid-state features can still be important to address processability or 
formulability issues at the production and processing levels. For example, it can 
highlight the conditions of possible interconversions between polymorphs, 
address their stability ranges and explain unexpected solid-state behaviour. 
As discussed in Chapter 1, there can be several different driving forces for 
polymorphism, for example, different hydrogen bonding scheme, molecular 
conformations or packing patterns. The comparison of crystal structures of 
similar molecules can offer insight into the solid-state behaviour of related 
species. As the class of tricyclic antidepressants is rich in structurally related 
molecules, similar crystal structures can be used for comparison with 
nortriptyline hydrochloride. In particular, the most similar compounds with 
solved crystal structures are the hydrochlorides of amitriptyline [5], 
cyclobenzaprine [6] and dothiepin [7], shown in Scheme 4.2. 
Scheme 4.2. Structural analogues of nortriptyline hydrochloride, a) 
amitriptyline hydrochloride, b) cyclobenzaprine hydrochloride,  c) dothiepin 














b) c)a)  
4.1 Nortriptyline Hydrochloride 
Nortriptyline hydrochloride exhibits polymorphism, as it can crystallize in 
two different anhydrous forms. In fact, a paper by McCalman and co-worker [8] 
reports the crystallization behaviour of the hydrochloride salt of nortriptyline, 
describing two different polymorphs,   and ! (respectively NOR*HCl  and 
NOR*HCl! in the text). However, little or no information was available until 
recently in the literature on the properties of the different crystal forms. 
Actually, while one crystal structure has been known for a long time, [9] it has 
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not been made clear to which polymorph it corresponds until our recent work. 
[10] 
The two crystalline forms of nortriptyline hydrochloride, forms  NOR*HCl  
and NOR*HCl!, show very similar properties including solubility, crystal habit 
and chemical stability. Moreover, both appear indefinitely stable once isolated. 
In order to investigate the solid state properties, the missing structure was 
solved by powder diffraction methods and structural comparison was used as a 
tool to understand polymorphic behavior. 
4.1.1 Crystal Data 
By comparing XRPD data and the published coordinates, the crystal 
structure present in the literature was found to be form NOR*HCl!. The 
structure of  NOR*HCl  was therefore solved by powder diffraction methods. 
Initially, laboratory powder diffraction data was used for indexing, crystal cell 
determination and structure resolution. However, several unusual 
characteristics of NOR*HCl  were observed. Firstly, the proposed space group, 
P2/c, is rather unusual. Secondly, the structure found, instead of having one 
single site for the chloride ion, showed two crystallographically independent 
sites, each lying on a special position (as will be discussed in paragraph 4.1.2). 
For these reasons, it was decided to verify the structure using powder diffraction 
data obtained on a synchrotron source (see Chapter 2). The peculiar 
characteristics of NOR*HCl  were confirmed. 
Both forms were found to belong to a monoclinic space group and to have 
rather similar cell constants, though with a different interaxial angle and 
different space group symmetry. The crystal data for the two forms are reported 
in Table 4.1, while Figure 4.1 reports the final Rietveld refinement plot for form 




Table 4.1. Comparative crystal cell data of forms  NOR*HCl  and 
NOR*HCl! (E.s.d.s in parentheses). 
 NOR*HCl! NOR*HCl  
Reference [9] [10] 
Chemical Forumula C19H21N·HCl C19H21N·HCl 
Formula weight [g mol-1] 299.84 299.84 
Crystal System Monoclinic Monoclinic 
Space Group P21/c P2/c 
a [Å] 5.070(2) 9.99126(6) 
b [Å] 34.088(5) 5.10021(3) 
c [Å] 9.976(1) 34.1636(1) 
!"[°] 90.74(2) 98.684(6) 
V [Å3] , Z 1723.97, 4 1720.93, 4 
V/Z 431 430 
T [K] 295 293 
#"[Å] 0.70930 0.827006 
$(calc) [g cm
-1] 1.16 1.16 
RBragg 0.046 0.047 
Figure 4.1. Final Rietveld Refinement plot for NOR*HCl "on synchrotron 
data with difference plot and peak markers at the bottom. The insert shows the 
high angle region, magnified 5´. 
 
4.1.2 Structural Analysis 
The"molecule"of"nortriptyline"was"characterized"by"a"number"of"chemically"
relevant"conformational"parameters,"as"well"as"by" the" relative"conformation"of"





to" compare" molecular" conformation" in" the" different" crystal" structures" under"
analysis." Nortriptyline" is" shown" in" Scheme" 4.3" in" its" non-protonated" neutral"
form,"but"it"was"modelled"as"protonated"in"structure"solution." 
The" torsion" angles" of" the" N-protonated" nortriptyline" molecule" in" both"
NOR*HCl " and" NOR*HCl!" phases" are" very" similar," as" is" shown" by" the" values"
reported" in"Table"4.2"and"pictorially"exemplified" in" Figure"4.2." Importantly,"not"
only"the"torsional"features"of"the"flexible"side"chain"can"be"considered"analogous"
(addressed" with" angles" %1-4)," but" also" the" twisting" at" the" ethylene" group"
(addressed"by" the"&1-2" angles),"which"describe" the"conformation"of" the" seven-
membered"ring." 
Scheme" 4.3." Schematic" drawing" of" the" nortriptyline" molecule" together"
with"the"torsion"angles"discussed. 
 






Table" 4.2." Synoptic collection of the most relevant conformational 
features of the nortriptyline molecule (E.s.d.s, where available, in parentheses). 
 NOR*HCl! NOR*HCl  
%1 [°] 1.4 3.0(5) 
%2 [°] -113.0 -112.8(4) 
%3 [°] -155.9 -149.2(3) 
%4 [°] -175.1 177.5(3) 
&1 [°] -7.7 -7.3(1) 
&2 [°] -71.1 -70.5(2) 
The"main"conformational"parameter"describing"the"nortriptyline"molecule"
is" the" position" of" the" side" chain" with" respect" to" the" (conformationally"
asymmetric)" seven-membered" ring." The" conformation" of" the" nortriptyline"





ring"manifests"a"much" larger" (ca."70°")" torsion"at"the"aryl-C2H4"bond"(see"Table"
4.2,"torsion"angle"&2)." 
Figure" 4.3." Schematic" representation" of" the" conformation" of" the"
nortriptyline"molecules"defined"as"anti:"the"side"chain"on"the"exocyclic"C=C"bond"





Crystals" of" NOR*HCl!" crystallizing" in" the" monoclinic" P21/c" space" group,"
contain"protonated"nortryptiline"molecules"and"isolated"chloride"ions"(both"lying"
on" a" general" position)," linked" by" hydrogen" bonding" between" the" protonated"





NOR*HCl " crystallizes" in" the" less" common"monoclinic" P2/c" space" group,"




ammonium" group" acting" as" donor"with" both" hydrogens" and" the" chloride" ions"
acting" as" acceptors" from" two" neighbouring" ammonium" groups." This" creates"
another" "hydrogen"bond"motif,"analogously"to"NOR*HCl!,""shown"in"Figure"
4.4a. 
Figure" 4.4." The" one-dimensional" chains" of" '2-Cl" hydrogen-bonded" N-





The" conformational" flexibility" of" the" tricyclic" system" described" above"
allows" the" protonated" nortriptyline"molecule" to" exist" in" the" solid" state" in" two"
different" anti" conformations" which" are" non-superimposable" mirror" images" of"
each"other."In"solution,"on"the"other"hand,"the"situation"changes."Many"studies"
exist"on"the"possible"conformations"of"tricyclic"antidepressants" in"solution,"[11,"
12]"where""the flipping from one 7-membered ring conformation to the other is 
possible, causing two"different"syn"conformations"to"exist."This"is"exemplified"in"
Scheme" 4.4," where" all" different" possible" conformations" of" the" nortriptyline"
molecule"are"depicted."Variable"temperature"NMR"[13]"has"demonstrated"that,"
in" solution," these" kinds" of" systems" can" easily" flip" from" one" 7-membered" ring"
conformation" to" the" other." In" the" case" of" nortriptyline"molecules," the" flipping"
from" one" 7-membered" ring" conformation" to" the" other" also" means" switching"
from"an"anti" to"a"syn" conformation,"as" the"double"bond"on"the"chain"does"not"
allow" rotation." Therefore," one" of" the" possible" anti" conformations" is" in"
equilibrium" in"solution"with"one" syn" conformation,"but"not"with"the"other"anti"
conformation."This"is"pictorially"summarized"in"Figure"4.5. 
Scheme"4.4."Possible"conformations"of"the"nortriptyline"molecule,"shown"
here" in" the" neutral" form:" two" anti" conformations" a)" and" b)," and" two" syn"
conformations,"c)"and"d). 
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A1 and A2 represent the two anti conformations which are non 
superimposable mirror images of one another,  while S1 and S2 represent the syn 
conformations which are in equilibrium with the anti conformations due to the 
inversion of the 7-membered ring. The two anti conformations crystallize in two 
different supramolecular structures to give origin to NOR*HCl  and NOR*HCl!, 
while the two syn conformations do not appear in any known polymorph. 
 
In" NOR*HCl ," the" single" hydrogen-bonded" chains" are" built" by"
nortriptyline"molecules" which" are" all" in" the" same" conformation" (A1" or" A2," as"
defined"in"Figure"4.5)."The"adjacent"chain"contains"nortriptyline"molecules"in"the"
other" (enantiomeric)" conformation." Therefore," if"we" define"*" and"-" the" two"
anti" conformations" A1" and" A2" of" the" protonated" nortriptyline" molecule,"
NOR*HCl "is"made"up"of"****"and"----"parallel"chains. 
In"NOR*HCl!,"protonated"nortryptiline"molecules"are"again"organized"in"
hydrogen"bonded" chains" (as" shown" in" Figure" 4.4)" and," similarily" to"NOR*HCl ,"
exist" in" the" solid" state" in" two" different" non-superimposable"mirror" image" anti"
conformations."In"this"case,"however,"each"single"chain"contains"molecules"which"
alternate" in" the" two" conformations." Thus," using" the" same" notation" as" above,"
NOR*HCl!"chains"can"be"described"as"built"by"the"*-*-"sequence." 
From" the" symmetry" point" of" view," the" chains" " found" in"NOR*HCl!" are"
generated" by" glide" planes" perpendicular" to" b" (pg" frieze" group)," [14]" while" in"
NOR*HCl " chain" repetition" is" ensured" by" the" two-fold" axes" of" the" P2/c" space"
group"(p2"frieze"group)."Consistently,"the"axes"of"the"unit"cells"show"very"similar"
values," even" though" the" space" group" (and" therefore" axis" denomination)" is"
obviously" different" due" to" the" different" symmetry"elements"of" the" chains." The"
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major" difference" between" the" cell" dimensions" of" the" two" polymorphs" is" the"
monoclinic" !" angle," which," inter alia," refers" to" unique" axes" (b)" of" markedly"
different"lengths." 
The"differences"between" the" supramolecular"organization"of"NOR*HCl "
and"NOR*HCl!"suggest"that"solid-state"conversion"from"one"form"into"the"other"




4.1.3 Related Structures 
As mentioned at the beginning of the chapter, the class of tricyclic 
antidepressants contains many different molecules which share marked 
chemical similarities. In particular, they all contain a tricyclic structure with a 
long side chain bound to the middle ring. The molecules reported in Scheme 4.2, 
amitriptyline, cyclobenzaprine and dothiepin, are all marketed in hydrochloride 
salt form and all have solved crystal structures reported in the literature. [5, 6, 7] 
They are therefore perfect candidates for structural comparison with 
nortriptyline hydrochloride. The crystal data for the five different structures to 
be compared (two crystalline forms of nortriptyline hydrochloride and one each 
for amitriptyline, cyclobenzaprine and dothiepin hydrochloride) are reported in 
Table 4.3. The main conformational features of the constituent molecules are 
reported in Table 4.4. The"torsion"angles"for"amitriptyline,"cyclobenzaprine"and"
dothiepin" are" defined" in" analogy" to" those" of" nortriptyline." Worthy" of" note,"
among"these"chemical"analogues,"cyclobenzaprine"is"the"only"species"unable"to"
exist"in"the"syn"and"anti"conformations"described"above,"as"it"possesses"a"double"
bond" on" the" 7-membered" ring." The" tricyclic" system" is" therefore" rigid" and"
possesses" no" conformational" freedom" necessary" to" generate" syn" and" anti"
conformers." Moreover," cyclobenzaprine contains two crystallographically 
independent molecules, and therefore two sets of dihedral angles are necessary. 
Among"this"small"group"of"structures,"only" in"dothiepin"chemically different E,Z"
species" exist," manifested" by" the" existence" of" two" isomers." This" is" due" to" the"
presence," on" the" ethylene" bridge" of" the" seven-membered" ring," of" a" sulphur"
atom."The"known"crystal"structure"of" this"molecule,"however," refers" to"a"single"
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isomer" (E)," which" adopts" the" same" anti" conformation" as" the" other"molecular"
species"collected"in"Table"4.4." 
Table 4.3. Crystal data for NOR*HCl , NOR*HCl! and three related crystal 
structures, amitriptyline hydrochloride, cyclobenzaprine hydrochloride and 
dothiepin hydrochloride. (E.s.d.s in parentheses). 







Reference [9] [10] [5] [6] [7] 
Chemical 
Forumula 
C19H21N·HCl C19H21N·HCl C20H23N·HCl C20H21N·HCl C19H21NS·HCl 
Formula weight 
[g mol-1] 
299.84 299.84 313.86 311.84 331.90 
Crystal System Monoclinic Monoclinic Monoclinic Tetragonal Monoclinic 
Space Group P21/c P2/c P21/c I41/a P21/c 
a [Å] 5.070(2) 9.99126(6) 14.345(4) 32.0959(7) 14.296(5) 
b [Å] 34.088(5) 5.10021(3) 9.140(2) 32.0959(7) 9.364(3) 
c [Å] 9.976(1) 34.1636(1) 13.812(4) 13.7578(5) 13.724(3) 
!"[°] 90.74(2) 98.684(6) 96.82(2) 90 97.77(3) 
V [Å3] , Z 1723.97, 4 1720.93, 4 1798.12, 4 14172.6, 32 1820.33, 4 
V/Z 431 430 450 443 455 
*In ref [5], the space group given for amitriptyline hydrochloride is P21/a. It 
was chosen here to invert axes a and c, turning it to P21/a, in order to highlight 
the similarities with dothiepin hydrochloride. 
Even"though"amitriptyline"and"dothiepin"belong"to"the"same"space"group"
as"NOR*HCl!," P21/c," they shows no other similarity in the crystallographic cell. 
Interestingly, amitriptyline and dothiepin show remarkable similarities in their 
lattice parameters. Crystal data for cyclobenzaprine also does not show any 
resemblance to the crystal data of the two forms of nortriptyline. However, the 
conformational features of all molecules show some interesting similarities. First 
of all, the molecules of nortriptyline, amitriptyline and dothiepin are all in anti 
conformation, as is shown in Figure 4.6 (the molecules of cyclobenzaprine 
cannot show syn-anti conformations, as discussed above). However, the 
molecules of nortriptyline in the two forms and the molecules of amitriptyline 
and dothiepin show an important difference in the side chain conformation 
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addressed by the sign of  %2. This is responsible for the orientation of the side 
chain, as visible in Figure 4.6. While in the two forms of nortriptyline the side 
chain is oriented almost parallel to the tricyclic moiety, in amitriptyline and 
dothiepin the side chain is oriented almost perpendicular to it. Cyclobenzaprine, 
which has two crystallographically independent molecules in the asymmetric 
unit, exhibits one molecule with the side chain analogous to nortriptyline (see 
figure 4.6f) and the other with the side chain analogous to amitriptyline and 
dothiepin (see figure 4.6e). 
Figure"4.6."Plots"of"the"molecules"present"in"a)"NOR*HCl , b) NOR*HCl!,"c)"
amitriptyline"hydrochloride"and"d)"dothiepin"hydrochloride."Cyclobenzaprine"has"
two"crystallographically"independent"molecules,"depicted"in"e)"and"f). 
a) b)   
c) d)  
e) f)  
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Table" 4.4." Synoptic collection of the most relevant conformational 
features in NOR*HCl , NOR*HCl! and in three related crystal structures, 
amitriptyline hydrochloride, cyclobenzaprine hydrochloride and dothiepin 
hydrochloride. 







%1 [°] 1.4 3.0 8.3 -2.8  3.1 6.4 
%2 [°] -113.0 -112.8 121.1 -134.8 -122.7 125.6 
%3 [°] -155.9 -149.2 -173.0 -173.0 179.9 -171.5 
%4 [°] -175.1 -177.5 -173.4 -163.0 -173.7 -174.5 
&1 [°] -7.7 -7.3 -8.5 31.1 30.4 -7.6 
&2 [°] -71.1 -70.5 -69.7 -30.0 -31.2 -76.0 
As far as the packing arrangements are concerned, none of the other 
tricyclic antidepressants analyzed can give a hydrogen bond motif similar to 
those encountered in the two forms of nortriptyline, as the protonated forms 
(shown in Figure 4.6) of amitriptyline, dothiepin and cyclobenzaprine only have 
one hydrogen bond donor, the hydrogen on the ammonium group. This is due to 
the presence of a methyl group bonded to the nitrogen atom. Therefore, it is 
impossible for the molecules to form the long "chains"found"in"NOR*HCl  
and NOR*HCl!." In" all" the" other" structures," amitriptyline," dothiepin" and"
cyclobenzaprine" hydrochloride," only" discrete" hydrogen" bonds" between" the"
ammonium"groups"and"the"chlorine"ion"exist."No"more"complex"hydrogen"bond"
structures"are"present." In"particular,"amitriptyline"and"dothiepin"were" found" to"
be"isostructural,"the"only"difference"being"the"presence"on"the"seven-membered"
ring"of"dothiepin"of"a"sulphur"atom"instead"of"a"methylene"group."In"the"case"of"
the" tricyclic" antidepressants" analysed," therefore," the" ability" to" form" hydrogen"
bonds"and"the"existence"of"different"anti"conformations"are"the"driving"force"of"
crystal"structure"formation. 
The" fact" that" four" different" crystalline" structures" (NOR*HCl , NOR*HCl!,"
amitriptyline" hydrochloride" and" dothiepin" hydrochloride)" all" contain"molecules"
in" the" anti conformation," suggests" that" the" adoption" of" the" syn/anti"
conformation" in" the" solid-state" is" likely" driven" by" intermolecular" interactions,"
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rather" than" evident" stereochemical" (intramolecular)" effects." The" anti"
conformation"stereochemical"preference,"however,"is"not"ubiquitous"in"the"solid"
state" of" related" chemical" structures," since" a" rare" case" of" a" syn" disposition" has"
been" found" in" the" crystal" structure" of" an" analogous" species" having"antiallergic"
activity," the" formula" of" which" is" reported" in" Scheme" 4.5." [15]" In" this" case,"
however," the" structure" is" not" directly" comparable" with" the" tricyclic"
antidepressants"reported"above"for"several"reasons."First"of"all,"the"conformation"




zwitterionic" form)" and"not" of" the" hydrochloride" salt."Moreover," the" phase" is" a"










Chemical Forumula C21H23NO3·3H2O 
Crystal System Monoclinic 
Space Group P21 
a [Å] 12.4158"(9) 
b [Å] 19.209"(2) 
c [Å] 8.7081"(7) 
!"[°] 92.924"(6) 
V [Å3] , Z 2074.1,"4 
4.2 Thermal Analysis and Thermodynamic Considerations 
As discussed in previous chapters, the knowledge of the thermodynamic 
relations between different polymorphic forms can be crucial to the 
understanding of polymorphic behavior. For this reason, the relationship 
between NOR*HCl  and NOR*HCl! was investigated using thermal methods. 
4.2.1 DSC Analysis 
DSC analysis often gives precious information regarding thermodynamic 
relationships." However," in" this" case," it" doesnt" help" much." Both polymorphs 
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NOR*HCl  and NOR*HCl! show only one thermal event, an endothermic peak 
having a nearly identical onset temperature of 216-217°C (see Figure 4.7). This 
was attributed to a melting event, as verified by visual observation with a 
melting point apparatus. However, the fusion enthalpy was found to be different 
for the two forms, higher for NOR*HCl  (34.3 kJ mol
-1) than for NOR*HCl! (32.2 
kJ mol-1). 
Figure 4.7. DSC characterization of NOR*HCl  (a) and NOR*HCl! (b). The 
analyses were run between 30 and 220°C at 10°C/min under nitrogen flow. 
a)  b)  
4.2.2 Thermodiffractometry 
As DSC analyses alone could not unravel the thermodynamic relationships 
between the forms, thermodiffractometric analyses were also carried out on 
NOR*HCl  and NOR*HCl!. Consistently with what observed in the DSC traces, 
both crystalline forms remained substantially unchanged up to the melting 
point, with minor peak shifts, attributed to thermal expansion. The linear 
thermal expansion coefficients, ;lnx/;T (x = a, b, c), derived by the parametric 
approach described by Stinton and Evans, [16] are reported in Table 4.5, and 
show manifestly different trends, with very anisotropic inflation (or, for 
NOR*HCl!, even shortening of the b axis). A closer look into the crystal packing 
did not reveal any specific (or evident to us) reason for these observations 
(particularly the shrinking of b in the NOR*HCl! phase), which, however, speak 
for a rather different flexibility of the frameworks, unrelated to chain 
propagation axes. 
 Upon melting, form NOR*HCl! converted into form NOR*HCl . This was 
demonstrated by keeping a sample of NOR*HCl! close to the melting point and 
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collecting several XRPD spectra in isothermal conditions and following the 
NOR*HCl!<NOR*HCl  transition (see Figure 4.8). This event, not observed in 
the DSC trace, can be easily explained by the thermal gradients present in the 
sample positioned in diffractometer chamber, which, open to the air (see 
Chapter 2, section 2.1.5), induces melting and subsequent recrystallization near 
the (slightly colder) surface. 
Table 4.5. Linear thermal expansion coefficients expressed in [10-6 K-1] for 
NOR*HCl  and NOR*HCl!. The order of the axes for NOR*HCl! has been 
rearranged to reflect geometrical similarities between the axes of the two 
phases, as shown in Table 4.1. 
 NOR*HCl   NOR*HCl! 
;lna/;T 17.1 ;lnc/;T 50.8 
;lnb/;T 28.8 ;lna/;T 123.6 





Figure 4.8. Thermodiffractometric plots for NOR*HCl  (top) and NOR*HCl! 
(bottom).  
 
Horizontal scale: 10<2!<30°; powder diffraction traces were recorded in 
isothermal conditions from room temperature, up to 220°C, in 20°C steps. Blue 
traces in the background are lower temperature scans, the red traces in the 
foreground are higher temperature scans 
4.2.3 Thermodynamic Relationship between polymorphs 
The higher fusion enthalpy of NOR*HCl , coupled with the fact that 
NOR*HCl! converts into form NOR*HCl  upon melting and recrystallization, 
suggest that the two crystalline forms are monotropically related to one 
another, with form NOR*HCl  more stable than NOR*HCl! at every temperature. 
This hypothesis is supported by the fact that the form that crystallizes out of the 
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melt, regardless of the cooling rate and of the starting polymorph, appears 
always to be NOR*HCl . However, the similarities in melting points and fusion 
enthalpies, as well as the crystal structure analogies, suggest the two forms have 
only small differences in energy and stability. This is demonstrated by the fact 
that both polymorphs are indefinitely stable once isolated. Moreover, the 
supramolecular organization in infinitely-long hydrogen-bonded chains of the 
different conformers discussed above can help explain the lack of 
interconversion from NOR*HCl! to NOR*HCl  unless melting occurs, as 
mentioned earlier, effectively severing the whole hydrogen bond system within 
the crystal.  
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5. Interconverting Polymorphs of Ibuprofen Lysinate 
Solid-solid phase transitions between polymorphs can be induced by 
temperature, pressure, humidity, presence of solvents and other factors. The 
understanding of the characterisitics of a phase transition and the conditions in 
which it takes place, along with the knowledge of reversibility, can be very 
important. In particular, temperature-phase transitions are crucial in API 
polymophism. As many industrial processes, including drying, granulation and 
melt-extrusion, can involve heating, the detailed knowledge of the behavior of 
active pharmaceutical ingredients at temperatures above ambient conditions can 
be useful. 
The most important types of phase transitions between polymorphs [1] are: 
a) Displacive transformations of secondary coordination, where the crystal 
lattice is deformed but not broken. 
b) Reconstructive transformations of secondary coordination, where the 
lattice framework is broken and reformed into a new arrangement. 
c) Reorientation transformations of disorder, where some intermolecular 
bonds are broken and reformed to accommodate changes in 
conformation of the constituent molecules. 
Generally, temperature-induced phase transitions of any kind are 
accompanied by change, typically  upon heating  increase, in symmetry. 
However, in some cases, symmetry is preserved. These kinds of transformations, 
more often induced by pressure but occasionally also by temperature, are called 
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isosymmetric and are relatively rare and difficult to study in organic molecules. [2] 
In isosymmetric transformations, not only does the space group remain the same 
before and after the transitions, but both phases are made up of the same atoms 
occupying the same Wyckoff positions. This implies that the transition is 
accompanied by an abrupt (but small) change in volume and lattice constants, but 
not of space group. Occasionally, these kinds of transitions are difficult to detect 
because the changes are often so small they can sometimes be misinterpreted as 
continuous lattice modifications due to temperature or pressure.  
5.1 Thermal Behavior of Ibuprofen Lysinate 
Ibuprofen, or (RS)-2-(4-(2-methylpropyl)phenyl)propanoic acid, is a well-
known, over-the-counter analgesic belonging to the class of nonsteroidal anti-
inflammatory drugs (NSAID). [3] Ibuprofen is a non-selective cyclooxygenase (COX) 
inhibitor, acting on both COX-1 and COX-2 forms. However, most of its effect is 
achieved through COX-2 inhibition. [4] It is widely used for pain relief, fever and 
inflammatory diseases. Known from the 1960s, it has been marketed in a great 
variety of forms and under numerous trade names. Although very effective as an 
anti-inflammatory drug, Ibuprofen in the free acid form has a low solubility which 
causes a slow onset of therapeutic efficacy. For this reason, different salts having 
better solubility characteristics have been studied, in particular the lysine [5] and 
sodium salts. [6] While the crystal structures and solid state characteristics of both 
ibuprofen free acid [7, 8] and ibuprofen sodium salt [9] have been studied, the 
lysine salt of ibuprofen, shown in Scheme 5.1, remains relatively absent from solid 
state literature. This is surprising, considering the widespread use made of 
ibuprofen lysine salt in solid formulations.  










The only known characteristic of the lysine salt of ibuprofen is the existence 
of a reversible polymorphic conversion occurring upon heating. [10] Ibuprofen 
lysine salt therefore exists in two different polymorphic forms, one existing at 
lower temperatures and one existing at higher temperature. As no denomination 
has been previously used for the two forms of ibuprofen lysine salt, the crystal 
form which exists at room temperature will be referred to as IBL-I, while the high 
temperature crystal form will be referred to as IBL-II. 
5.1.1 DSC Analysis 
The DSC analysis of ibuprofen lysine salt, reported in Figure 5.1a, shows a 
small but sharp endothermic transition at about 70°C (onset temperature 69.5°C 
with a heating rate of 10°C min-1,  H = +2.3 kJ mol-1) and a melting event at 
182.8°C ( Hfus = +58.4 kJ mol
-1). The endothermic event around 70°C is reported in 
the literature as being a fully reversible transition into another polymorph. [11] 
This was verified by using a custom-made temperature program, heating a sample 
of Ibuprofen lysine salt to 90°C and cooling back to room temperature to observe 
the reversibility of the transitions (as shown in Figure 5.1b). In order to determine 
the transition temperature at nearly equilibrium conditions (zero heating rate), 
DSC analyses were run at different heating rates (2, 5 and 10°C min-1). The 
observed transition temperature (evaluated using the onset method, see Chapter 
2) at each heating rate was plotted as a function of the heating rate (as shown in 
Figure 5.2) and the transition temperature at zero heating rate was extrapolated 




Figure 5.1. DSC Analyses of Ibuprofen lysine salt, showing a) the 
endothermic transition from IBL-I to IBL-II followed by fusion and b) the fully 
reversible nature of the transition. 
a)   b)  




The sharp transition between IBL-I and IBL-II observed in the DSC analyses 
was followed using thermodiffractometric methods. An extract of the data 
collected is reported in Figure 5.3. The transition was found to be quite evident, 
even though the diffraction profile of the two forms shows many similarities. In 
particular, the XRPD traces of forms IBL-I and IBL-II, shown in the range 3-25° in 
2q in Figure 5.4, appear to differ only slightly in the more intense peaks at low 
y = 0,0522x + 67,56 





















Heating Rate [°C min-1] 
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angles, suggesting similarities in the lattice constants. The phase transition was 
observed between 70 and 90°C similarly to what observed in DSC, but traces of 
IBL-I were visible up to about 110°C, when the conversion was complete. This can 
be attributed to the fact that the heated sample holder used is open to air. This 
can cause a temperature gradient in the sample, where the sample portion in 
contact with the sample holder is significantly warmer than the portion in contact 
with air at room temperature. The sample holder must therefore be heated to a 
higher temperature in order to ensure the whole sample is well above 70°C. 
Figure 5.3. Thermodiffractometry (7-14° in 2q portion) of IBL-I (blue area), 
showing the conversion into IBL-II (red area) at about 70°C. 
 
Figure 5.4. Overlaid powder diffractograms of IBL-I measured at room 




5.2 Structural Analysis  
The structures of the two phases, IBL-I and IBL-II, were solved from powder 
diffraction data. Thermodiffractometric methods allowed to acquire powder 
diffraction data for IBL-II at 110°C, but it was not possible to explore the full range 
usually used for structure solution, because the aluminum heated sample holder 
did not allow the quality needed for structure solution at high angles. Moreover, 
keeping the sample overnight at 110°C (as a full range diffractogram usually 
requires about 15 hours of measurement to yield satisfactory results at high 
angles) might have degraded the sample. It was therefore unadvisable to collect 
such a wide range. For form IBL-I, an acquisition using transmission geometry on a 
cylindrical sample was preferred, due to marked preferred orientation effects. 
Indexing of IBL-II proved to be difficult, as no unique or sensible solution was 
found by the conventional methods described in Chapter 2 (probably because of 
uncontrolled instrumental effects and evident peak broadening and overlap). 
However, the reversibility of the phase transition and the already mentioned 
similarity of some of the low-angle diffraction features allowed to estimate the 
cell parameters of IBL-II using a deformation of the pristine cell, made 
accessible by the use of the CELL program. [12] 
5.2.1 Crystal Data 
The crystal data for both phases is reported in Table 5.1, while Figure 5.5 
shows the final Rietveld refinement plots. The identity of the space group in the 
two phases and the analogies in the cell constants, explaining the similarities 
between the XRPD traces, suggest a strong structural correlation between the 
phases. As is to be expected, the higher temperature phase, IBL-II, appears to be 
less dense. However, the difference between IBL-I and IBL-II, though small, is too 
large to be attributable merely to thermal expansion. Moreover, the expansion is 
very anisotropic. In fact, while on the b axis there is a strong expansion (about 5 
%), axis a exhibits only a very small contraction (about 0.2%). This thermally 
induced kind of strain cannot be attributed to vibrational effects only and must be 
attributed to structural reasons, i.e. an isosymmetric displacive phase transition.  
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Figure 5.5. Final Rietveld refinement plot for a) IBL-I and b) IBL-II. For IBL-I, 
the insert shows the high angle portion magnified 5x. For IBL-II, the high angle 
portion was not acquired, as explained in the text. The two peaks of the heated 
aluminum sample holder (visible) were modelled separately using the 
Fundamental Parameter Approach. 
a)  
b)  
Table 5.1. Comparative crystal cell data of forms IBL-I and IBL-II. (E.s.d.s!in!
parentheses). 
 IBL-I IBL-II 
Chemical Formula C19H32N2O4 C19H32N2O4 
Formula weight [g mol-1] 352.47 352.47 
Crystal System Monoclinic Monoclinic 
Space Group P21/n P21/n 
a [Å] 8.4664(6) 8.450(1) 
b [Å] 40.619(3) 42.619(7) 
c [Å] 5.7929(4) 5.8226(6) 
 ![°] 86.326(7) 85.72 (1) 
V [Å3] , Z 1988.1(2), 4 2091.1(5), 4 
V/Z 497 523 
T [K] 298 383 
"![Å] 1.5418 1.5418 
#(calc) [g cm
-1] 1.178 1.120 
$![mm-1] 0.665 0.632 
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5.2.2 Structural Comparison 
The conformation of the ibuprofen and lysine molecules was described by 
two separate set of dihedral angles, shown in Scheme 5.2. 
Scheme 5.2. Torsion angles used to describe the molecular conformation 


























The conformation of the ibuprofen and lysine molecules in IBL-I and IBL-II 
was found to be rather similar, as is clearly shown in Figure 5.6. When comparing 
the dihedral angles used to describe molecular conformation, as is done in Table 
5.2, the value which appears to change the most from one phase to the other for 
the ibuprofen molecule is !3, responsible for the orientation of the isopropyl 
group of ibuprofen, going from about 56° to about 67°. The other values have 
variations below 2°. This will be further explored and explained in the following 
paragraphs. The lysine molecule changes slightly from IBL-I to IBL-II, with three 
out of five dihedral angles varying of between 10 and 15°. This can be due to the 
fact that lysine has three functional groups involved in a complex hydrogen 
bonding structure, as described below. Therefore, even a small change in the 
positioning relative to the ibuprofen molecule, due to the phase transition, will 




Table 5.2. Synoptic collection of the most relevant conformational features 
of the Ibuprofen and Lysine molecule (!1-4 and "1-5, respectively, as defined in 
Scheme 5.2) for forms IBL-I and IBL-II (E.s.d.s!in!parentheses). 
 IBL-I IBL-II 
%1 [°] 103.6(5) 101.8(9) 
% 2 [°] -16.7(8) -18(1) 
% 3 [°] 56.3(2) 66.5(3) 
% 4 [°] -161.2(4) -160.2(7) 
&1 [°] 177.3(4) 162.9(7) 
& 2 [°] -93.9(2) -98.7(3) 
& 3 [°] -76.4(2) -86.8(3) 
& 4 [°] -79.7(3) -74.4(5) 
& 5 [°] 133.9(5) 146.2(9) 
 
Figure 5.6. Conformation of Ibuprofen and lysine molecules in a) IBL-I and 
b) IBL-II. The most different portions for each molecule are indicated by colored 
circles (see actual torsion angles collected in Table 5.2). 
a) b  
Interestingly, the hydrogen bonding scheme, identical in the two phases, is 
quite complex. Using the Graph set notation [13, 14] to analyze the hydrogen 
bonding scheme, five different kinds of discrete hydrogen bonds are identified 
(first order motifs), which then combine in several different second order 
patterns, including a  ring structure and several chain structures. The 
hydrogen bonding in IBL-I and IBL-II is depicted in Scheme 5.3. Worthy of note, as 
X-ray diffraction does not usually allow to determine hydrogen positions, much 
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less structure solution from powder data, the structures of Ibuprofen lysine salt 
here reported were solved using neutral ibuprofen and lysine molecules. As can 
be observed in the hydrogen bonding scheme depicted in Scheme 5.3, the 
carboxyl group of ibuprofen (C9O1O2H6) is involved in hydrogen bonding with the 
more basic amine group of lysine (N2H31H32). The hydrogen, though positioned by 
us on the carboxyl group, could also be positioned on the amine group. Other 
techniques are necessary to determine the degree of proton transfer. Considering 
the significant difference between the pKa values of Ibuprofen [15] and lysine, the 
proton transfer should be considered complete and the proton should be 
positioned on the nitrogen atom of the lysine side chain.  
Scheme 5.3. a) Hydrogen bonding present in both IBL-I and IBL-II and b) 
atom numbering for the ibuprofen and lysine molecules. 
a)    
b)  
The analysis of the packing of ibuprofen and lysine molecules in forms IBL-I 
and IBL-II confirms the similarities already observed in lattice constants and 
molecular conformation, as can be seen in Figure 5.7. In both phases, the 
molecules are stacked so that the more hydrophilic groups (the whole lysine 
molecule and the carboxyl group of the ibuprofen molecule), responsible for the 
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hydrogen bonding, are organized in long and complex chains, while the more 
hydrophobic groups (the aromatic ring and isopropyl group of the ibuprofen 
molecules) are interacting with each other in long columns along the a axis, 
separately from the more polar groups. 
Figure 5.7. Packing of Ibuprofen and lysine molecules in IBL-I and IBL-II 
viewed along the c axis. The red rectangles indicate the areas where the hydrogen 
bonding is located. 
a)     b)  
In order to understand the most significant differences between the 
structures of IBL-I and IBL-II, the thermal and structural strain tensors were 
calculated for comparable temperature differences. The thermal strain tensor was 
evaluated by refining cell parameters for IBL-I at 30 and 70°C and calculating the 
resulting strain tensor using a publicly available software tool [16, 17]. The 
structural strain tensor was evaluated using the cell of IBL-I refined at 70°C and 
the cell of IBL-II at 110°C. The tensors thus obtained were plotted using 
WinTensorTM [18] and compared (see Figure 5.8). The first obvious difference 
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between the thermal and structural strain tensors is the size, as the structural 
strain tensor is about an order of magnitude larger than the thermal tensor. This 
is particularly evident in Figure 5.8c, where the thermal strain tensor is plotted on 
a scale ten times smaller and is comparable in size with the structural strain 
tensor reported in Figure 5.8b. Secondly, even though the general shape is the 
same in both cases, the thermal strain is always positive (even though 
anisotropic), while the structural strain tensor has negative values (though small) 
in one direction (shown in Figure 5.8b as red areas). Thirdly, both the structural 
and the thermal strain tensors have the largest component in the same direction, 
in particular along the b axis. All together, these observations, together with the 
variation in dihedral angle !3 (responsible for the orientation of the isopropyl 
group of the ibuprofen molecule, as discussed previously) and the similarities of 
the hydrogen bonding scheme in the two phases, gave indication as to where to 
look to find the key differences between the structures of IBL-I and IBL-II. 
Figure 5.8. Graphical representations of the a) structural and b) thermal 
strain tensors represented on the same scale and c) an expansion (10x) of the 
thermal strain tensor to show its shape. x, y and z are orthogonal coordinates, 
nearly, or exactly, aligned with a, b and c. 
 
A closer inspection of the hydrophobic areas of the crystal structures 
allowed to understand not only the key differences between IBL-I and IBL-II, but 
especially the driving force of the phase transition. In fact, while in IBL-I the 
isopropyl groups are lodged into one another, in IBL-II they are unfastened and 
almost one next to the other. This is shown in Figure 5.9. The shape of the thermal 
strain tensor suggests that, upon heating, the structure of IBL-I expands 
147 
 
anisotropically in all directions, causing the isopropyl groups to move away from 
each other. When a critical distance is reached, the isopropyl groups disengage, 
causing the conversion from IBL-I to IBL-II to occur. Figure 5.10 schematically 
explains this transformation, which also explains the small shortening of the a 
axis: the disengaged isopropyl groups, having moved free of one another along 
the b axis, can now move closer along the a axis. The major difference between 
forms IBL-I and IBL-II, therefore, is the distance between neighboring ibuprofen 
molecules.  
Figure 5.9. Closer view of IBL-I and IBL-II packing to show the differences in 
the relative positions of adjacent isopropyl groups (highlighted by blue circles). 
a) b)  
Figure 5.10. Schematic representation of a) thermal expansion and b) 
structural modification induced by the disengagement of the isopropyl groups of 
adjacent ibuprofen molecules. 
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6. Quantitation Methods: Venlafaxine Hydrochloride 
6.1 Quantitation of Polymorphs 
 The importance of quantitation of different crystalline forms in a sample 
has already been discussed in previous Chapters. Many different techniques have 
been successfully employed for quantitative phase analysis of pharmaceutical 
solids, including infra-red spectroscopy (both mid- and near-IR), X-ray powder 
diffraction, thermal methods and SS-NMR. However, not all techniques are 
equally suited to all cases. For example, while infra-red spectroscopy can yield 
excellent results in cases where the hydrogen bonding scheme is very different in 
the phases to be analyzed, [1] it is not as successful in cases where there are 
similarities in the hydrogen bonding scheme of phases. In fact, infra-red 
spectroscopy is particularly sensitive to specific molecular features, like X-H bond 
overtones and combinations. [2] Different hydrogen bonding schemes will 
therefore generate very different IR spectra. Conversely, similar hydrogen-
bonding schemes will often lead to similar IR spectra, as is the case with 
nortriptyline polymorphs NOR*HCl  and NOR*HCl! discussed in Chapter 4 (the IR 
spectra for NOR*HCl  and NOR*HCl! are reported in Figure 6.1). 
Differential Scanning Calorimetry, on the other hand, can generally only be 
used for quantitative phase analysis when quantifying a solvate or a hydrate in an 
anhydrous form, like for example the quantitation of lactose monohydrate, done 
by using the well-defined dehydration peak. [3] 
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Figure 6.1. Infra-red spectra of a) NOR*HCl  and b) NOR*HCl! collected in 
the range 4000-650 cm
-1
.  
a)  b)  
The only instrumental technique which always yields a unique response for 
each different crystalline form is X-ray diffraction. This is the main advantage of X-
ray powder diffraction over other instrumental techniques used for quantification. 
[4] XRPD data, however, can be used in different ways to yield quantitative 
information. The most common quantitation methods used are the single peak 
method and the Rietveld method. [5] Both methods have advantages and 
disadvantages. The single peak method requires the identification of a well-
defined, isolated and possibly intense peak for each phase analyzed. 
Subsequently, it requires the construction of a calibration curve, therefore 
monophasic samples of all the phases under examination must be available. [6] 
The Rietveld method, generally recognized as more precise and accurate than the 
single peak method, requires the knowledge of the crystal structures of all phases 
analyzed. [7] This can be difficult to obtain when dealing with polymorphs of 
APIs.  
In the Rietveld method, the ratio between the analyzed crystalline forms is 
obtained by simulating the powder diffraction profile of the various phases using 
the knowledge of the crystal structure and then varying the scale factor for each 
phase to fit the experimental data. No monophasic standard is required and there 
is no need to construct calibration curves. However, the main advantage of the 
Rietveld method over the single peak method is the fact that it uses the full 
diffraction profile and is therefore much less affected by preferred orientation 
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effects. Preferred orientation, rather common in crystalline forms of APIs, is a 
major source of error for XPRD quantitation. [8] 
One of the disadvantages of the Rietveld method is its complex nature. 
Calculations of the powder diffraction profiles from the crystal structure are 
necessary. Many software programs are available to carry out Rietveld 
calculations, including TOPAS-R [9] and QUANTO. [10] 
6.1.2 Proposed Method 
As the strongest advantage of the Rietveld method over other quantitation 
methods based on XRPD is the use of the full diffraction profile, while the main 
disadvantage is the requirement of the knowledge of the crystalline structures, a 
full-profile quantitation method using extracted intensities but does not require 
full structure characterization has been proposed, as described in Chapter 2, 
paragraph 2.2.4. [11] This method, which makes use of the Wilson plot to put 
experimental extracted intensities on the absolute scale in absence of a structural 
model, is implemented in the quantitative phase analysis (QPA) program 
QUANTO. Analogously to other XRPD quantitation methods, samples of the pure 
phases to be quantified are necessary for intensity extraction, but no calibration 
curve is needed. Worthy of note, the knowledge of the lattice parameters is 
necessary for correct indexing and intensity extraction, but lattice parameter 
determination is much easier than full structure determination and can be carried 
out reasonably quickly from powder data, as described in Chapter 2, paragraph 
2.2.1. 
 As the structure-less full-profile method implemented in the software 
QUANTO has not been fully tested on APIs, having been used only once, [12] it 
was decided to select a test API candidate and to compare the results obtainable 
from the structure-less method with the classical Rietveld approach.  
6.2 Quantitative Phase Analysis on Venlafaxine Hydrochloride 
Venlafaxine, or (RS)-1-[2-dimethylamino-1-(4-methoxyphenyl)-
ethyl]cyclohexanol, shown in Scheme 6.1,  is an antidepressant which acts as a 
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serotonin and norepinephrine reuptake inhibitor. Known since the 1990s, it is 
marketed as a hydrochloride salt.  
Scheme 6.1. Venlafaxine Hydrochloride 
 
 Venlafaxine hydrochloride is known to exhibit polymorphism, crystallizing 
in two anhydrous forms (forms I and II). The structures of both forms have been 
solved from single crystal X-ray diffraction and have been reported in the 
literature. [13, 14] The powder diffractograms for forms I and II, reported in Figure 
6.2, show some overlapping but appear suitable for quantification using XRPD, as 
many intense peaks dont overlap. Interestingly, form II (red trace in Figure 6.2) 
has several intense peaks well isolated from peaks of form I, but the opposite is 
not true. This means small amounts of form II in form I might be easier to detect 
and quantify than the reverse.  
Figure 6.2. Overlaid powder diffractograms of Venlafaxine hydrochloride 
form I (black line) and  of Venlafaxine hydrochloride form II (red line)in the 5-35° 




Venlafaxine hydrochloride was therefore chosen to test the structure-less 
full-profile quantitation method and compare the results with the classical 
Rietveld approach. Binary mixtures of Venlafaxine hydrochloride forms I and II 
were prepared in the range 5-95% w/w. 
6.2.1 Preparation of Binary Mixtures 
Venlafaxine hydrochloride form I was supplied by Dipharma Francis Srl. 
Form II was prepared by dissolving  13.5 g of Venlafaxine hydrochloride form I in 
170 ml of refluxing isopropanol and cooling slowly back to room temperature. 
After filtration, the sample was dried under vacuum at 50°C overnight. In order to 
minimize preferred orientation and to make mixing more efficient, samples of 
both forms were ground in a mortar with a pestle and sieved using a 32 µm steel 
sieve. Karl Fischer analysis confirmed the samples to be anhydrous. Details of the 
preparation of the binary mixtures is reported in Table 6.1. 
Table 6.1. Binary mixtures of Venlafaxine hydrochloride forms I and II. 
Mixture 
Venlafaxine 
hydrochloride form I 
[mg] 
Venlafaxine 




[%form I: %form II] 
A 190.66 190.73 50:50 
B 239.18 82.10 75:25 
C 95.46 284.36 25:75 
D 455.97 23.96 95:5 
E 22.18 419.26 5:95 
Diffractograms of the pure phases and the five mixtures were collected in 
the range 5-105° in 2!. Intensities were extracted from the diffractograms of the 
pure phases using the lattice parameters reported in the literature using the 
QUANTO program. The intensities thus obtained were stored in separate files 
which could subsequently be used by QUANTO for quantitation. During the 
quantitation calculations using extracted intensity files, the software 




In order to test the capabilities of the method, calculations were performed 
in various ways. First of all, classical Rietveld calculations making use of the 
structural data were carried out to act as reference results. In order to verify the 
reference results, classical Rietveld calculations were also carried out using a 
different software, TOPAS-R. 
The calculations were then carried out with QUANTO making use of the 
extracted intensities. To verify the scope of the method, mixed cases were also 
taken into account, simulating cases in which one of the structures is known, and 
extracted intensities have to be used for a single phase only.  
6.2.2 Quantitation Results and Discussion 
The results of the quantitation calculations are reported in Table 6.2, 
together with the profile agreement index Rwp, the goodness of fit (GoF) values 
and the absolute error (Err). The error was calculated based on the reference 
result (classical Rietveld calculation obtained with QUANTO) even if this value was 
not always perfectly aligned with the nominal concentration of the mixtures, as is 
the case with Mixture E. This was done because our aim was to verify if a 
structure-less method would lead to the same results as the classical Rietveld 
method using the same data set. The discrepancy between the nominal 
concentration and the reference result has not been investigated, but might be 
due to non-homogeneous sampling, incomplete mixing,  weighing errors or other 
causes. Worthy of note, as discussed above, form I does not have many intense 
peaks well distinguishable from those of form II. This might also be a source of 
error for mixtures containing small amounts of form I in form II. 
The results obtained both by using extracted intensities for the two phases 
and by simulating mixed cases are well aligned with the reference results, most 
errors having absolute values below 0.5% and none above 1%. Interestingly, also 
the values of Rwp and GoF are not far from the reference values, indicating that 
the extracted intensities placed on the absolute scale using the Wilson plot allow 
the calculation of a diffraction profile analogous to that obtainable from the 
structural data. 
Figure 6.3 reports the results of the quantitation for each mixture using 
the classical Rietveld method plotted against the results obtained with the 
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extracted intensities for both phases and with extracted intensity for one phase 
and structure information for the other. The good agreement of the data confirms 
linearity comparable to that of the classical Rietveld method. 
Figure 6.3. Plots of the results obtained with the classical Rietveld method 
against the results obtained using a) extracted intensities for form I, structure 
information for form II, b) structure information for form I, extracted intensities 
for form II and c) extracted intensities for both phases. The equation for the 
regression line is reported on the graphs. 
a)  b)  
c)  
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7. Technology Transfer and Knowledge Sharing 
Solid state of active pharmaceutical ingredients is a field in which different 
disciplines, environments and interests meet: industrial, scientific and legal issues 
all have important roles to play in almost every aspect of API polymorphism. 
Obviously, APIs are produced, formulated and sold not only to offer the 
population a longer lifespan and a better quality of life, but also to allow the 
companies which produce and sell APIs enough profit to sustain the industry and 
be able to research and market new products. Therefore, a strong commercial 
interest surrounds APIs. Industry needs to focus on what is necessary and not 
employ resources on purely scientific issues. 
Conversely, the scientific aspect also needs to be addressed. Advancements 
in knowledge and understanding of solid-state issues, cutting-edge research and 
excellence are necessary to all parties involved. This is mostly the interest of 
academia, where more resources can be employed on purely scientific issues or 
on the devising of new techniques for the preparation and characterization of 
crystalline forms. This can lead to better, safer and more effective products. Also, 
scientific publications strongly contribute to the sharing and promulgation of 
knowledge. 
Finally, legal and intellectual property issues come into play for industry but 
also for academia, protecting the interests mostly of companies but also of 
academic organizations. Moreover, the essence of intellectual property is to offer 
a protection which is limited in time, in exchange for the divulgation of an 
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invention. The subject matter of an invention must be publicly available at the end 
of the protection period, ideally contributing to knowledge promulgation. 
These three aspects are strongly entwined. In the world of APIs, all are 
necessary to successful problem solving in the quest for better medicinal 
products. The roles of each must necessarily be separate and different, and it is 
the synergy between industry and academia that can lead to the best results. 
Industry needs academia to offer scientific excellence, and academia needs 
industry to offer directions and pose questions which need answering. This is 
demonstrated by the growing number of joint ventures and collaborations which 
exist between pharmaceutical companies and universities, or by the many events 
organized by academia and industry alike as occasions of meeting and discussion. 
During this thesis work, which lies on the boundary between industry and 
academia, these issues have been met and addressed over and over again. As a 
consequence, some of the contributions which have emerged in these years have 
not been purely scientific or purely industrial in nature, but have trod on the 
boundary, addressing the need to share knowledge and information.  
7.1 Written Contributions 
7.1.1 Structural Analysis by Powder Diffraction Methods 
In occasion of the 2012 International Insubria Summer School dedicated to 
crystallography, having title Crystallography for Health and Biosciences, a 
volume was published, summarizing the issues addressed. The purpose of the 
school was to explore multiple aspects of crystallography, regarding both 
crystallization techniques and  characterization methods. A focus was placed on 
applications to health and bio-science issues. As the main focus of this thesis work 
was structural analysis from powder diffraction data and knowledge sharing also 
played an important part, as discussed in the previous paragraphs, the chapter 
dedicated to structural analysis from powder diffraction finds place here. [1] 
7.1.2 API Polymorphism: Uses and Abuses of Intellectual Property Protection 
It is a well-known fact that polymorphism has been gaining importance in 
the pharmaceutical industry over the past years. The importance of solid-state 
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issues has been discussed extensively in this work. However, there are many 
instances in which polymorphism and solid-state issues are used not to address 
serious scientific issues, but, opportunely employing intellectual property 
protection, to hinder or disincentive competition. A brief discussion about this 
was published in a journal specifically designed to scientifically address industrial 
issues, effectively linking industry and academia. [2]  
7.2 Oral Presentations 
7.2.1 Use of XPRD for Fingerprinting 
A presentation was given in April 2011, having title Utilizzo di XRPD per 
lidentificazione di fasi cristalline di principi attivi farmaceutici: esempi di casi non 
ovvi, during a workshop organized by Bruker AXS on non-destructive techniques 
used on solid APIs, XRD e non solo: tecniche analitiche non distruttive per il 
mondo farmaceutico. The main technique discussed during the workshop was 
XRPD, but SS-NMR and IR were also mentioned. The workshop was intended as a 
meeting occasion between industry and academia. 
My presentation was centered on the use of X-ray powder diffraction as a 
fingerprinting technique, therefore meant only to identify the crystalline form 
under examination by comparing the experimental measurement with a reference 
XRPD trace. The aim of this presentation was to illustrate, with numerous 
examples, the unexpected complexity which can await behind the apparently 
simple task of overlapping two diffractograms.  
Obviously, overlapping two diffractograms can give any range of results 
from perfect correspondence to no correspondence at all. [3] However, the more 
complex and interesting cases arise when there is some correspondence, but is 
not total. Extra, missing or shifted peaks can all suggest different problems. In 
these cases, a great deal of information can be inferred from the XRPD data.  
What this presentation meant to highlight is that XRPD, even when used as 
a fingerprinting technique, can offer a lot more information to the attentive (and 
prepared!) observer. For example, positioning, shape and number of the peaks 
which do not match the reference can give insight into where and how to search 
for an answer. To give a couple of examples, few sharp peaks at high angles can 
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suggest an inorganic contaminant, while several low intensity peaks at lower 
angles can suggest the presence of small amounts of a different crystalline form. 
Very different peak intensities, which can sometimes make two diffractograms 
appear not to overlap at first glance, can be due to preferred orientation effects, 
as is the case with crystals of very different shapes of Ibuprofen lysine salt 
reported in Figure 7.1. 
Figure 7.1. Crystals of Ibuprofen lysine salt in a) needle and b) prism shape 
obtained by crystallization from different solvent systems, giving rise to c) very 
different XPRD traces (shown overlapped). The picture were taken with a light 
microscope at 100x. 
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7.2.2 The XRPD technique in the Pharmaceutical Industry 
A different meeting point between industry and academia revolving around 
APIs was the workshop organized by the University of Florence in May 2014, 
having title SIMPLy CRIST: SoluzIoni per Materiali PoLicristallini. The aim of my 
presentation, having title Principi Attivi Farmaceutici: a cosa serve la diffrazione 
da Polveri was to explore the aspects of powder diffraction, and of the 
information that can be obtained from the technique, which hold particular 
industrial interest.  
While most of the issues discussed have already been addressed in this 
work, one aspect which has not been mentioned is the use of XRPD as process 
control during the synthesis of a specific target crystalline form. In some cases, a 
specific crystalline form may be obtainable only from desolvation of a specific 
solvate or from crystallization from a specific starting form. This implies that even 
small amounts of a crystalline contaminant at any step can cause problems on the 
polymorphic purity of the finished product. A general example of an industrial 
procedure used to obtain two different crystalline forms of the same product is 
reported in Figure 7.2.  
Figure 7.2. Synthetic Scheme for two different crystal forms of an API. 
Each red rectangle represents a solid form which is isolated and analyzed via 
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8. Conclusions and future perspectives 
This thesis work, focusing on structural analysis of active pharmaceutical 
ingredients using mainly X-ray powder diffraction, has highlighted and 
demonstrated the usefulness of solving structures from powder data and the 
richness of information that can be obtained from structural analysis. Even though 
it is undoubtedly true that crystallography is a mature science, it is still growing 
and is still a mining field for novelty, innovation and scientific excellence. Many of 
these aspects have been brought to public attention during the numerous events 
organized this year to celebrate the International Year of Crystallography declared 
by the United Nations.  
8.1 Conslusions 
8.1.1 Bupropion Hydrohalides 
We have presented the complete structural analysis of six new bupropion 
hydrohalide crystal unsolvated phases and three new bupropion hydrobromide 
solvates, performed with the aid of state-of-the art ab-initio powder diffraction 
methods. A full comparative crystallo-chemical analysis, including structural 
results of six additional crystal phases appeared in the literature (two 
hydrochloride and two hydrobromide  unsolvated salts, one solvate of bupropion 
hydrochloride and one solvate of bupropion hydrobromide), has been performed, 
showing the persistency of a two-fold embrace, in which halides are 
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systematically hidden in a dimeric (centrosymmetric) moiety, interacting with two 
secondary ammonium sites. More relevantly, the large diversity of different 
crystal packing motifs (8 for 15 different crystal phases, several of which are 
isomorphous) shows that even in the presence of simple molecules with limited 
conformational freedom, subtle modifications on the preparation conditions may 
selectively drive the formation of distinct phases.  
Even though Bupropion hydrochloride and hydrobromide salts are both in 
BCS (Biopharmaceutics Classification System) Class I and is therefore highly 
unlikely that polymorphism will affect overall therapeutic efficacy, structural 
analysis yielded information that can still be precious and useful at the industrial 
level. For example, it allowed to explain the relative stability of the solvate phases 
and their desolvation behavior. Moreover, desolvation studies led to the 
discovery of new bupropion hydrochloride phases. Comparative structural 
analysis and structure solution from X-ray powder diffraction data proved to be a 
powerful tool to study API polymorphism. 
8.1.2 Nortriptyline Hydrochloride 
 A polymorphic form of nortriptyline hydrochloride, NOR*HCl , has been 
characterized by structural and variable temperature powder diffraction methods 
and differential scanning calorimetry, revealing it to be monotropically related to 
NOR*HCl!, previously characterized by single crystal analysis. NOR*HCl  
represents the thermodynamically stable phase, as demonstrated by the higher 
fusion enthalpy and the conversion of NOR*HCl! into NOR*HCl  upon melting. 
The structure determination from synchrotron radiation powder diffraction data 
of NOR*HCl  allowed to perform a comparative stereochemical analysis between 
the two crystal phases, revealing a distinct pattern in the sequence of the 
hydrogen bonds. Both polymorphs present a  hydrogen bond motif, 
constituted of alternating protonated nortriptyline molecules and !2-chlorine 
ions. As the conformation of the nortriptyline molecules is nearly identical in the 
two polymorphs, the major difference between the two crystal phases was found 
to reside in the presence of homochiral hydrogen-bonded chains in NOR*HCl  and 
of racemic ones in NOR*HCl!. The supramolecular arrangement of the two 
polymorphs allowed to explain the lack of solid-solid interconversion between the 
forms upon heating. 
167 
 
8.1.3 Ibuprofen Lysine Salt 
The structure of two polymorphs of Ibuprofen lysine salt, one existing at 
lower temperatures and one existing at higher temperatures, were solved using 
powder diffraction methods. Structural analysis was then carried out to 
understand and explain the transition between the two forms and its full 
reversibility.  
Fully reversible thermally induced phase transitions occurring at relatively 
low temperature are normally associated to minor packing rearrangements. In 
these cases,  an enthalpy change limited to a few kJ mol
-1
 and relative atomic 
positions only marginally affected by the phase transformation suggest the 
occurrence of a displacive transformation, not requiring significant bond breaking. 
In the transition between the two forms, the integrity of the molecular skeletons, 
as well as that of the primary supramolecular network (the extensive hydrogen-
bond interactions occurring among the polar carboxyl and amino groups of 
ibuprofen and lysine) together with the symmetry preservation, indicate a 
displacive isosymmetric phase transition. Isosymmetric reversible phase 
transitions are rare for organic compounds, and often, but not uniquely, 
associated to pressure-driven processes.  
Since structural similarities between interconverting phases are not always 
easy to study, as conventional single crystal structure determination of these 
kinds of systems can present unavoidable experimental difficulties (for example, 
sample polyfragmentation). In such cases, state-of-the-art structural powder 
diffraction methods may become the only viable tool, as here demonstrated by 
our variable-temperature XRPD study, which allowed the molecular details and 
changes at the heart of the phase transformation to be easily tracked. 
8.1.4 Structure-less Full-Profile Quantitation Method 
A method has been tested to extend the application of QPA (Quantitative 
Phase Analysis) making use of the full diffraction profile (Rietveld-like) to APIs of 
which no structural information is known, providing that the pure phases are 
available for XRPD analysis and intensity extraction. The method makes use of the 
full diffraction profile, using the Wilson plot to place extracted experimental 
intensities on an absolute scale. Moreover, mixed cases in which one structure is 
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known have been simulated to test the method further. A test candidate, 
venlafaxine hydrochloride, has been chosen to verify the applicability of the 
method to binary mixtures of API polymorphs. 
The quantitation results obtained have shown good correspondence with 
the reference results (obtained by classical Rietveld calculation methods) and 
demonstrate the applicability of the structure-less full-profile method to APIs. 
The software QUANTO was moreover demonstrated to allow intensity extraction 
and quantitation calculations to be performed simply and rapidly. 
8.2 Future Perspectives 
This work has demonstrated how useful structural analysis can be when 
studying API polymorphism. However, the work is by no means finished, and 
represents more of a starting point than a finish line. The world of polymorphism 
of pharmaceuticals is wide and rich, raising more and more questions and issues 
to be addressed with growing scientific knowledge. 
8.2.1 Structural Analysis 
As the quest for new crystalline form in search of better characteristics and 
bulk properties plays an important role in solid-state studies of APIs, one of the 
future issues what will be addressed is the possibility of coupling structure 
solution from powder diffraction data with molecular modelling, in order to verify 
the possibility of forcing crystallization of a different stable molecular 
conformation. This can be done for example by adding a specifically chosen 
solvent for complexation or chelation.  As demonstrated in this work, tailored 
desolvations may then lead to discovery of new crystalline forms.  
In order to test the hypothesis proposed, the syn/anti conformations of 
nortriptyline hydrochloride seem a good starting point. As described in Chapter 4, 
solution NMR studies have demonstrated the existence of different 
conformations in solution which do not (yet) exist in the solid state. Molecular 
modelling on the nortriptyline molecule might suggest a co-former to be used in 
the quest of a solvated crystal structure containing molecules having syn 
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conformation. If this were possible, tailored desolvations might lead to a new 
nortriptyline form.  
8.2.2 Quantitation Methods 
As the structure-less full-profile quantitation method has given good results 
when applied to APIs, the scope and potential of the method should be explored 
further. First of all, binary mixtures containing smaller amounts of a crystalline 
contaminant will be prepared to verify the limit of detection (LOD) and limit of 
quantitation (LOQ) of the method. Mixtures of Venlafaxine hydrochloride forms I 
and II of 98:2 and 99:1 composition will be prepared and tested for this 
investigation. 
In order to test the method further, a candidate has been selected to try 
quantitation of ternary mixtures. Piroxicam, a non-steroidal anti-inflammatory 
drug (NSAID), is known to exist in two anhydrous and one hydrated form, all of 
which have been characterized by single crystal. As the three crystalline structures 
















Appendix A. Atomic Coordinates 
A.1 Atomic Coordinates of Bupropion Hydrohalides 
A.1.1 Bupropion Hydrochloride 
Bupropion Hydrochloride Form III 
Crystal System: triclinic 
Space Group: P-1 
a[Å]:   7.7478(2) 
b[Å]:   8.1124(2) 
c[Å]:   13.1768(3) 
alpha[°]: 117.03(2) 
beta[°]:  81.34(2) 
gamma[°]: 89.00(2) 
volume[Å3]:  725.9(3) 
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
Cl2       -0.22765    -0.03739    0.09541  1   2.5(1) 
Cl1        0.35454    -0.24922    0.58215  1   2.5(1) 
O1         0.05931    -0.09149    0.30175  1   2.5(1) 
N1         0.13947     0.06048    0.15605  1   2.5(1) 
C1         0.42036    -0.24192    0.45215  1   2.5(1) 
C2         0.59458    -0.28242    0.40198  1   2.5(1) 
C3         0.64788    -0.26704    0.30153  1   2.5(1) 
C4         0.52654    -0.21245    0.25281  1   2.5(1) 
C5         0.35105    -0.17653    0.30326  1   2.5(1) 
C6         0.29758    -0.19196    0.40431  1   2.5(1) 
C7         0.21200    -0.11774    0.25626  1   2.5(1) 
C8         0.26217    -0.09168    0.14764  1   2.5(1) 
C9         0.24406    -0.27246    0.04233  1   2.5(1) 
C10        0.17366     0.26103    0.22872  1   2.5(1) 
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C11        0.15680     0.30608    0.35548  1   2.5(1) 
C12        0.35932     0.28706    0.18215  1   2.5(1) 
C13        0.03656     0.37933    0.21200  1   2.5(1) 
H1         0.02354     0.05399    0.18120  1   2.5(1) 
H2         0.13480     0.03965    0.08361  1   2.5(1) 
H3         0.67558    -0.31957    0.43482  1   2.5(1) 
H4         0.76553    -0.29337    0.26684  1   2.5(1) 
H5         0.56307    -0.19980    0.18634  1   2.5(1) 
H6         0.17986    -0.16876    0.43856  1   2.5(1) 
H7         0.38332    -0.05947    0.14139  1   2.5(1) 
H8         0.27510    -0.25828   -0.02637  1   2.5(1) 
H9         0.12502    -0.30250    0.04889  1   2.5(1) 
H10        0.32067    -0.37054    0.03812  1   2.5(1) 
H11        0.24444     0.22978    0.36351  1   2.5(1) 
H12        0.04236     0.28207    0.38225  1   2.5(1) 
H13        0.17280     0.43470    0.40078  1   2.5(1) 
H14        0.36807     0.25825    0.10228  1   2.5(1) 
H15        0.44302     0.20565    0.18891  1   2.5(1) 
H16        0.38294     0.41357    0.22605  1   2.5(1) 
H17        0.05022     0.34811    0.13145  1   2.5(1) 
H18        0.05184     0.50850    0.25619  1   2.5(1) 
H19       -0.07870     0.35588    0.23767  1   2.5(1) 
Bupropion Hydrochloride Form III 
Crystal System: triclinic 
Space Group: P-1 
a[Å]:   7.5154(3) 
b[Å]:   7.8712(3) 
c[Å]:  13.7033(6) 
alpha[°]: 88.12(3) 
beta[°]:  86.41(2) 
gamma[°]: 67.78(2) 
volume[Å3]:  748.9(5) 
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
Cl1     0.19880    0.57302    0.40324    1  7.8(2)   
Cl2    -0.44868    0.80935    0.86472    1  7.8(2)   
C1     -0.50948    0.76574    0.98346    1  7.8(2)   
C2     -0.69400    0.77371    1.00829    1  7.8(2)   
C3     -0.74319    0.73731    1.10363    1  7.8(2)   
C4     -0.60782    0.69269    1.17410    1  7.8(2)   
C5     -0.42335    0.68533    1.14938    1  7.8(2)   
C6     -0.37427    0.72172    1.05400    1  7.8(2)   
C7     -0.27804    0.63785    1.22372    1  7.8(2)   
C8     -0.32145    0.58555    1.32683    1  7.8(2)   
C9     -0.39990    0.75673    1.39080    1  7.8(2)   
O1     -0.12038    0.63955    1.20162    1  7.8(2)   
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N1     -0.14334    0.45321    1.36605    1  7.8(2)   
C10    -0.08525    0.25861    1.33980    1  7.8(2)   
C11    -0.23928    0.18439    1.37536    1  7.8(2)   
C12    -0.05132    0.23516    1.22887    1  7.8(2)   
C13     0.10261    0.14848    1.38790    1  7.8(2)   
H1     -0.15495    0.46215    1.43993    1  7.8(2)   
H2     -0.03575    0.49297    1.34072    1  7.8(2)   
H3     -0.80221    0.80842    0.95161    1  7.8(2)   
H4     -0.89109    0.74340    1.12333    1  7.8(2)   
H5     -0.64717    0.66257    1.25021    1  7.8(2)   
H6     -0.22624    0.71494    1.03401    1  7.8(2)   
H7     -0.43107    0.52238    1.32645    1  7.8(2)   
H8     -0.55975    0.81592    1.39173    1  7.8(2)   
H9     -0.35456    0.71897    1.46681    1  7.8(2)   
H10    -0.34505    0.86211    1.36144    1  7.8(2)   
H11    -0.22413    0.06150    1.33282    1  7.8(2)   
H12    -0.22131    0.14529    1.45381    1  7.8(2)   
H13    -0.38560    0.28976    1.36629    1  7.8(2)   
H14     0.04226    0.30757    1.19974    1  7.8(2)   
H15     0.01961    0.08646    1.21273    1  7.8(2)   
H16    -0.18973    0.29161    1.19238    1  7.8(2)   
H17     0.16203    0.00462    1.36163    1  7.8(2)   
H18     0.20789    0.21430    1.36897    1  7.8(2)   
H19     0.07712    0.14717    1.46861    1  7.8(2)   
A.1.2 Bupropione Hydrobromide  
Bupropion Hydrbromide Form I 
Crystal System: triclinic 
Space Group: P-1 
a[Å]:   7.69386(22)   
b[Å]:   7.93659(19)   
c[Å]:   13.84976(25)  
alpha[°]: 94.0622(17) 
beta[°]:  94.4074(17) 
gamma[°]: 65.9613(19) 
volume[Å3]:  769.350(34)      
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
Br   0.28974(57)   -0.06438(49)    0.39847(21)   1   4.34(12) 
Cl   0.9772411     -0.2999097      0.8621458     1   4.34(12) 
C1   1.025362      -0.2637468      0.9834176     1   4.34(12) 
C2   1.208781      -0.2897566      1.016353      1   4.34(12) 
C3   1.247905      -0.2594234      1.1138        1   4.34(12) 
C4   1.103592      -0.2028305      1.178288      1   4.34(12) 
C5   0.9201546     -0.1774028      1.145437      1   4.34(12) 
C6   0.8811589     -0.2077422      1.04795       1   4.34(12) 
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C7   0.7653945     -0.117064       1.213361      1   4.34(12) 
C8   0.7999572     -0.07554804     1.31938       1   4.34(12) 
C9   0.8637006     -0.2519713      1.375573      1   4.34(12) 
O1   0.6071797     -0.09917726     1.183562      1   4.34(12) 
N1   0.6223041      0.06403734     1.357223      1   4.34(12) 
C10  0.5777745      0.259738       1.341923      1   4.34(12) 
C11  0.3951987      0.3867591      1.390685      1   4.34(12) 
C12  0.7416494      0.3104417      1.382819      1   4.34(12) 
C13  0.5510707      0.2885281      1.233013      1   4.34(12) 
H1   0.6240198      0.04826715     1.429288      1   4.34(12) 
H2   0.5146737      0.03629749     1.324008      1   4.34(12) 
H3   1.32427       -0.3340714      0.9645039     1   4.34(12) 
H4   1.394971      -0.2799866      1.140017      1   4.34(12) 
H5   1.13498       -0.1775989      1.256133      1   4.34(12) 
H6   0.7340416     -0.186502       1.021482      1   4.34(12) 
H7   0.9134509     -0.02197218     1.327855      1   4.34(12) 
H8   1.021882      -0.3213815      1.380474      1   4.34(12) 
H9   0.8112097     -0.2164854      1.450066      1   4.34(12) 
H10  0.8067773     -0.3488556      1.338076      1   4.34(12) 
H11  0.3918802      0.5277308      1.403679      1   4.34(12) 
H12  0.2702862      0.3944678      1.342398      1   4.34(12) 
H13  0.3870432      0.3334005      1.461427      1   4.34(12) 
H14  0.879493       0.2065532      1.35743       1   4.34(12) 
H15  0.7171631      0.448342       1.357437      1   4.34(12) 
H16  0.7482169      0.3161241      1.463215      1   4.34(12) 
H17  0.5373481      0.429222       1.217917      1   4.34(12) 
H18  0.6771089      0.1836287      1.197191      1   4.34(12) 
H19  0.4205049      0.2716926      1.203328      1   4.34(12) 
Bupropion Hydrobromide Form II 
Crystal System: orthorhombic 
Space Group: Pbca 
a[Å]:   8.63283(63)  
b[Å]:   12.40924(93) 
c[Å]:   27.70399(84) 
alpha[°]: 90         
beta[°]:  90         
gamma[°]: 90         
volume[Å3]:  2967.84(32)  
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
Br     0.47147(77)   0.34316(67)   0.04484(14)  1 3.03(16) 
Cl     0.8382352    -0.6521145     0.3138388    1 5.03(16) 
C1     0.9183345    -0.7781465     0.3067078    1 5.03(16) 
C2     0.8696037    -0.8435112     0.2691206    1 5.03(16) 
C3     0.9346095    -0.9447092     0.2630084    1 5.03(16) 
C4     1.048489     -0.9804866     0.2944334    1 5.03(16) 
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C5     1.096922     -0.9152712     0.3321557    1 5.03(16) 
C6     1.031852     -0.8140545     0.3382326    1 5.03(16) 
C7     1.218102     -0.9524348     0.3658009    1 5.03(16) 
C8     1.217859     -0.9188644     0.4181657    1 5.03(16) 
C9     1.15114      -0.8050813     0.4229624    1 5.03(16) 
O1     1.31924      -1.011595      0.3513043    1 5.03(16) 
N1     1.377801     -0.9206876     0.4364798    1 5.03(16) 
C10    1.49368      -0.8537202     0.4113337    1 5.03(16) 
C11    1.658391     -0.8872685     0.4251291    1 5.03(16) 
C12    1.474924     -0.8635501     0.3565601    1 5.03(16) 
C13    1.467892     -0.7363053     0.4257763    1 5.03(16) 
H1     1.41565      -0.9979643     0.4364676    1 5.03(16) 
H2     1.373402     -0.8943618     0.4709752    1 5.03(16) 
H3     0.7789174    -0.8145229     0.2437433    1 5.03(16) 
H4     0.8956005    -0.9968918     0.2327902    1 5.03(16) 
H5     1.100987     -1.061234      0.2893078    1 5.03(16) 
H6     1.071137     -0.7615313     0.3682963    1 5.03(16) 
H7     1.145233     -0.9757415     0.4393826    1 5.03(16) 
H8     1.024531     -0.8094684     0.43         1 5.03(16) 
H9     1.208227     -0.762826      0.4535742    1 5.03(16) 
H10    1.170132     -0.7588739     0.389103     1 5.03(16) 
H11    1.741817     -0.860628      0.3970357    1 5.03(16) 
H12    1.689479     -0.8488918     0.4600303    1 5.03(16) 
H13    1.666685     -0.9762185     0.4286632    1 5.03(16) 
H14    1.35172      -0.8522654     0.346273     1 5.03(16) 
H15    1.546853     -0.8005936     0.3389757    1 5.03(16) 
H16    1.513722     -0.9439329     0.3438841    1 5.03(16) 
H17    1.541927     -0.6819674     0.403755     1 5.03(16) 
H18    1.343889     -0.7158527     0.4198528    1 5.03(16) 
H19    1.496905     -0.7247088     0.4644959    1 5.03(16) 
A.1.3 Bupropion Hydroiodide 
Bupropion Hydroiodide Form I 
Crystal System: monoclinic 
Space Group: C2/c      
a[Å]:   8.5910(2)    
b[Å]:   14.6100(3)   
c[Å]:   25.6710(6)   
alpha[°]: 90         
beta[°]:  92.626(2)  
gamma[°]: 90         
volume[Å3]:  3218.3(1)     
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
I      0.09367       -0.16116       -0.56341    1  6.53(8)   
Cl     0.38944       -0.01048        0.34224    1  6.53(8)   
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C1     0.30231       -0.03145        0.28169    1  6.53(8)   
C2     0.23861       -0.11677        0.27065    1  6.53(8)   
C3     0.16727       -0.13376        0.22210    1  6.53(8)   
C4     0.15941       -0.06541        0.18462    1  6.53(8)   
C5     0.22361        0.01988        0.19558    1  6.53(8)   
C6     0.29492        0.03681        0.24416    1  6.53(8)   
C7     0.21585        0.09317        0.15603    1  6.53(8)   
C8     0.15198        0.07541        0.10121    1  6.53(8)   
C9     0.28088        0.03738        0.06811    1  6.53(8)   
O1     0.26052        0.16925        0.16775    1  6.53(8)   
N1     0.09279        0.16182        0.07851    1  6.53(8)   
C10   -0.06546        0.19092        0.09125    1  6.53(8)   
C11   -0.09495        0.29064        0.07548    1  6.53(8)   
C12   -0.18825        0.13033        0.06325    1  6.53(8)   
C13   -0.08096        0.18113        0.15002    1  6.53(8)   
H1     0.09723        0.15785        0.03921    1  6.53(8)   
H2     0.16656        0.21154        0.09152    1  6.53(8)   
H3     0.24410       -0.17141        0.30084    1  6.53(8)   
H4     0.11599       -0.20214        0.21337    1  6.53(8)   
H5     0.10147       -0.07898        0.14591    1  6.53(8)   
H6     0.34569        0.10527        0.25307    1  6.53(8)   
H7     0.05571        0.02463        0.10214    1  6.53(8)   
H8     0.27913       -0.03868        0.06904    1  6.53(8)   
H9     0.26159        0.06070        0.02708    1  6.53(8)   
H10    0.39684        0.06122        0.08359    1  6.53(8)   
H11   -0.22209        0.30403        0.07077    1  6.53(8)   
H12   -0.04401        0.33613        0.10646    1  6.53(8)   
H13   -0.04120        0.30607        0.03795    1  6.53(8)   
H14   -0.15850        0.05699        0.06904    1  6.53(8)   
H15   -0.30323        0.14463        0.07958    1  6.53(8)   
H16   -0.19526        0.14512        0.02082    1  6.53(8)   
H17   -0.20339        0.19306        0.16052    1  6.53(8)   
H18   -0.04489        0.11071        0.16180    1  6.53(8)   
H19   -0.00462        0.23156        0.17113    1  6.53(8)   
Bupropion Hydroiodide Form II 
Crystal System: monoclinic   
Space Group: C2/c        
a[Å]:   14.6084(3)                      
b[Å]:   8.0869(2)                       
c[Å]:   27.0461(4)                      
alpha[°]: 90                            
beta[°]:  92.760(1)                     
gamma[°]: 90                            
volume[Å3]:  3191.4(1)        
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
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I1     0.60703       0.856391    -0.94383    1  5.5(1) 
Cl     0.27906      -0.90676      0.33710    1  5.5(1) 
C1     0.24995      -0.89209      0.27482    1  5.5(1) 
C2     0.16135      -0.84908      0.25934    1  5.5(1) 
C3     0.13778      -0.83586      0.20925    1  5.5(1) 
C4     0.20282      -0.86540      0.17464    1  5.5(1) 
C5     0.29140      -0.90901      0.19010    1  5.5(1) 
C6     0.31492      -0.92218      0.24021    1  5.5(1) 
C7     0.36122      -0.94062      0.15362    1  5.5(1) 
C8     0.34367      -0.89998      0.09952    1  5.5(1) 
C9     0.30801      -0.05351      0.07166    1  5.5(1) 
O1     0.43428      -0.99923      0.16729    1  5.5(1) 
N1     0.42982      -0.84453      0.07887    1  5.5(1) 
C10    0.46046      -0.67406      0.08989    1  5.5(1) 
C11    0.39198      -0.54774      0.06788    1  5.5(1) 
C12    0.47152      -0.64668      0.14587    1  5.5(1) 
C13    0.55330      -0.64806      0.06742    1  5.5(1) 
H1     0.42451      -0.85867      0.04163    1  5.5(1) 
H2     0.47952      -0.92080      0.09271    1  5.5(1) 
H3     0.10934      -0.82441      0.28712    1  5.5(1) 
H4     0.06676      -0.80102      0.19692    1  5.5(1) 
H5     0.18394      -0.85381      0.13458    1  5.5(1) 
H6     0.38599      -0.95629      0.25264    1  5.5(1) 
H7     0.29153      -0.80006      0.09563    1  5.5(1) 
H8     0.23184      -0.05451      0.07017    1  5.5(1) 
H9     0.33191      -0.05165      0.03323    1  5.5(1) 
H10    0.33314      -0.16760      0.09080    1  5.5(1) 
H11    0.40001      -0.42754      0.08748    1  5.5(1) 
H12    0.40514      -0.52940      0.02814    1  5.5(1) 
H13    0.32057      -0.59157      0.07145    1  5.5(1) 
H14    0.51208      -0.74873      0.16349    1  5.5(1) 
H15    0.50752      -0.52739      0.15282    1  5.5(1) 
H16    0.40367      -0.64171      0.16255    1  5.5(1) 
H17    0.58332      -0.52734      0.07932    1  5.5(1) 
H18    0.59999      -0.74990      0.08002    1  5.5(1) 
H19    0.54533      -0.64983      0.02637    1  5.5(1)                 
Bupropion Hydroiodide Form III 
Crystal System: triclinic       
Space Group: P-1 
a[Å]:   7.9819(4)   
b[Å]:   8.2163(5)   
c[Å]:   13.7557(8)  
alpha[°]: 84.51(4)  
beta[°]:  84.75(4)  
gamma[°]: 63.07(4)  
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volume[Å3]:  799.42(9)      
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
I       0.04972      0.22615      -0.61361    1  4.6(2) 
Cl     -0.27339      0.47408      -0.85454    1  4.6(2) 
C1     -0.26140      0.51394      -0.97953    1  4.6(2) 
C2     -0.31897      0.69111      -1.01948    1  4.6(2) 
C3     -0.30822      0.72374      -1.12004    1  4.6(2) 
C4     -0.23964      0.57922      -1.18063    1  4.6(2) 
C5     -0.18262      0.40197      -1.14071    1  4.6(2) 
C6     -0.19340      0.36947      -1.04013    1  4.6(2) 
C7     -0.10927      0.24707      -1.20445    1  4.6(2) 
C8     -0.07578      0.27362      -1.31330    1  4.6(2) 
C9     -0.25228      0.31162      -1.36557    1  4.6(2) 
O1     -0.07393      0.09538      -1.16886    1  4.6(2) 
N1      0.08356      0.10680      -1.34838    1  4.6(2) 
C10     0.27433      0.07138      -1.32504    1  4.6(2) 
C11     0.32518      0.21974      -1.37373    1  4.6(2) 
C12     0.28835      0.06464      -1.21434    1  4.6(2) 
C13     0.41419     -0.11381      -1.36247    1  4.6(2) 
H1      0.08010      0.10881      -1.42194    1  4.6(2) 
H2      0.06254      0.00023      -1.31779    1  4.6(2) 
H3     -0.37290      0.80690      -0.97083    1  4.6(2) 
H4     -0.35408      0.86585      -1.15190    1  4.6(2) 
H5     -0.23013      0.60554      -1.26104    1  4.6(2) 
H6     -0.14686      0.22741      -1.00806    1  4.6(2) 
H7     -0.04301      0.39179      -1.32882    1  4.6(2) 
H8     -0.34249      0.46155      -1.37489    1  4.6(2) 
H9     -0.21079      0.25426      -1.43887    1  4.6(2) 
H10    -0.33467      0.24869      -1.32199    1  4.6(2) 
H11     0.43912      0.22412      -1.33502    1  4.6(2) 
H12     0.37473      0.18797      -1.45088    1  4.6(2) 
H13     0.20111      0.35615      -1.37181    1  4.6(2) 
H14     0.23059     -0.02600      -1.17642    1  4.6(2) 
H15     0.43876      0.01082      -1.19843    1  4.6(2) 
H16     0.20865      0.20328      -1.18658    1  4.6(2) 
H17     0.55696     -0.15454      -1.33727    1  4.6(2) 
H18     0.36575     -0.21759      -1.33396    1  4.6(2) 
H19     0.42133     -0.10666      -1.44370    1  4.6(2) 
Bupropion Hydroiodide Form IV 
Crystal System: monoclinic 
Space Group: P21/n    
a[Å]: 8.2635(5)  
b[Å]:   9.7799(3)  
c[Å]:   20.2113(6) 
alpha[°]: 90       
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beta[°]:  99.98(3) 
gamma[°]: 90       
volume[Å3]:  1608.6(1) 
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
I        0.20410    -0.13743    -0.04442   1  6.1(1) 
Cl      -0.88165     0.58142     0.76669   1  6.1(1) 
C1      -0.67373     0.55078     0.77646   1  6.1(1) 
C2      -0.61274     0.46825     0.73078   1  6.1(1) 
C3      -0.44530     0.44414     0.73814   1  6.1(1) 
C4      -0.33884     0.50271     0.79110   1  6.1(1) 
C5      -0.39986     0.58492     0.83697   1  6.1(1) 
C6      -0.56734     0.60899     0.82956   1  6.1(1) 
C7      -0.28776     0.64789     0.89350   1  6.1(1) 
C8      -0.33990     0.76940     0.93078   1  6.1(1) 
C9      -0.35311     0.89623     0.88578   1  6.1(1) 
O1      -0.15163     0.60083     0.91073   1  6.1(1) 
N1      -0.21709     0.79304     0.99166   1  6.1(1) 
C10     -0.22160     0.70315     0.04993   1  6.1(1) 
C11     -0.23235     0.55271     0.02885   1  6.1(1) 
C12     -0.06787     0.72380     0.10333   1  6.1(1) 
C13     -0.37251     0.74042     0.08037   1  6.1(1) 
H1      -0.22689     0.89120     0.00647   1  6.1(1) 
H2      -0.10569     0.78035     0.97833   1  6.1(1) 
H3      -0.69807     0.42195     0.68806   1  6.1(1) 
H4      -0.39663     0.37818     0.70138   1  6.1(1) 
H5      -0.20483     0.48394     0.79667   1  6.1(1) 
H6      -0.61625     0.67540     0.86608   1  6.1(1) 
H7      -0.46169     0.74853     0.94497   1  6.1(1) 
H8      -0.48110     0.90734     0.85827   1  6.1(1) 
H9      -0.31998     0.98873     0.91723   1  6.1(1) 
H10     -0.26947     0.88679     0.84847   1  6.1(1) 
H11     -0.18846     0.48605     0.07280   1  6.1(1) 
H12     -0.36241     0.52717     0.00845   1  6.1(1) 
H13     -0.15540     0.53287     0.98996   1  6.1(1) 
H14     -0.04647     0.83444     0.11355   1  6.1(1) 
H15     -0.08631     0.67115     0.15013   1  6.1(1) 
H16     -9.95819     0.68003     0.08633   1  6.1(1) 
H17     -0.37105     0.68518     0.12853   1  6.1(1) 
H18     -0.37142     0.85257     0.08960   1  6.1(1) 






A.1.4  Bupropion Solvates 
Bupropion Hydrobromide 1-Propanol solvate 
Crystal System: triclinic     
Space Group: P-1              
a[Å]:  7.827(6)                                
b[Å]:  9.392(6)                                 
c[Å]:  11.838(9)                            
alpha[°]: 85.70(6)                            
beta[°]: 101.75(7)                             
gamma[°]: 90.37(6)                             
volume[Å3]:  849.6(11) 
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
Br      0.19594  0.36417  0.58242   1     0.0541 
Cl      0.4949   0.31127  0.03314   1     0.0874 
O1      0.1573  -0.1177   0.2890    1     0.0664 
N1      0.2027  -0.3005   0.4684    1     0.0351 
H1A     0.1975  -0.3934   0.4939    1     0.042  
H1B     0.1017  -0.2797   0.4459    1     0.042  
C1      0.5472   0.1457   0.0936    1     0.0553 
C2      0.7166   0.1015   0.0749    1     0.0710 
H2      0.8037   0.1572   0.0267    1     0.085  
C3      0.7574  -0.0254   0.1278    1     0.0683 
H3      0.8727  -0.0555   0.1157    1     0.082  
C4      0.6283  -0.1091   0.1990    1     0.0545 
H4      0.6573  -0.1939   0.2361    1     0.065  
C5      0.4553  -0.0662   0.2150    1     0.0421 
C6      0.4142   0.0635   0.1609    1     0.0488 
H6      0.2991   0.0936   0.1702    1     0.059  
C7      0.3080  -0.1498   0.2877    1     0.0446 
C8      0.3474  -0.2821   0.3635    1     0.0387 
H8      0.4593  -0.2697   0.3866    1     0.046  
C9      0.3527  -0.4130   0.2936    1     0.0543 
H9A     0.3776  -0.4963   0.3394    1     0.081  
H9B     0.4421  -0.3999   0.2248    1     0.081  
H9C     0.2418  -0.4250   0.2726    1     0.081  
C10     0.2117  -0.2135   0.5702    1     0.0425 
C11     0.3619  -0.2679   0.6248    1     0.0565 
H11A    0.4702  -0.2498   0.5708    1     0.085  
H11B    0.3478  -0.3688   0.6447    1     0.085  
H11C    0.3625  -0.2196   0.6934    1     0.085  
C12     0.2371  -0.0547   0.5302    1     0.0606 
H12A    0.1411  -0.0222   0.4962    1     0.091  
H12B    0.3441  -0.0414   0.4741    1     0.091  
H12C    0.2419  -0.0011   0.5955    1     0.091  
C13     0.0373  -0.2397   0.6537    1     0.0566 
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H13A   -0.0552  -0.2038   0.6177    1     0.085  
H13B    0.0367  -0.1915   0.7225    1     0.085  
H13C    0.0205  -0.3403   0.6737    1     0.085  
O1S     0.0028   0.3283)  0.8731    0.50  0.098  
C1S     0.113    0.449    0.9168    0.50  0.127  
C2S    -0.003    0.546    0.9589    0.50  0.129  
C3S    -0.026    0.567    1.0908    0.50  0.104  
Bupropion Hydrobromide Ethanol solvate 
Crystal System: triclinic     
Space Group: P-1              
a[Å]:  7.7746(2) 
b[Å]:  9.3626(3) 
c[Å]:  11.6801(2) 
alpha[°]: 85.99)1) 
beta[°]: 101.39(2)                             
gamma[°]: 90.18(3)                             
volume[Å3]:  828.3 
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
Br    0.3103042 -0.1270082   0.08699004  1   2.935038 
Cl    1.013941   1.192782    0.4710263   1   4.935038 
C1    1.060798   1.355913    0.407934    1   4.935038 
C2    1.234078   1.399375    0.4217168   1   4.935038 
C3    1.272556   1.530124    0.3703215   1   4.935038 
C4    1.13781    1.617316    0.3050089   1   4.935038 
C5    0.9643347  1.574116    0.2915248   1   4.935038 
C6    0.9259879  1.443306    0.3429463   1   4.935038 
C7    0.8198532  1.665933    0.2221454   1   4.935038 
C8    0.8551471  1.789782    0.1408219   1   4.935038 
C9    0.8757175  1.927459    0.2055996   1   4.935038 
O1    0.6698367  1.641116    0.2298114   1   4.935038 
N1    0.706651   1.805881    0.03867177  1   4.935038 
C10   0.7101437  1.718682   -0.06125601  1   4.935038 
C11   0.7231039  1.558944   -0.02218842  1   4.935038 
C12   0.5439662  1.746205   -0.1577915   1   4.935038 
C13   0.8704005  1.761454   -0.1113833   1   4.935038 
H1    0.695916   1.910315    0.008616808 1   4.935038 
H2    0.5971444  1.778519    0.06818159  1   4.935038 
H3    1.342217   1.329014    0.4735201   1   4.935038 
H4    1.411595   1.564627    0.3812783   1   4.935038 
H5    1.168971   1.721514    0.2633906   1   4.935038 
H6    0.7871169  1.40828     0.3316951   1   4.935038 
H7    0.9785917  1.768423    0.1110022   1   4.935038 
H8    1.016965   1.944146    0.2452161   1   4.935038 
H9    0.8258297  2.020207    0.142557    1   4.935038 
H10   0.8010829  1.920259    0.2769723   1   4.935038 
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H11   0.6751579  1.494275   -0.0986056   1   4.935038 
H12   0.8629649  1.530107    0.0165323   1   4.935038 
H13   0.6421222  1.533542    0.04401515  1   4.935038 
H14   0.5201705  1.863036   -0.1776432   1   4.935038 
H15   0.5625194  1.69662    -0.2380001   1   4.935038 
H16   0.4274303  1.698267   -0.1300428   1   4.935038 
H17   0.867638   1.709294   -0.194354    1   4.935038 
H18   0.868344   1.879791   -0.1290608   1   4.935038 
H19   0.9934486  1.728521   -0.04721448  1   4.935038 
C01   0.5606401  0.01456266  0.5592663   1   6.935038 
O03   0.4852087  0.1285083   0.6114834   0.5 6.935038 
HO    0.5560867  0.1455296   0.6807557   1   6.935038 
H011  0.6732903  0.04224282  0.5469298   1   6.935038 
H012  0.5722964 -0.0699107   0.6104637   1   6.935038 
Bupropion Hydrobromide Trifluoroethanol solvate 
Crystal System: triclinic     
Space Group: P-1              
a[Å]:  7.9000(2) 
b[Å]:  9.3673(2) 
c[Å]:  11.7354(3) 
alpha[°]: 86.425(1) 
beta[°]: 102.501(2)                             
gamma[°]: 91.033(2)                             
volume[Å3]:  846.2 
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
Br    0.31096(45) -0.13460(39) 0.08417(28)  1   5.17(12)   
Cl    1.008971     1.200165    0.4674276    1   7.17(12)   
C1    1.054052     1.3632      0.4042038    1   7.17(12)   
C2    1.223972     1.41125     0.4203316    1   7.17(12)   
C3    1.261049     1.541928    0.3688563    1   7.17(12)   
C4    1.128268     1.624462    0.3011221    1   7.17(12)   
C5    0.958137     1.576676    0.2852836    1   7.17(12)   
C6    0.9211904    1.445939    0.3367877    1   7.17(12)   
C7    0.8157756    1.663511    0.2133173    1   7.17(12)   
C8    0.8515592    1.792338    0.1381068    1   7.17(12)   
C9    0.8625349    1.926902    0.2070096    1   7.17(12)   
O1    0.6672303    1.630478    0.2138143    1   7.17(12)   
N1    0.710368     1.807294    0.0334035    1   7.17(12)   
C10   0.7171293    1.717695    0.06452996   1   7.17(12)   
C11   0.8618003    1.767718    0.1259802    1   7.17(12)   
C12   0.747972     1.560936    0.02079875   1   7.17(12)   
C13   0.5430705    1.728989    0.1517775    1   7.17(12)   
H1    0.704086     1.911114    0.003003533  1   7.17(12)   
H2    0.5994141    1.781567    0.05966505   1   7.17(12)   
H3    1.330565     1.344615    0.4740893    1   7.17(12)   
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H4    1.397404     1.580109    0.3816996    1   7.17(12)   
H5    1.158332     1.728604    0.2594563    1   7.17(12)   
H6    0.7850246    1.407233    0.3236615    1   7.17(12)   
H7    0.9768315    1.777786    0.111716     1   7.17(12)   
H8    0.9994514    1.947433    0.2508575    1   7.17(12)   
H9    0.8137406    2.02028     0.1462842    1   7.17(12)   
H10   0.7840124    1.912986    0.2749426    1   7.17(12)   
H11   0.8996249    1.679783    0.1745437    1   7.17(12)   
H12   0.8142586    1.859408    0.1887067    1   7.17(12)   
H13   0.9779851    1.801144    0.0613914    1   7.17(12)   
H14   0.6572275    1.527197    0.03608087   1   7.17(12)   
H15   0.7261993    1.494026    0.09755458   1   7.17(12)   
H16   0.8828243    1.545258    0.02985694   1   7.17(12)   
H17   0.5361222    1.651439    0.2205884    1   7.17(12)   
H18   0.4377193    1.705544    0.1038866    1   7.17(12)   
H19   0.5259008    1.838712    0.1941442    1   7.17(12)   
C01   0.5889      -0.90631     0.5658       0.5 7.17(12)   
O03   0.4922      -0.83445     0.6371       0.5 7.17(12)   
HO    0.5539      -0.83514     0.7112       0.5 7.17(12)   
H011  0.6277      -0.83808     0.5137       0.5 7.17(12)   
H012  0.6862      -0.95314     0.6148       0.5 7.17(12)   
C02   0.4715      -0.01746     0.4952       0.5 7.17(12)   
F021  0.5623      -0.08486     0.4284       0.5 7.17(12)   
F022  0.3323      -0.95054     0.425        0.5 7.17(12)   
F023  0.416       -0.11526     0.5698       0.5 7.17(12)   
Bupropion Hydrobromide Ethylene Glycol solvate 
Crystal System: triclinic     
Space Group: P-1              
a[Å]:  7.8338(2) 
b[Å]:  9.3544(2) 
c[Å]:  11.5267(2) 
alpha[°]: 87.05(1) 
beta[°]: 103.42(2)                             
gamma[°]: 90.29(3)                             
volume[Å3]:  820.5 
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
Br    0.3127971  -0.1332383  0.09396218 1 3.081075    
Cl    0.9832017   1.189821   0.4644801  1 5.081075    
C1    1.041808    1.350736   0.4060156  1 5.081075    
C2    1.217243    1.387958   0.4261823  1 5.081075    
C3    1.26517     1.516894   0.3785187  1 5.081075    
C4    1.137717    1.608511   0.3105526  1 5.081075    
C5    0.9620901   1.57156    0.2906868  1 5.081075    
C6    0.9142902   1.442557   0.3383794  1 5.081075    
C7    0.8253081   1.668127   0.2184296  1 5.081075    
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C8    0.8705636   1.789346   0.1395325  1 5.081075    
C9    0.9080893   1.924816   0.2099762  1 5.081075    
O1    0.6735871   1.649435   0.2216836  1 5.081075    
N1    0.721795    1.815425   0.03622332 1 5.081075    
C10   0.7057222   1.722307  -0.06519688 1 5.081075    
C11   0.7262233   1.564497  -0.02216265 1 5.081075    
C12   0.5271415   1.74434   -0.1527278  1 5.081075    
C13   0.849633    1.762278  -0.1302573  1 5.081075    
H1    0.7263685   1.918415   0.0053622  1 5.081075    
H2    0.6115635   1.802193   0.0668388  1 5.081075    
H3    1.319529    1.314044   0.480102   1 5.081075    
H4    1.405921    1.54639    0.3945887  1 5.081075    
H5    1.176432    1.711244   0.2719189  1 5.081075    
H6    0.7736885   1.412532   0.3220063  1 5.081075    
H7    0.989187    1.760102   0.1082457  1 5.081075    
H8    1.050942    1.932048   0.2506461  1 5.081075    
H9    0.8664687   2.020599   0.1488392  1 5.081075    
H10   0.8361505   1.922305   0.2825918  1 5.081075    
H11   0.6653299   1.495307  -0.09587725 1 5.081075    
H12   0.8681807   1.537824   0.0077313  1 5.081075    
H13   0.6615418   1.542852   0.05300039 1 5.081075    
H14   0.5001154   1.860263  -0.1740974  1 5.081075    
H15   0.5293129   1.690044  -0.235817   1 5.081075    
H16   0.4208224   1.697906  -0.1140129  1 5.081075    
H17   0.8308026   1.705244  -0.2145002  1 5.081075    
H18   0.8439022   1.879834  -0.1510878  1 5.081075    
H19   0.9804583   1.732965  -0.07270268 1 5.081075    
C01   0.5644148  -0.0068766  0.5663485  1 7.081075    
O03   0.4977957   0.1187918  0.6103808  1 7.081075    
HO    0.5273261   0.197872   0.5718682  1 7.081075    
H011  0.6885766  -0.0015907  0.5800193  1 7.081075    
H012  0.5332439  -0.0903501  0.6070008  1 7.081075    
A.2 Atomic Coordinates of Nortriptyline Hydrochloride  
Nortriptyline Hydrochloride Form Alpha 
Crystal System: Monoclinic 
Space Group: P2/c 
a[Å]:   9.991260(7)    
b[Å]:   5.100210(3)    
c[Å]:   34.16361(2)    
alpha[°]: 90            
beta[°]:  98.68405(8)  
gamma[°]: 90            
volume[Å3]:  1720.935(2)   
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Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
Cl1    0          -0.2339       -0.25        1   8.313(87) 
Cl2    0.5        -0.2737(11)   -0.25        1   8.313(87) 
N1     0.2532397   0.08456877   -0.2572618   1   8.313(87) 
C1     0.6150856   0.2527944    -0.06534552  1   8.313(87) 
C2     0.6973394   0.3895128    -0.08680149  1   8.313(87) 
C3     0.6417282   0.5316338    -0.1196434   1   8.313(87) 
C4     0.5032649   0.5279877    -0.1309304   1   8.313(87) 
C5     0.4194916   0.388086     -0.110082    1   8.313(87) 
C6     0.4748363   0.2512259    -0.07643295  1   8.313(87) 
C7     0.382237    0.1115614    -0.05287344  1   8.313(87) 
C8     0.3019544   0.2997837    -0.03057117  1   8.313(87) 
C9     0.2021039   0.4824833    -0.05408921  1   8.313(87) 
C10    0.1140634   0.6239649    -0.0336185   1   8.313(87) 
C11    0.01906927  0.7926235    -0.05047435  1   8.313(87) 
C12    0.004967236 0.8306192    -0.09023033  1   8.313(87) 
C13    0.08652479  0.6924958    -0.11192     1   8.313(87) 
C14    0.1853392   0.5190847    -0.09516029  1   8.313(87) 
C15    0.2697953   0.385679     -0.1212835   1   8.313(87) 
C16    0.2099027   0.273918     -0.1547652   1   8.313(87) 
C17    0.2750598   0.1235582    -0.1842588   1   8.313(87) 
C18    0.2607912   0.267577     -0.223284    1   8.313(87) 
C19    0.2455693   0.2201625    -0.2955984   1   8.313(87) 
H1     0.3242807  -0.02096691   -0.2531184   1   8.313(87) 
H2     0.1674347  -0.02697227   -0.2591366   1   8.313(87) 
H3     0.6523016   0.1474456    -0.04351914  1   8.313(87) 
H4     0.7943359   0.3968716    -0.07960605  1   8.313(87) 
H5     0.7014485   0.6423524    -0.1341738   1   8.313(87) 
H6     0.4678218   0.6185278    -0.1518482   1   8.313(87) 
H7     0.3201532   0.001951403  -0.06921087  1   8.313(87) 
H8     0.4372245  -0.005734197  -0.03072126  1   8.313(87) 
H9     0.3710803   0.4033882    -0.01765408  1   8.313(87) 
H10    0.2536023   0.1980258    -0.01077908  1   8.313(87) 
H11    0.1285381   0.595017     -0.007578621 1   8.313(87) 
H12   -0.04454056  0.8826547    -0.0333042   1   8.313(87) 
H13   -0.06103766  0.951671     -0.102916    1   8.313(87) 
H14    0.08017943  0.7070498    -0.1353278   1   8.313(87) 
H15    0.1062486   0.288817     -0.1619472   1   8.313(87) 
H16    0.3721433   0.08047892   -0.1736326   1   8.313(87) 
H17    0.2244574  -0.02403209   -0.190264    1   8.313(87) 
H18    0.1753032   0.377335     -0.2286228   1   8.313(87) 
H19    0.3412545   0.3835846    -0.2257086   1   8.313(87) 
H20    0.3312234   0.3340013    -0.2995984   1   8.313(87) 
H21    0.2372183   0.1177676    -0.3183534   1   8.313(87) 
H22    0.1556602   0.317134     -0.3041755   1   8.313(87)  
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A.3 Atomic Coordinates of Ibuprofen Lysine Salts 
A.3.1 IBL-I 
Ibuprofen Lysine Salt Form I 
Crystal System: Monoclinic 
Space Group: P21/n 
a[Å]:   8.46665(53)   
b[Å]:   40.6211(25)   
c[Å]:   5.79317(33)   
alpha[°]: 90          
beta[°]:  86.3382(63) 
gamma[°]: 90          
volume[Å3]:  1988.35(21)   
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
O1    0.0909802  -0.1756606   -0.7513078 1 3.92(24)           
O2    0.301643   -0.1510493   -0.9984207 1 3.92(24)           
C1    0.123069   -0.09389852  -0.6685384 1 3.92(24)           
C2    0.2277418  -0.1077672   -0.520824  1 3.92(24)           
C3    0.2470521  -0.093626    -0.3059527 1 3.92(24)           
C4    0.1616895  -0.06561603  -0.2387958 1 3.92(24)           
C5    0.05701672 -0.0517473   -0.3865102 1 3.92(24)           
C6    0.03770645 -0.06588854  -0.6013815 1 3.92(24)           
C7    0.3198597  -0.1379938   -0.5932955 1 3.92(24)           
C8    0.4913282  -0.1280203   -0.6662459 1 3.92(24)           
C9    0.2424214  -0.1541655   -0.7983112 1 3.92(24)           
C10  -0.03510114 -0.0215207   -0.3140387 1 3.92(24)           
C11  -0.2130012  -0.02864304  -0.3265951 1 3.92(24)           
C12  -0.2721943  -0.04824097  -0.1110664 1 3.92(24)           
C13  -0.3024253   0.004535733 -0.3332947 1 3.92(24)           
H1    0.1098713  -0.1035634   -0.8153929 1 3.92(24)           
H2    0.3185911  -0.1031046   -0.2049968 1 3.92(24)           
H3    0.1748872  -0.05595115  -0.0919412 1 3.92(24)           
H4   -0.03383252 -0.05640992  -0.7023374 1 3.92(24)           
H5    0.3188362  -0.1528679   -0.4666523 1 3.92(24)           
H6    0.2303417  -0.159501    -1.103981  1 3.92(24)           
H7    0.537187   -0.1178929   -0.5387164 1 3.92(24)           
H8    0.4904401  -0.1129949   -0.7918303 1 3.92(24)           
H9    0.5496695  -0.1471638   -0.7121445 1 3.92(24)           
H10  -0.00447153 -0.003945766 -0.4154546 1 3.92(24)           
H11  -0.01296945 -0.01600444  -0.1600474 1 3.92(24)           
H12  -0.2290482  -0.04076804  -0.4623732 1 3.92(24)           
H13  -0.254634   -0.03573215   0.0234685 1 3.92(24)           
H14  -0.3820552  -0.05251629  -0.1186795 1 3.92(24)           
H15  -0.2154439  -0.06839807  -0.1082592 1 3.92(24)           
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H16  -0.2641066   0.01655648  -0.4659796 1 3.92(24)           
H17  -0.4122862   0.000260422 -0.3409078 1 3.92(24)           
H18  -0.2846477   0.01666534  -0.197163  1 3.92(24)           
O3    0.1486683   0.2660886    0.7475858 1 3.92(24)           
N1   -0.2211726   0.2322047    0.8149658 1 3.92(24)           
N2   -0.5753757   0.3198268    0.7134542 1 3.92(24)           
C14   0.04427517  0.2548184    0.8882575 1 3.92(24)           
C15  -0.131112    0.2630611    0.8611418 1 3.92(24)           
C16  -0.1429048   0.2867651    0.6554839 1 3.92(24)           
C17  -0.1461914   0.3224262    0.7459197 1 3.92(24)           
C18  -0.3118645   0.3298605    0.859243  1 3.92(24)           
C19  -0.4254845   0.337551     0.6711881 1 3.92(24)           
O4    0.09135375  0.2325471    1.089982  1 3.92(24)           
H19   0.1691636   0.2434757    1.172288  1 3.92(24)           
H20  -0.1751617   0.2734062    0.9975707 1 3.92(24)           
H21  -0.2827671   0.2261875    0.9516118 1 3.92(24)           
H22  -0.1482093   0.2151449    0.7728221 1 3.92(24)           
H23  -0.2373201   0.2821783    0.5812797 1 3.92(24)           
H24  -0.05356722  0.283635     0.5499884 1 3.92(24)           
H25  -0.1233059   0.3369835    0.6198386 1 3.92(24)           
H26  -0.06885634  0.324769     0.8565824 1 3.92(24)           
H27  -0.3051719   0.3477962    0.9621574 1 3.92(24)           
H28  -0.3480521   0.3106693    0.9450346 1 3.92(24)           
H29  -0.3729649   0.331034     0.5225283 1 3.92(24)           
H30  -0.4401661   0.3608624    0.6658537 1 3.92(24)           
H31  -0.5570913   0.301693     0.8025881 1 3.92(24)           
H32  -0.6168257   0.3139162    0.5690299 1 3.92(24)           
A.3.2 IBL-II 
Ibuprofen Lysine Salt Form II 
Crystal System: Monoclinic 
Space Group: P21/n 
a[Å]:   8.4507(8)          
b[Å]:   42.631(5)          
c[Å]:   5.8229(5)          
alpha[°]: 90                 
beta[°]:  85.721(9)        
gamma[°]: 90                 
volume[Å3]:  2091.9(4)   
Atom Name, Fractional Coordinates (x,y,z), Occupancy, B 
O1    0.1265316   -0.176482    -0.7148897   1 0.99(57)                                                
O2    0.3247713   -0.1475704   -0.9531673   1 0.99(57)                                                
C1    0.1046568   -0.09680342  -0.647389    1 0.99(57)                                                
C2    0.2081302   -0.107164    -0.4888483   1 0.99(57)                                                
C3    0.2078312   -0.09293053  -0.2740257   1 0.99(57)                                                
188 
 
C4    0.1040588   -0.06833648  -0.2177438   1 0.99(57)                                                
C5    0.0005853   -0.0579759   -0.3762846   1 0.99(57)                                                
C6    0.0008843   -0.07220936  -0.5911072   1 0.99(57)                                                
C7    0.3201148   -0.1337043   -0.5495841   1 0.99(57)                                                
C8    0.4870675   -0.1202726   -0.6113478   1 0.99(57)                                                
C9    0.2619711   -0.1515844   -0.7571666   1 0.99(57)                                                
C10  -0.1113992   -0.03143556  -0.3155488   1 0.99(57)                                                
C11  -0.2828005   -0.04395902  -0.3013374   1 0.99(57)                                                
C12  -0.3188755   -0.06014672  -0.0669579   1 0.99(57)                                                
C13  -0.397424    -0.01618768  -0.3252167   1 0.99(57)                                                
H1    0.1048611   -0.1065313   -0.7942103   1 0.99(57)                                                
H2    0.2785505   -0.1000115   -0.1656705   1 0.99(57)                                                
H3    0.1038545   -0.05860857  -0.07092264  1 0.99(57)                                                
H4   -0.0698349   -0.06512839  -0.6994624   1 0.99(57)                                                
H5    0.3222638   -0.1473776   -0.4209989   1 0.99(57)                                                
H6    0.2637044   -0.1579838   -1.061205    1 0.99(57)                                                
H7    0.5209096   -0.1091434   -0.4824018   1 0.99(57)                                                
H8    0.4828927   -0.1065      -0.7390411   1 0.99(57)                                       
H9    0.5579911   -0.1370815   -0.6498138   1 0.99(57)                                                
H10  -0.098342    -0.0157482   -0.4313241   1 0.99(57)                                                
H11  -0.08799334  -0.02298009  -0.1709704   1 0.99(57)                                                
H12  -0.2933861   -0.05850164  -0.4225593   1 0.99(57)                                                
H13  -0.306897    -0.04534538   0.0525023   1 0.99(57)                                                
H14  -0.4246704   -0.06783989  -0.05817598  1 0.99(57)                                                
H15  -0.2467358   -0.07703975  -0.05399825  1 0.99(57)                              
H16  -0.3731751   -0.006278984 -0.4697168   1 0.99(57)                                                
H17  -0.5032189   -0.02388085  -0.3164347   1 0.99(57)                                                
H18  -0.3848811   -0.001702202 -0.2039008   1 0.99(57)                                                
O3    0.1239177    0.2556122    0.7174117   1 0.99(57)                                                
N1   -0.246947     0.2304387    0.7983181   1 0.99(57)                                                
N2   -0.60014      0.320129     0.6592564   1 0.99(57)                                                
C14   0.02253727   0.2491984    0.8779117   1 0.99(57)                                                
C15  -0.1521533    0.2585547    0.8601244   1 0.99(57)                                                
C16  -0.1610282    0.2835642    0.6706186   1 0.99(57)                                                
C17  -0.1734853    0.3162382    0.783464    1 0.99(57)                                                
C18  -0.3493308    0.323563     0.8506174   1 0.99(57)                                                
C19  -0.4331535    0.3314642    0.6332268   1 0.99(57)                                                
O4    0.07265047   0.2318283    1.094835    1 0.99(57)                                                
H19   0.1586507    0.2429262    1.154459    1 0.99(57)                                                
H20  -0.1945337    0.2670646    1.002475    1 0.99(57)                                                
H21  -0.3092908    0.2235341    0.9312836   1 0.99(57)                                                
H22  -0.1763091    0.2142566    0.7444141   1 0.99(57)                                                
H23  -0.2519237    0.2796777    0.5882303   1 0.99(57)                                                
H24  -0.06779527   0.2823632    0.5692148   1 0.99(57)                                                
H25  -0.1307164    0.3314131    0.6765987   1 0.99(57)                                       
H26  -0.1152837    0.3162312    0.9168943   1 0.99(57)                                                
H27  -0.3560975    0.3405744    0.9552164   1 0.99(57)                                                
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H28  -0.3971935    0.3053247    0.9237617   1 0.99(57)                                                
H29  -0.3769829    0.3215287    0.5037669   1 0.99(57)                                                
H30  -0.4299023    0.3536174    0.6113065   1 0.99(57)                                                
H31  -0.6067891    0.301603     0.7323569   1 0.99(57)                                                
H32  -0.640956     0.3193949    0.5080416   1 0.99(57)                                                
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